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“In a varying environment, changes in the character of the population take
place. In every instance we are concerned to understand (a) whence the
change in character of the individual components arises and (b) the nature
of the process by which the constitution of the population is modified to
conform to the requirements of the changing environment.”
Frank Macfarlane Burnet
From ‘The Clonal Selection Theory of Acquired Immunity’.
1958
“... [A] knowledge of sequences could contribute much to our
understanding of living matter.”
Frederick Sanger
From the autobiography given to the Nobel Foundation upon receiving his second Prize.
1980
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Abstract
The adaptive immune systems of jawed vertebrates are based upon lymphocytes bear-
ing a huge variety of antigen receptors. Produced by somatic DNA recombination,
these receptors are clonally expressed on T- and B-lymphocytes, where they are used
to help detect and control infections and help maintain regular bodily function. Full
understanding of various aspects of the immune system relies upon accurate measure-
ment of the individual receptors that make up these repertoires. In order to obtain such
data, protocols were developed to permit unbiased amplification, high-throughput deep-
sequencing, and error-correcting bioinformatic analysis of T-cell receptor sequences.
These techniques have been applied to peripheral blood samples to further charac-
terise aspects of the TCR repertoire of healthy individuals, such as V(D)J TCR gene
usage and pairing distributions. A large number of sequences are also found to be
shared across multiple individuals, including sequences matching receptors belonging
to known and proposed T-cell subsets making use of invariant rearrangements. The res-
olution provided also permitted detection of low-frequency recombination events that
use unexpected gene segments, or contained alternative splicing events.
Deep-sequencing was further used to study the effect of HIV infection, and sub-
sequent antiretroviral therapy, upon the TCR repertoire. HIV-patient repertoires are
typified by marked clonal inequality and perturbed population structures, relative to
healthy controls. The data presented support a model in which HIV infection drives ex-
pansion of an subset of CD8+ clones, which – in combination with the virally-mediated
loss of CD4+ cells – is responsible for driving repertoires towards an idiosyncratic popu-
lation with low diversity. Moreover these altered repertoire features do not significantly
recover after three months of therapy.
Deep-sequencing therefore presents opportunities to investigate the properties of
TCR repertoires both in health and disease, which could be useful when analysing a
wide variety of immune phenomena.
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tion protocol)
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BSA Bovine serum albumin
BV Barcoded V (amplification protocol)
CD Cluster of differentiation
cDNA Complementary deoxyribonucleic
acid
CDR Complementarity determining region
DCR Shorthand for the five-part TCR clas-
sifier produced by Decombinator
Decombinator The software used to perform
basic TCR analysis in this thesis, in
which each TCR chain sequence is
classified using a five-field identifier
from which the entire nucleotide se-
quence can be recapitulated
DN Double negative
DNA Deoxyribonucleic acid
dNTP Deoxyribose nucleoside triphosphate
DOI Digital Object Identifier
DP Double positive
Epitope The part of an antigen to which a
TCR , BCR or antigen binds
FACS Flow assisted cell sorting
Functional IMGT definition: A germline V(D)J
gene predicted to be able to con-
tribute to productive rearrangements
gDNA Genomic DNA
GEM T-cell Germline-Encoded Mycolyl-
reactive T-cells
HF High fidelity buffer for Phusion poly-
merase
HLA Human leukocyte antigen
HSCT Haematopoietic stem cell transplan-
tation
HTS High-throughput sequencing
Ig Immunoglobulin
IMGT ImMunoGeneTics; the organisation
responsible for collating and annotat-
ing TCR and Ig information
Index One of a list of pre-determined nu-
cleotide sequences that is incorpo-
rated to all amplicons of a given sam-
ple before sequencing, to allow multi-
plexing of many samples on one run
iNKT cell Invariant natural killer T-cell
JSD Jensen-Shannon divergence
kb Kilobase (1000 nucleotide base pairs)
L-PART1/2 The two sections of the leader
sequence, which lie immediately up-
stream of each V gene and are spliced
together in mature TCR mRNA
Library Set of DNA molecules prepared to be
sequenced
m7G 7-methylguanosine
MACS Magnetic assisted cell sorting
MAIT cell Mucosal associated invariant T-cell
Mbp mega base pair (1,000,000 base pairs)
MHC Major histocompatibility antigen
mRNA Messenger ribonucleic acid
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N N represents an ambiguous, unknown
or random nucleotide
NEB New England Biolabs
NGS Next-generation sequencing
NKT cell Natural killer T-cell
NP (Non-productive) IMGT definition: A re-
arrangement predicted to not be ca-
pable of forming valid receptors
ORF IMGT definition: A germline V(D)J
gene predicted to be unlikely to be
able to contribute to productive re-
arrangements
P (Pseudogene) IMGT definition: A germline
V(D)J gene predicted to not be able
to contribute to productive rearrange-
ments
P5 One of two sequences required for Il-
lumina bridge amplification
P7 One of two sequences required for Il-
lumina bridge amplification
PBMC Peripheral blood mononuclear cells
PCR Polymerase chain reaction
PE Paired end
PEG Polyethylene glycol
pMHC Peptide major histocompatability
complex
Productive IMGT definition: A rearrangement
predicted to be capable of forming
valid receptors
RACE Rapid amplification of cDNA ends
Regex Regular expression; a sequence of
characters used to find strings that
match certain criteria
Rep-Seq Repertoire sequencing
RNA Ribonucleic acid
SBS Sequence-by-synthesis
SMS Single molecule sequencing
SP Single positive
SP1 Illumina’s sequencing primer 1
SP2 Illumina’s sequencing primer 2
SRA Sequence Read Archive
TCR T-cell receptor
TCR gene/segment A section of DNA that
can be assembled through V(D)J re-
combination to produce a TCR
Tdt terminal deoxynucleotidyl transferase
TEMRA T effector memory CD45RA+
TRA T-cell receptor alpha
TRAJ T-cell receptor alpha chain J gene
TRAV T-cell receptor alpha chain V gene
TRB T-cell receptor beta
TRBJ T-cell receptor beta chain J gene
TRBV T-cell receptor beta chain V gene
TRD T-cell receptor delta
TRG T-cell receptor gamma
UCL University College London
vDCR Verbose Decombinator, the spe-
cific version of Decombinator de-
veloped during this thesis to permit
error-correcting TCR analysis
w/v Weight per volume
15
1Introduction
1.1 Adaptive immunity
Various mechanisms have evolved across the domains of life to protect organisms from
the negative consequences of being infected or parasitised by other organisms. In ver-
tebrates these defences are typically grouped into one of two functional distinctions.
Germline-encoded mechanisms that provide generic barriers and rapid responses to
conserved elements of infectious agents constitute innate immunity. Working in con-
junction with these innate mechanisms is the adaptive immune system, that de novo
generates novel protein-coding genes in certain lymphocyte cell types to provide defence
from a potentially near-infinite array of different biological and chemical entities. While
typically less rapid than innate mechanisms, adaptive responses develop immunological
memory, leading to faster responses during subsequent exposures. Despite these differ-
ences, both innate and adaptive immune mechanisms involve the dynamic regulation
of different tissues, cells and effector molecules.
One of the most important immunological questions is how the body distinguishes
what is foreign – and potentially harmful – from its own component parts, many of
which will be composed of the same basic chemical structures. This problem was fa-
mously addressed by Frank Macfarlane Burnet in 1949 with his theory of immunologi-
cal tolerance (1). This theory states that during embryogenesis the developing immune
system should essentially only be exposed to the ‘self’, i.e. the sum total of identifi-
able molecular entities expressed throughout the body. Developing animals become
‘tolerant’ to these self-features, and can therefore reserve immunological reactions to
anything else that is ‘non-self’, thus targeting foreign material while limiting damage
to themselves. While modern theories have moved on – not least due to the knowledge
that the adaptive immune system does indeed mount responses towards self molecules
– this concept of ‘self’ and ‘non-self’ remains central to our understanding of immune
processes.
The mode of adaptive immunity that humans enjoy is shared by all gnathostomes
(jawed-vertebrates), having evolved approximately 500 million years ago in our shared
ancestors (2). In this system a series of DNA recombination events is used to generate
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populations of cells bearing a wide-range of different receptors, which can detect a huge
assortment of different molecules in order to trigger immune responses. These cells – B
and T lymphocytes, or B-cells and T-cells – are derived from a common haematopoietic
progenitor (3, 4), and express a variable recombined receptor based on their cell type.
B-cells express B-cell receptors (BCRs) and secrete soluble variations as antibodies (or
immunoglobulins), while T-cells express T-cell receptors (TCRs), which are the focus
of this thesis.
1.2 V(D)J recombination
TCRs exist as surface-expressed glycoproteins composed of two polypeptide chains. In
humans, most T-cells express a heterodimer consisting of an α and a β chain (although
a second lineage accounting for 5% of total T-cells makes use of an alternative TCR,
composed of a γ chain paired with a δ (5)). Unlike the majority of genes, TCRs (and
BCRs) are not functionally encoded in the germline. Instead, the loci encoding each
chain contain a number of non-contiguous sections of DNA that can be recombined
together to form complete coding sequences. This somatic DNA recombination was
first observed in B-cells (6), and was found to be due to a number of related gene
segments (7, 8) bordered by specific recombination sequences (9, 10) being brought
together.
These recombinable genes fall into one of three categories, or types: ‘variable’ (V),
‘diversity’ (D) or ‘joining’ (J). These can be physically joined together through the
action of a recombinase complex which is recruited to conserved recognition signal
sequences (RSS) at the gene boundaries (11). This complex is the product of two
recombinase activating genes (RAG), RAG-1 and RAG-2, which work co-operatively
to mediate recombination between RSS (12, 13). Each RSS consists of a conserved
nonamer and heptamer nucleotide sequence, separated by either 12 or 23 nucleotides;
the correct order of assembly is promoted by recombination only occurring efficiently
between pairs of genes that are bordered by RSS with different length spacers (the
‘12/23 rule’) (14). The complement of genes types are not equally distributed between
chains, as only one per heterodimer contains a D gene in its rearrangement: in the TCR
it is the β chain1. The distribution of RSS therefore directs recombination between Dβ
and Jβ, and Vβ with Dβ (see Figure 1.1). There is only one type of recombination
event in the α chain, that between a Vα and a Jα. However recombination at this locus
is complicated as the panel of V genes is shared between both α and δ rearrangements;
1D regions are also components of TCR δ and BCR heavy chain rearrangements.
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1.2 V(D)J recombination
the δ locus resides within the α (see Figure 1.2) (15, 16). Following transcription,
rearranged V(D)J sections are spliced onto a constant region, which is required for
surface expression and intracellular transmission of TCR binding signals.
The consequence of using V(D)J recombination to produce variable antigen re-
ceptors is the breadth of molecules that it can produce. Recombinatorial diversity is
generated by merit of there being multiple V, D and J genes, and from the final protein
being a heterodimer of two recombined chains: without any other mechanism in place
this system could produce over 2.8 million different TCRs2. However the majority of
the potential diversity arises due to mechanisms that result in the non-templated ad-
dition and deletion of nucleotides at the recombination junction. The RAG enzymes
catalyse formation of a DNA hairpin intermediate during recombination; action of the
DNA repair enzymes recruited to this site can lead to exonucleolytic ‘nibbling’ away of
nucleotides, and formation of ‘P-nucleotides’ (where non-symmetrical hairpin resolution
causes insertion of a short palindromic repeat) at the recombining edges (22, 23).
However the greatest source of diversity is the non-templated addition of nucleotides
(‘N-nucleotides’) (24) via the action of terminal deoxynucleotidyl transferase (Tdt)
(25, 26, 27). Hypothetically, allowing up to ten non-templated additions and deletions
at each recombination junction raises the potential diversity to more than 1016 possible
different TCR heterodimers. While these diversities will not even be approached in an
individual – not least because this theoretical estimate is orders of magnitude greater
than the total number of eukaryotic cells in a body – they serve to illustrate how a
few megabases of DNA are able to produce a vast array of antigen receptors that can
be used to detect and protect from a far greater number of immune challenges than a
static genome could.
2(45V α×50 Jα)× (48V β×2Dβ×13 Jβ) = 2, 808, 000. Values taken from IMGT/GENE-DB (19),
considering only the prototypical allele (thus ignoring the effect of polymorphism), for those V(D)J
genes predicted to be functional. Note that this value is two orders of magnitude greater than the
number of genes in the rest of the human genome, the estimated value of which varies between 19,000
and 31,000 (depending on the definition of ‘gene’) (20, 21).
Figure 1.1 (preceding page): V(D)J recombination in the human TRB locus. A:
Overview of the germline layout of the locus, with inset zoomed in on the DJC section. B:
Whole locus view of the rearrangement found in the β chain of the Jurkat cell line (genes
used marked with asterisks), with inset zoomed in on the rearrangement. C: Fully spliced
mRNA of the Jurkat β rearrangement. ‘A’ represents the poly-A signal. Complementarity
determining region 3 (CDR3) formed at the recombination site is marked.
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←
δ δ δ δ δ δ δ δ 
Shared TRAV-TRDV pool TRDD/J TRAJ cluster
TRACTRDC
Figure 1.2: The human alpha-delta germline locus. Schematic representation of the
human TRA/TRD locus. Successful recombination of an α chain prevents expression of
a δ chain by excision. Genes are coloured as per the IMGT standard system (described
later in Section 2.1): V genes are green, D genes dark blue, J genes yellow and constant
regions lighter blue. Black ‘δ’ characters indicate a IMGT-designated TRA/DV gene, while
red ‘δ’ characters indicate those which are supposed to only contribute towards delta chain
rearrangements. Note the furthest 3’ V gene is underscored by a leftwards arrow: this signifies
TRDV3, which appears downstream of the TRD cluster, forcing it to recombine by inversion
(as opposed to standard deletional joining) (17, 18). Double grey lines indicate omitted genes.
1.3 TCR structure, function and selection
T-cells broadly fall into one of two cell types that perform separate immune functions.
Cytotoxic T-lymphocytes (CTLs) survey cells of the body for indications of viral infec-
tion or tumour development, and kill such potentially dangerous cells. In constrast, T
helper (TH) cells are non-cytolytic and release cytokines to modulate the local immune
response of other cells. These contrasting abilities are both mediated by their TCRs
binding to specific ligands. These cell types can generally be distinguished by the mu-
tually exclusive expression of a glycoprotein co-receptor: CTLs express CD8 while TH
cells express CD4.
The exact nature of the TCR ligand was gradually revealed by a number of im-
portant experiments, starting with the discovery that CTLs from one animal could
only lyse cells derived from an animal which shares a major histocompatibility complex
(MHC) allele (29); TCRs are thus ‘MHC-restricted’. Unlike antibodies, TCRs were not
found to be able to bind ‘native’ antigens; instead their protein antigens must first be
processed and presented by cells (30). In combination with the solved crystal structure
of an MHC molecule3 (31), the observation that addition of appropriate synthetic pep-
tides to cells could cause T-cells to specifically activate against them (32, 33) lead to the
realisation that TCR ligands consist of short peptides, bound in the membrane-distal
groove of MHC molecules (34, 35) (Figure 1.3A). CD4 and CD8 contribute by binding
specific families of MHC molecules: CD8 on CTLs binds to MHC class I, while CD4
binds to MHC class II, directing T-cell restriction (36). Further structural data revealed
that the region of each TCR polypeptide chain encoded by the hypervariable DNA at
3Human leukocyte antigen (HLA)-A2.
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A
B C
Constant Variable pMHC
Figure 1.3: TCR binding to peptide-MHC (pMHC). Images of the A6 TCR recognis-
ing a self-peptide from neuronal protein HuD, bound in the context of the class I MHC HLA
A2 (28). A: Whole structure profile revealing the peptide (yellow), bound in the groove of the
MHC molecule (light grey, β2-microglobulin in dark grey). Constant and variable domains
of the TCR are indicated above. α chain is coloured green, β chain is coloured purple. B
and C: Demonstration of the proximity of the α and β chain CDR3 regions (coloured red
and aqua respectively) with the MHC-bound peptide (note that C is taken from the point
of view of the MHC, not shown). Crystal structure obtained via the PDB accession 3PWP,
images made using PyMol.
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the site of recombination – named complementarity determining region 3 (CDR3) –
forms the primary contacts with the peptide bound in the MHC groove (Figure 1.3B
and C), while other (germline encoded) variable sites (CDR1 and CDR2) usually make
contacts elsewhere on the MHC (37).
T-cells are derived from lymphoid progenitor cells that originate in the bone mar-
row, which must travel to the thymus to develop4. Thymocytes begin their thymic
development with unrearranged TCR gene loci, double negative (DN) with respect to
the TCR co-receptors. As they navigate through various thymic compartments they
undergo various genetic events and checkpoints including the rearrangement of their
β chain, which must be confirmed by successfully pairing with an invariant pre-TCR
to pass ‘β-selection’, and expression of both CD4 and CD8 during a double positive
stage (DP), followed by recombination of their α chain (39). DP cells must then un-
dergo two rounds of selection to ensure their TCR has the required properties, through
interaction with thymic epithelial cells expressing a wide variety of self peptide-MHC
(pMHC) antigens: cells must demonstrate the ability to bind to pMHC (positive selec-
tion), while not binding so strongly to self antigens so as to pose an autoimmune risk
(negative selection) (40). DP cells that pass through thymic selection lose expression
of one of the co-receptors, becoming CD4 or CD8 single positive (SP), and can leave
the thymus to enter the periphery as a na¨ıve T-cell.
This system of T-cell development therefore uses a somatic DNA recombination
process to produce a diverse anticipatory array of different TCRs – the TCR repertoire
– that stands to activate in response to antigens derived from a world of unknown and
potentially pathogenic organisms.
1.4 TCR discovery
Study of the TCR began with its discovery in the early 1980s. By this time it was
already known that different T lymphocyte clones (or ‘clonotypes’) could respond to
specific antigens, producing the cellular immune response (41). However the quest to
find the receptor responsible for this specificity proved difficult, perhaps hampered by
initial expectations that such receptors would resemble the B-cell style immunoglobulins
(42). In the space of one year, three groups had raised monoclonal antibodies against
T-cell lines which recognised clonotype-specific surface-expressed disulphide-linked het-
erodimeric glycoproteins, in both mouse and man (43, 44, 45). These heterodimers
4Jacques Miller’s discovery of this immune function for the thymus not only finally answered the
long standing mystery of what role the organ fulfilled, but also began the chain of events that lead to
the identification of T-cells and B-cells as separate lymphocyte lineages (38).
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associated with CD35, which was already known to be a marker of T lymphocytes
that promoted activation when targeted by antibodies (44). These clonotypic protein
structures – that were of similar structure but comprised of different protein sequences
– were found on T-cells, but not other cells such as B-cells, providing the first clue
that these discoveries might correspond to the TCR (46, 47). These findings began the
search for the transcripts and genes encoding these proteins. Two groups headed by
Mark Davis and Tak Mak published back to back papers describing this achievement,
using similar strategies working on the hypothesis that TCR genes would possess quali-
ties of rearranged immunoglobulin genes (having both a variable, recombined region for
antigen binding and a constant region for signalling) yet only be expressed in T-cells,
not B-cells (48, 49). These assumptions informed experimental designs that allowed
isolation of the first human and murine TCR sequences through a process of cDNA
screening called subtraction6. Sequence analysis revealed homology to immunoglobulin
genes (49, 50), as well as a comparable arrangement scheme consisting of a constant
and a variable region, which was further divided into separate segments (51). The first
TCRβ sequences had been found, beginning the modern age of TCR analyses. Two
additional chains were cloned soon afterwards using similar techniques and proposed as
potential binding partners of TCRβ (52, 53). Partial peptide sequences of the TCRβ-
associated molecules revealed that one of these chains (the second to be discovered)
was the partner of the β chain, and therefore the α chain (54)7. The remaining chain
would become known as the γ chain, whose contribution to TCR receptors would re-
main unknown until pulsed-field gel electrophoresis experiments revealed an additional
recombining locus nestled within that encoding the α chain (15), which was found to
produce δ chains, the binding partner of γ.
5Then known as ‘T3’.
6Subtraction consists of incubating labelled cDNA from the cell of interest (T-cell clones) with
unlabelled RNA from a related cell (B-cells), which removes the sequences that are common to both
by separating single and double stranded sequences.
7The chains had already been named arbitrarily upon initial discovery of the protein heterodimer,
following electrophoresis under denaturing conditions: the larger chain was named α, while the smaller
chain was named β (55).
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1.5 Historical methods of investigating TCR repertoires
Having identified the individual TCR chains, the challenge then became how to study
the distribution of different rearrangements within a sample. However, the complexity
produced by V(D)J recombination presents a number of technical challenges to study.
Various technologies have been employed to monitor the TCR repertoire with varying
throughput, resolution, and capabilities.
Since their role in the discovery of the TCR proteins, monoclonal antibodies directed
against specific V families have been widely used to measure T-cells bearing TCRs using
particular V genes via flow cytometry (56). Flow cytometry is able to screen millions of
cells for surface expression of specific Vs, both quickly and at relatively low cost (57).
Modern flow cytometers can detect up to 18 colours, theoretically giving simultaneous
recording of large swathes of the repertoire in one experiment; the advent of mass
cytometry – in which mass spectrometry is used to detect antibody-bound rare-earth
elements, instead of fluorescence detection via CCDs – could even allow detection of all
Vs of a given chain (58). Cytometric techniques can be used to further characterise V-
specific T-cells by staining for phenotypic and lineage cell markers. However, in practice
even modern studies using flow cytometry tend to only monitor the β chain, using a
panel of antibodies designed to cover the majority of TRBV genes (57, 59), and there are
currently no published accounts of mass cytometry being employed for TCR repertoire
studies. Furthermore cytometry can only provide information as to the frequency
of cells using particular V genes in a population, providing no further information
about the nature of the rearrangement. Therefore despite the large throughput, flow
cytometry produces very low resolution data. The availability of antibodies covering the
majority of V genes can also be limiting (47, 60), particularly in non-model organisms,
and V gene polymorphisms may prevent binding.
The discovery of TCR genes was contemporaneous with the development of poly-
merase chain reaction (PCR) (61, 62); this technology was rapidly adopted by immu-
nologists to quantitatively monitor the expression of V gene families (63, 64). PCR
has the advantage of being able to selectively amplify nucleic acids bearing specific
sequences, allowing one to target TCR chains at various levels. One can target and
amplify individual clonotypes (to track leukaemic clones (65), for instance), individual
V or J gene families (64) or even all TCRs within a chain. PCR has also facilitated the
development of almost every other technique to measure TCR repertoires which uses
genetic information.
One of the more widely used PCR-based techniques to study repertoires of vari-
able immune receptors involves amplifying from RNA using specific V gene family and
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constant region primers, before visualising the profile of CDR3 lengths produced by
electrophoresis (66, 67)8. These ‘spectratypes’ give a great deal of information about
the spread of clonalities within a V family; expansions of clones can be visualised as
departures from the typical Gaussian-like distribution of CDR3 lengths. Spectratyp-
ing therefore provides a relative increase in resolution with respect to flow cytometry,
providing information regarding clonal expansions within a V family. Variations upon
spectratyping such as heteroduplex analysis (69) or single-strand conformation poly-
morphism analysis (70) exist that further separate amplicons based on their nucleotide
conformational properties, which can offer resolution beyond CDR3 length distribu-
tions.
Having played a key role in the identification of TCR chains, sequencing of cloned
TCR cDNA molecules remains an important means of assessing TCR identity and
diversity (71). Sequencing produces the highest resolution data of all methods discussed
thus far: nucleotide level information, often for the complete variable region. This
information typically comes at the cost of throughput, as cloning and sequencing are
relatively time, labour and expense intensive. However, cloning and sequencing from
single cells allows extraction of paired α and β chain sequences, giving the actual
complete clonotype of each cell (72, 73).
1.6 TCR repertoire analysis by deep-sequencing
As with the emergent technologies described above, the field of immunology has begun
to adopt high-throughput sequencing (HTS) (described in detail in Chapter 5) in order
to study TCR repertoires. These technologies offer both high-throughput and high-
resolution data, as they can produce nucleotide sequence information for thousands to
millions of clones in one experiment. Whilst still a technique in its infancy, repertoire
sequencing (or ‘RepSeq’ (74)) has revealed a number of interesting features of T-cell
biology.
The earliest TCR deep-sequencing papers set out to parameterise the TCRβ reper-
toires of healthy individuals, measuring clonotype frequencies, CDR3 length and V(D)J
usage (75, 76). Early reports used such data to estimate the lower bound of number
of distinct peripheral TCRβ rearrangements. Values ranged from one to four million
sequences (76, 77), in agreement with the oft-cited estimate from Arstila et al (78),
although at least one group claims it could be two order of magnitude greater (79). A
8It is also possible to perform this procedure using gDNA as a template, but this requires using
primers directed against the J genes instead of the constant region, due to the presence of the large
J-C intron(68).
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profound decrease in repertoire diversity has also been reported to occur with increased
age, consistent with findings from previous technologies (79, 80). The repertoires of
T-cell responses to Epstein-Barr Virus (EBV) and cytomegalovirus (CMV) have been
found to be very stable, with the hierarchy of expanded sequences being maintained
over several years (81).
TCR RepSeq has also shown its use in answering various other immunological re-
search questions. For instance, αβ and γδ T-cells were sorted from healthy donors
and both TCRβ and γ chains were sequenced; while only a small number of β se-
quences were present in the γδ cell libraries, recombined γ chain sequences were found
at high frequency in αβ populations, supporting the hypothesis that TCRγ rearrange-
ment occurs prior to T-cell lineage commitment, while TCRβ rearranges afterwards
(82). Similarly, the presence of some sequences in multiple different T-helper subsets
of the same individual argues against the possibility that TCRs are deterministic with
regards to T-helper fate (83). Extensive profiling of repertoires of multiple different
tissues from organ donors reveals considerable compartmentalisation of different clono-
types to different tissues (84). Patients with various immunodeficiencies, including
aplastic anaemia (85), Wiskott-Aldrich syndrome (86, 87), and Omenn syndrome (88)
have been sequenced, invariably revealing restriction or skewing of the TCR repertoire
relative to healthy controls.
One of the first major clinical applications of TCR RepSeq is in identifying and
tracking the clonal sequences of T-cell derived leukaemias and lymphomas (89, 90, 91,
92), as the clonal rearrangement of the original cell acts a specific marker of neoplastic
cells. Different groups have employed sequencing of β and/or γ chains, depending on
the nature of progenitor cell’s lineage 9. Deep-sequencing has shown itself to be a par-
ticularly sensitive tool for detecting minimal residual disease (MRD), i.e. the continued
presence of neoplastic cells during therapy, out-performing the existing techniques of
flow-cytometry (89) allele-specific oligonucleotide PCR(90), and (in a model system of
MRD) capillary sequencing (96). In a recent study by Logan et al, MRD detected by
HTS was completely predictive of relapse to disease following haematopoietic stem cell
transplantation (HSCT) (95). In addition to detecting MRD, TCR sequencing pro-
duces other data that could be of diagnostic or prognostic value in cancer patients,
such as monitoring the dynamics of the repertoire fluctuation on treatment.
Measuring immune system reconstitution following HSCT is another important clin-
ical application of repertoire sequencing, which has been explored beyond treatment of
9Immunoglobulin rearrangements have also been sequenced to track B-cell neoplasms (90, 91, 93,
94, 95).
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cancer. One patient with ankylosing spondylitis who received HSCT has been exten-
sively studied in order to evaluate immune recovery (97, 98). Not only did sequencing
reveal the emergence of a skewed but stable repertoire, but a number of clones that
were present at low frequency pre-transplantation were found to be both retained and
expanded at later timepoints. A later study aimed to test whether whether TCR se-
quencing might stratify responses in patients receiving transplants from different stem
cell sources (99). Six months after transfusion, cord blood stem cell recipients developed
repertoires with diversities approaching that of healthy donors, while those who received
stem cells derived from adult peripheral blood were far less diverse, potentially leaving
them at greater risk of opportunistic infections and cancer relapse. Graft-versus-host
disease (GVHD), a major risk factor for HSCT patients, has also been investigated
with HTS. Steroid-refractory patients showed greater repertoire conservation between
samples from multiple gastrointestinal (GI) sites (100). Moreover, clones identified in
these GI samples were found to be expanded in longitudinal peripheral blood sam-
ples. Therefore TCR RepSeq potentially offers both a means of quantifying immune
reconstitution in HSCT patients and stratifying those who might fail to respond to
therapy.
1.7 Aims of this thesis
TCR repertoire sequencing represents a powerful tool that can be applied in the study
of diverse immunological and clinical phenomena. However it is still a developing tech-
nology, and its full potential is yet to be fully realised. Therefore the first aim of
this thesis was to develop protocols for the amplification, high-throughput sequenc-
ing and bioinformatic analysis of TCR repertoires from human blood samples. These
protocols should be robust, repeatable, and incorporate as little bias as possible. Hav-
ing established repertoire-sequencing techniques, the next aim was to apply them to
blood samples taken from healthy volunteers. This should allow both testing of the
capabilities and limitations of the method, as well as produce an understanding of the
nature of the repertoire features in healthy adult individuals using such high-resolution
data. The final aim of this thesis was to sequence the repertoires of patients suffering
from a clinically relevant infection, to assess the merit of using such technologies to
understand the effect of infection upon the immune system. As a pathogen of global
clinical importance, that is known to have a large impact on the T-cell compartment,
human immunodeficiency virus (HIV) was chosen as a suitable model. Patient samples
were to be sequenced and compared to those of healthy, uninfected donors, to allow
measurement of the differences between the two groups.
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2.1 The international ImMunoGeneTics (IMGT)
information system and nomenclature
The IMGT system was established in the Montpelier Laboratoire d’Immuno Ge´ne´tique
Mole´culaire under the direction of Professor Marie-Paule Lefranc, to provide standard-
ised references for immunogenetic and immunogenomic research (101). I have made
frequent use of IMGT system throughout the generation of my data and the writing of
this thesis. All annotated TCR gene sequences were obtained from the IMGT database
IMGT/GENE-DB (19), and IMGT/LocusView was very useful in the production of a
number of schematics in this thesis.
The IMGT-defined and Human Genome Organisation (HUGO)-approved TCR nomen-
clature has been used throughout this document (102, 103). In this system, TCR (and
immunoglobulin) loci are first divided into gene types, i.e. V, D and J1 Any genes within
a given locus of a species that share 75% nucleotide sequence identity with each other
are designated as subgroups. Specific genes can furthermore exist as one of several al-
leles. Genes are referred to with identifiers that incorporate all of this information. For
example, TRAV8-4*01: TR indicates a TCR gene, AV indicates that it’s an α chain V
gene; 8-4 signifies that it’s the fourth gene in the eighth subgroup in that locus, while
*01 indicates that it’s the prototypical allele of that gene2.
Where possible, I have also adopted the IMGT colour conventions for use in schematic
illustrations, as detailed in the IMGT Scientific Chart (104, 105). Accordingly, V genes
have been coloured green (hexadecimal colour code #00EE00 ), D genes dark blue
( #0000E4 ), J genes yellow ( #FFE400 ), constant regions light blue ( #0099FA ),
N nucleotides red ( #FF0000 ) and where featured, leader sequences in light yellow
( #FFFF00 and bordered in black to distinguish from J sequences).
1The recombinable DNA segments are referred to as ‘genes’ under IMGT terminology, for both
practical and biological reasons. Practically, as labelling them as genes was a requirement for them
to be indexed in various databases, and biologically on the grounds that each can be transcribed
independently as they have their own promoters.
2Note that in this system variable antigen receptor gene names are not italicised, in contrast to the
standard convention for human genes.
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2.2 General considerations and RNA extraction
In order to minimise the risk of contamination or biohazards, all molecular or cell biol-
ogy was undertaken with appropriate control measures. Handling of nucleic acids prior
to amplification was undertaken in UV- and chemically-treated PCR hoods, and highly-
concentrated PCR or cloning products were purified in separate rooms, to minimise the
potential for DNA contamination. Peripheral blood and cell lines were manipulated
in laminar flow hoods. Bacterial cloning was carried out at the bench under asceptic
conditions.
RNA samples were obtained from consenting adults in one of two ways. RNA for
protocols that did not use molecular barcoding (i.e. simple V and poly-T amplification),
was derived from peripheral blood mononuclear cells (PBMC) or sorted cell fractions,
obtained by density centrifugation of up to 120 ml of peripheral blood using Lympho-
prep (Axis-Shield). PBMC were then lysed in RLT buffer (Qiagen) and RNA extracted
using the Qiagen RNeasy kits and eluted in 60 µl of water. RNA for the protocols using
random barcodes (BV and BLR amplification) was extracted by other researchers (see
relevant sections) by drawing 2.5 ml of peripheral blood into Tempus tubes (Life Tech-
nologies) and eluting RNA in approximately 90 µl of water. All cell lysates, RNA and
Tempus tubes were stored at -80°C, while cDNA and amplified DNA products were
stored at -20°C. RNeasy and Tempus extractions, and Lymphoprep separation were
performed as per the manufacturer’s instructions (APMI).
2.3 Amplification and deep-sequencing protocols
The development and application of the following protocols made up the major com-
ponent of all practical molecular biology undertaken during this body of work; the
rationale and details of this development is covered in detail in Chapter 5. Primer
sequences for all protocols are detailed below in Section 2.3.7.1.
2.3.1 Reverse transcription
After extraction, residual genomic DNA (gDNA) was removed from RNA samples using
commerically available DNase I (or derivative engineered forms). For all protocols
except the BLR protocol, RNA was incubated with 0.1 U/µl of RQ1 DNase (Promega)
in 1X reaction buffer for 30 min at 37°C. Samples processed using the BLR protocol
had gDNA removed using the TURBO DNase kit, and globin mRNA was depleted
using GLOBINclear3 (both Life Technologies, APMI).
3Globin message was removed so that this RNA could be used for additional microarray studies.
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Reverse transcription was carried out using oligonucleotides named αRC2 and
βRC2, which are complementary with sequences towards the 5’ end of the α and β
constant regions respectively. βRC2 targets a region that is conversed between the two
human β constant regions, TRBC1 and TRBC2. RNA (typically 500 ng) was mixed
with 1 µl of each RC2 primer (10 µM) and 1 µl of a 10mM dNTP mix and heated at
65°C, 5 min and cooled rapidly on ice. 1 µl of DTT (0.1 µM), 1 µl of RNasin (RNase
inhibitor, 20-40U/µl, Promega), 1 µl of SuperScript III reverse transcriptase (RT) (200
U/µl, Life Technologies) and 4 µl of 5X FS buffer was added, before incubation at 55°C,
20 min, then 70°C, 15 min for heat inactivation. Complementary DNA (cDNA) from
RT reactions was purified and eluted into either 10 µl or 30 µl of buffered Tris-Cl using
MinElute or QIAquick columns respectively (Qiagen).
2.3.2 Simple V amplification
Primers were designed against TRAV8-4 and TRBV12-3 (named αF1 and βF3) and
the very 5’-most end of TRAC and TRBC (αRC1 and βRC1). The two β chain
constant region genes differ at two positions in this region, therefore βRC1 contains
two degenerate bases. Also note that while αRC1 ends at the most 5’ nucleotide of
the constant region, the beta primer actually overlaps with the last nucleotide of the J
gene, as all TRBJ genes end with the same nucleotide.
1 µl reverse transcribed cDNA from lysed PBMC or sorted cells underwent a mul-
tiplex PCR using all four primers (αF1, βF3, αRC1 and βRC1). Reagent final concen-
trations in 50 µl reaction volumes were: 1X GoTaq Green buffer (Promega); 0.1 mM
each dNTP; 0.2 µM each primer; 0.5 mM additional MgCl2 and 2.5 U GoTaq DNA
Polymerase (Promega). PCR mixtures were subjected to 30 cycles of: 94°C, 30 sec;
60°C, 2 min; 72°C, 1 min, with a 1 min final extension. PCR products were visualised
on 1% agarose gels, and gel purified before submission for 100 bp paired-end (PE)
Illumina HiSeq sequencing. Sequencing was performed at the Wellcome Trust Sanger
Institute, in collaboration with Professor Paul Kellam’s group.
2.3.2.1 Magnetic assisted cell sorting and flow cytometry
PBMC from two donors – D3 and D4 – were sorted into CD4+CD45RA+ and
CD4+CD45RO+ populations (broadly representative of CD4+ na¨ıve and memory cells)
prior to lysis, using negative-selection magnetic assisted cell sorting (MACS). Negative-
selection refers to the targets of the selection: antibodies are used to target beads to
cells other than those of interest by binding surface antigens that they do not express,
and collecting unbound enriched desired cells from the eluate.
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After isolation, PBMC were divided in two and subjected to either the Na¨ıve or
Memory CD4+ T cell Isolation Kit (Miltenyi Biotech). Cells were counted and sus-
pended in 40 µl of MACS buffer, before adding 10 µl of relevant antibody cocktail and
incubating at 4°C for 10 min, after which the protocols diverge.
• Na¨ıve: cells were washed in 20 ml of MACS buffer, spun down and supernatants
removed. Cells were then resuspended in 80 µl of buffer before adding 20 µl of
microbeads, before mixing and incubation at 4°C for 15 min. Another wash with
20 ml of MACS buffer followed, before cells were spun down and supernatants
removed. Sorted cells were resuspended in 500 µl of buffer.
• Memory: 30 µl MACS buffer was added, followed by 20 µl of microbeads, before
mixing and incubation at 4°C for 15 min. Cells were then washed in 20 ml buffer,
spun down and supernatants were discarded. Sorted cells were finally resuspended
in 500 µl buffer.
Cells underwent two rounds of negative selection to achieve greater purification,
which was assessed by flow cytometry. Staining was performed in PBS with 10% goat
serum. The following antibodies were used: CD3-FITC (Miltenyi), CD4-RPE (Dako),
CD45RO-PeCy7 (BD) and CD45RA-APC (BD). Cells were incubated with antibodies
at 4°C for a minimum of 30 min, before being washed and resuspended in a suitable
volume. Flow cytometry was performed on a FACS Calibur (BD Biosciences) and
analysed in FlowJo.
2.3.3 Poly-T RACE amplification
Rapid amplification of cDNA ends (RACE) was performed by addition of an adenosine
tail to cDNA followed by ampification using a poly-T containing primer. First, 5 µl of
cDNA was polyadenylated using terminal deoxytidyl transferase (Tdt, Promega). Final
concentrations were: 1X Tdt reaction buffer; 0.4 mM ATP and 30 U Tdt (Promega).
Reagents were mixed and incubated at 37°C for one hour, heat inactivated at 75°C for
15 min and purified using QIAquick PCR purification columns (Qiagen).
5 µl of poly-adenylated cDNA was then amplified using a combination of two differ-
ent poly-T containing oligonucleotides (αL2 and βL2), and the constant region primers
αRC1 and βRC1. Unequal representation of TRBJ genes from the two TRBD clusters
in the 454 data was observed, leading to the degenerate βRC1 oligonucleotide being re-
placed with an equimolar pool of two primers that specifically target each TRBC gene
(βRC1.1 and βRC1.2). This allows for greater control of the concentration of each
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desired oligonucleotide sequence in the mixture, and removes the additional unwanted
DNA species that would be produced in the original degenerate βRC1 formulation.
Final concentrations for the poly-T PCR were: 0.2 mM each dNTP; 0.5 µM each
primer; 1 U Phusion polymerase (New England Biolabs, or NEB) and 1X HF buffer.
Due to the reported strong 3’→5’ endonuclease activity of Phusion, all reagents save
enzyme and buffer were mixed separately first, followed by rapid addition of a mixture
of enzyme in buffer on ice immediately before commencing thermal cycling, APMI.
Thermal cycling conditions were: 98°C, 3 min; 54°C, 1 min; 72°C, 1 min, then 35 to
40 cycles of: 98°C, 15 sec; 70.7°C, 30 sec; 72°C, 20 sec, before final extension at 72°C,
5 min. Amplified TCRs were then selected and purified by gel extraction from 1-2%
agarose gels. Amplicons for 454 sequencing were sent to the Wellcome Trust Sanger
Institute for sequencing on the GS FLX instrument.
2.3.3.1 Poly-T RACE MiSeq library preparation
A second PCR was developed to add the required Illumina sequences specifically to the
ends of the poly-T amplicons to allow processing on the MiSeq. Sequencing Primer 1
and 2 (SP1 and SP2) – the binding sites which define the start of the two sequencing
reads – must reside immediately adjacent to amplicons sequences. P5 and P7 sequences
are required immediately adjacent to the sequencing primers, as these bind to the flow-
cell bound oligonucleotides to facilitate bridge amplification. Therefore I designed a
set of primers to add each of these elements in one reaction by adding the innermost
primers at limiting dilutions: as the reaction progresses these should be outcompeted
by the higher concentration outermost primers, promoting the assembly of full length
amplicons. SP1 and SP2 were added to the constant regions and poly-T sequences re-
spectively with long primers SP1-N6-αRC1 or SP1-N6-βRC1.1+2 (where N6 represents
a random hexamer to augment nucleotide diversity), and SP2-pT. P5 and P7 elements
were then added to these by extension with long primers P5-SP1 and P7-X-SP2, where
X is a six-base index to allow sequencing of multiple samples. This index is read in
a separate read from a primer targeting the reverse complement of the SP2 sequence.
Finally, two primers at the highest concentration target the outermost sequences: a 3’
shortened version of P5 (P5s, or short) and P7. α and β reactions were carried out
separately.
Final concentrations were: SP1-N6-α/βRC1 and SP2-pT, 0.05 µM; P5-SP1 and
P7-X-SP2 0.1 µM; P5s and P7, 0.5 µM; 0.2 mM each dNTP, 1 U Phusion and 1X HF
buffer (enzyme in buffer added last). Thermal cycler steps were: 98°C, 3 min; 3 cycles
of 98°C for 15 sec, 56°C for 45 sec, 72°C for 45 sec; then 17 cycles of: 98°C, 15 sec; 69°C,
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30 sec; 72°C, 30 sec; final extension at 72°C, 5 min. The first three cycles with lower
annealing temperatures allow annealing of homopolymer RACE sequences, which have
low melting temperatures. Amplified TCRs were purified by gel extraction from 1-2%
agarose gels and processed for MiSeq sequencing.
2.3.3.2 Cloning
Initial clones produced to test the efficacy of the Tdt-RACE PCR were produced
through blunt-ended cloning of PCR products into pUC19. Plasmid DNA was lin-
earised using the restriction enzyme SmaI and dephosphorylated using calf intestinal
alkaline phosphatase (both NEB, APMI) to prevent recircularisation, before gel exci-
sion and purification. Phusion DNA polymerase produces blunt-ended products and
therefore required no further treatment post-purification. Ligation reactions using 2 U
T4 DNA ligase (Promega), 1X reaction buffer and varying ratios of purified insert and
linearised vector DNA were incubated overnight at 4°C. 10 µl of ligation mixtures were
used to transform 50 µl of α-Select Silver competent E. coli (Bioline). Ligation mixes
were added to bacteria (thawed on ice), before being briefly flick-mixed and incubated
on ice for 30 min. Cells were then heat-treated (42°, 30 sec), immediately cooled on ice
(2 min) and diluted in 1 ml antibiotic-free lysogeny broth (LB, Sigma-Aldrich) before
shaking at 37°C, 220 rpm for 1 hour. Cells were then spread on AIX LB agar plates
(0.1 g/ml ampicillin, 0.04 g/ml IPTG and 0.03 g/ml X-gal) and incubated overnight
at 37°C. Potential recombinants were selected by blue/white screening and digested to
check for the presence of inserts.
Clones generated to test for the correct incorporation of MiSeq elements were lig-
ated into pGEM-T-Easy (Promega) to allow TA-cloning, facilitated by amplification
using GoTaq polymerase (which produces amplicons with a single adenosine overhang).
Purified amplicons produced from the Phusion reaction were re-amplified using GoTaq.
PCR mixtures consisted of: 1X GoTaq Green buffer (Promega); 0.1 mM each dNTP;
0.2 µM of P5s and P7 primers; 0.5 mM additional MgCl2 and 2.5 U GoTaq DNA Poly-
merase (Promega). PCR mixtures were subjected to 35 cycles of: 95°C, 30 sec; 64°C,
30 sec; 72°C, 1 min, with a 5 min final extension. PCR products were gel-purified and
ligation into pGEM-T-Easy in an equivalent protocol as used above.
All plasmids were Sanger sequenced by the Wolfson Institute for Biomedical Re-
search DNA Sequencing Service at UCL4, using AB capillary sequencing technology.
Sequencing traces were processed using FinchTV (Geospiza); poor quality bases were
trimmed before analysis.
4Now defunct.
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2.3.4 Randomly barcoded V (BV) amplification
The BV srategy targets two more V genes than the simple V amplification protocol
(described in Section 2.3.2), while improving upon the MiSeq library preparation pro-
tocol developed for the poly-T RACE (Section 2.3.3.1). Long primers were designed
to add SP2 elements and random hexamers to four specific V genes: those targeted
in the simple V amplification, TRAV8-4 and TRBV12-3 (those used by Jurkat), and
TRAV21 and TRBV20-1 (which had both consistently appeared at high frequency in
previous experiments). These primers were used to peform a second strand exten-
sion on our cDNA, making double stranded DNA. A further extension reaction step
– which I refer to as a ‘third strand’ reaction – then uses long oligonucleotides to
add SP1 and random hexamer elements immediately downstream of the constant re-
gion sequence, allowing bidirectional sequencing through two random sequences, which
can be used as molecular barcodes. Two further PCRs are then performed, the first
adding P5 and P7 elements, the second amplifying to required concentrations. AMPure
XP bead purifications (Agencourt Bioscience) are performed in between each round of
DNA polymerisation using 1:1 bead:solution ratios to remove primers (APMI), eluting
into 30 µl of water each time. These purifications make use of the propensity of high
concentrations of polyethylene glycol (PEG) and salt to flocculate DNA (106) onto
carbonyl-coated paramagnetic beads, allowing contaminants or low-molecular weight
DNA to be removed by washing.
5 µl of cDNA was carried into 25 µl separate α or β second strand reactions, using:
0.2 mM each dNTP; 0.5 µM of each chain-specific primer pair (SP2-N6-TRAV21 and
SP2-N6-TRAV8-4 or SP2-N6-TRBV12-3 and SP2-N6-TRBV20-1); 0.4 U Phusion, and
1X HF buffer. Reactions underwent the following program: initial denaturation at
95°C, 3 min, followed by a slow ramp to 80°C, 10 sec and another slow ramp to 58°C,
45 sec, and final extension for 5 min at 72°C. Slow ramping involves descending at
0.5°C/sec; this slow descent aims to encourage optimal annealing of the V region specific
component of the long oligonucleotides to anneal at the highest possible temperature,
minimising the chance of off-target priming. After purification, all 30 µl of double-
stranded DNA is carried into 50 µl third strand synthesis reactions. These use the
same reagent concentrations and cycling conditions as the second strand reaction, save
that the SP2 primers are replaced by SP1-adding primers SP1-N6-I-αRC1 or SP1-N6-I-
βRC1.1+2, where ‘I’ represents a second indexing sequence, allowing greater flexibility
when planning sample multiplexing.
All of the purified third strand DNA undergoes ‘PCR1’ to add the P5 and P7
elements: 0.2 mM each dNTP; 0.5 µM of each primer (P5-SP1 and P7-X-SP2) and
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1 U Phusion in 1X HF buffer. Mixtures were then thermally cycled: initial denaturation
occurred at 95°C for 3 min, before ramping slowly to 69°C, 15 sec, and extended at
72°C, 1 min, before 3 cycles of 98°C, 10 sec to 72°C, 1 min. Final extension was at 72°C
for 5 min. DNA was purified and all carried into the final reaction, ‘PCR2’, to amplify
sufficient product for sequencing. Reaction conditions were the same as in PCR1, save
that the primers used were just the outermost sequences, P5s and P7. PCR program
began with initial denaturation at 95°C, 3 min, before 22 cycles of: 98°C, 10 sec; 69°C,
15 sec; 72°C, 40 sec, before final extension at 72°C for 5 min. Samples thus underwent a
total of 26 cycles of PCR. Samples were then bead purified before dilution to equilibrate
concentrations.
2.3.5 Barcoded ligation RACE (BLR) amplification
For each donor sequenced using the BLR protocol, 500 ng of RNA was reverse tran-
scribed and purified using MinElute RNeasy columns (Qiagen). Half of the purified
solution (5 µl of the 10 µl produced) was used in each experiment. The SP2 sequence,
followed by a hexamer of random bases, was ligated to the V region end of the cDNA.
T4 RNA ligase was used to ligate single stranded oligonucleotides to cDNA in a 30 µl
reaction mix containing: 1X T4 RNA ligase buffer; 20 U T4 RNA Ligase 1 (NEB), 0.33
mM dATP; 25% (w/v) PEG 8000; 1 mM hexamine chloride; 0.1 mg/ml acetylated-BSA,
and 0.33 µM SP2-6N ligation oligo. Master mixes were vortexed for several seconds to
ensure mixing with the PEG, added to cDNA and mixed thoroughly. Ligations were
incubated for 23 hours at 16°C, heat inactivated for 10 min at 65°C, diluted in 70 µl
water and bead purified.
All purified ligated DNA was subjected to second strand synthesis, using just the
SP2 sequence as the priming target. Final concentrations in the 50 µl reactions were:
0.2 µM of each dNTP; 0.5 µM SP2 primer and 1 U Phusion, in 1X HF buffer. The
single strand extension program was the same as that described for the BV protocol
in Section 2.3.4. Purified double-stranded samples were split in two and each half
underwent either α or β chain specific third strand synthesis. Reaction conditions
were the same as the second strand reaction, except the SP2 primer was replaced with
either SP1-6N-I-αRC1 or SP1-6N-I-βRC1. PCR1 and PCR2 were then performed to
add flowcell-binding elements and amplify as in Section 2.3.4, with the exception that
PCR2 instead contained 23 instead of 22 cycles. BLR samples thus underwent a total
of 27 PCR cycles. Samples were purified before normalisation.
Blood samples from HIV patients for BLR sequencing were obtained by the re-
search nurse team based in the Mortimer Market Centre Clinic, Bloomsbury, and RNA
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extraction was performed by Dr. Eleanor R. Gray. Samples from healthy donors were
obtained and had RNA extracted by Drs. Nandi Simpson and Jennifer Roe. RNA in
both cases was extracted from approximately 2.5 ml of whole peripheral blood lysed in
Tempus tubes (Life Technologies), APMI.
2.3.5.1 Flow assisted cell sorting
PBMC from two healthy donors were sorted into CD4+ and CD8+ populations by
FACS. Cells were isolated through density-gradient centrifugation using Ficoll-Paque
PLUS (GE Healthcare Lifescience) and incubated in 10% goat serum at 4°C for 30
min to block Fc-receptors. Cells were subsequently stained with CD8-FITC, CD3-PE,
CD4-PerCp-Cy5.5 (BD Biosciences) and LIVE/DEAD fixable far-red dead cell stain
(Life Technologies) APMI. CD3+CD4+CD8- and CD3+CD8+CD4- T-cells were sorted
on a BD FACS Aria machine (BD Biosciences). 7.2× 106 CD4+CD8- cells and 6× 106
CD8+CD4- T-cells were lysed in RLT buffer (Qiagen) prior to RNA extraction. Cell
sorting was performed by Dr. Theres Oakes, at the UCL Flow Cytometry Core Facility.
2.3.5.2 HIV patient criteria
Adult HIV+ HAART-naive patients due to start treatment imminently were recruited
to the study. Exclusion criteria included: febrile or AIDS-related illness; tumours;
coinfection with Hepatitis B or C; immunomodulatory therapy, or recent vaccination.
Interruption or adverse reactions to ART were further grounds for exclusion.
2.3.6 MiSeq operation
Apart from initial libraries amplified using the poly-T protocol (which were sequenced
commercially via UCL Genomics), all libraries were sequenced by myself. Purified
amplified samples were first normalised to a suitable concentration. Concentrations
were assessed using a Qubit fluorometer, using the dsDNA HS Kit (Life Technologies).
Approximately 2 ng of DNA per sample was then inspected on a Bioanalyzer using
the High Sensitivity DNA Analysis Kit (Agilent Technologies), allowing determination
of amplification success and peak band size. Amplicon length and concentration were
then used to normalise samples to 4 nM before pooling. Typically 10 to 12 amplified
samples (α and β samples from five to six donors) were pooled per run. MiSeq flowcells
were prepared as per Illumina’s instructions (107). Denatured libraries were loaded at
11-12 pM, using a 1% PhiX spike in. 2x250PE kits with version 2 chemistry were used.
Read quality was assessed using in-built MiSeq metric software in combination with
FastQC (108).
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2.3.7 Primers and indexes
2.3.7.1 Primer sequences
Primer Sequence
αRC2 GAGTCTCTCAGCTGGTACACG
βRC2 ACACAGCGACCTCGGGTGGGAA
αF1 AGCTTGGCAGCCACGTCTCTG
βF3 CCAATTTCAGGCCACAACTCC
αRC1 ACGGCAGGGTCAGGGTTCTGGATAT
βRC1 GGTGGGAACACSTTKTTCAGGTCCTC
αL2 TCACACAGGAAACAGCTATGACTTTTTTTTTTTTTTTTTTTTTTTVN
βL2 GTCATAGCTGTTTCCTGTGTGATTTTTTTTTTTTTTTTTTTTTTTVN
βRC1.1 GGTGGGAACACCTTGTTCAGGTCCTC
βRC1.2 GGTGGGAACACGTTTTTCAGGTCCTC
SP1-N6-αRC1 ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNNACGGCAGGGTCAGGGTTCTGGATAT
SP1-N6-βRC1.1 ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNNGGTGGGAACACCTTGTTCAGGTCCTC
SP1-N6-βRC1.2 ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNNGGTGGGAACACGTTTTTCAGGTCCTC
SP2-pT GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTTTTTTTTTTTTTTTTTTTTTTTVN
P5-SP1 AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTTCCGATCT
P7-X-SP2 CAAGCAGAAGACGGCATACGAGATxxxxxxGTGACTGGAGTTCAGACGTGTGCTCTTCCGATC
P5s AATGATACGGCGACCACCGAGATC
P7 CAAGCAGAAGACGGCATACGAGAT
SP2-N6-TRAV8-4 GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTNNNNNNTCATCGTCTGTTCCACCATATCTCTTCTG
SP2-N6-TRAV21 GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTNNNNNNAGACTTAATGCCTCGCTGGA
SP2-N6-TRBV12-3 GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTNNNNNNATGCCCGAGGATCGATTCTCAG
SP2-N6-TRBV20-1 GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTNNNNNNTTTGGTATCGTCAGTTCCCG
SP1-N6-I-αRC1 ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNNxxxxxxACGGCAGGGTCAGGGTTCTGGATAT
SP1-N6-I-βRC1.1 ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNNxxxxxxGGTGGGAACACCTTGTTCAGGTCCTC
SP1-N6-I-βRC1.2 ACACTCTTTCCCTACACGACGCTCTTCCGATCTNNNNNNxxxxxxGGTGGGAACACGTTTTTCAGGTCCTC
SP2-6N (ligation) [Phos]NNNNNNAGATCGGAAGAGCACACGTCTGAACTCCAGTCAC[SpcC3]
Table 2.1: Primer sequences used in the protocols described above. IUPAC nu-
cleotide codes used: ‘N’ = any base; ‘V’ = any base apart from T (A, C or G); ‘S’ = C or
G; ‘K’ = G or T. Variable bases for indexes are represented by ‘x’ (see Section 2.2). [Phos]
represents a 5’ phosphate group, to permit ligation with the 3’ hydroxyl group of the cDNA.
[SpcC3] = Spacer C3, a blocking moiety to prevent polymerisation of ligation oligonucleotides.
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2.3.7.2 Indexing sequences
Number P7-X-SP2 indexes SP1-N6-I-α/βRC1 indexes
1 ATCACG ATCACG
2 CGATGT CGATGT
3 TTAGGC TTAGGC
4 TGACCA TGACCA
5 ACAGTG ACAGTG
6 GCCAAT GCCAAT
7 CAGATC
8 ACTTGA
9 GATCAG
10 TAGCTT
11 GGCTAC GGCTAC
12 CTTGTA CTTGTA
13 AGTCAA TAGACT
14 AGTTCC ACACGG
Table 2.2: Index sequences used to multiplex samples. Note that the hexamer
index sequences (‘X’) in the P7-X-SP2 sequences are actually the reverse complement of
the equivalent standard Illumina indexes of the same number. This makes pooling libraries
with others easier (as it minimises the chance of sharing indexes) while maintaining the edit
distances between the sequences.
2.4 Bioinformatic analysis
2.4.1 General considerations
The bioinformatic work described in this thesis was almost exclusively run on a standard
work-range laptop computer, with a quad-core Intel i5 CPU (4×2.67GHz), with 7.6 GiB
of RAM, running 64-bit Ubuntu Linux. The majority of analyses were performed using
Python (v2.7.6) or R (v3.0.2) and custom scripts, while general text file exploration
and manipulation were performed on the command line using bash, awk or sed com-
mands. All manipulation of FASTQ data was performed using Biopython v1.63 (109).
Python was typically employed for any rearrangement- or sequence-specific analysis,
while R was used for plotting numerical features of whole files. The Python library
collections was regularly employed for storing TCR features, the difflib module
was used to compare sequences, and statistical analysis was achieved through a com-
bination of NumPy and SciPy libraries, with results plotted using Matplotlib. The
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R package lattice was additionally used in the production of heatmaps. Additional
sequence file manipulation was performed using the FASTX-toolkit (110). Schematics
were made and figures collated using Inkscape.
Unless otherwise stated, analyses are described in this section as they were applied
to the data produced using the BLR protocol, as this constitutes the majority of the
results of this thesis.
2.4.2 Demultiplexing BLR MiSeq data
High-throughput sequencing (HTS) machines produce data in FASTQ format. FASTQ
files are text files, where every four lines corresponds to a different sequencing read,
providing an identifier, the sequence, and quality data. Multiple samples are typically
processed on one run of a machine – or ‘multiplexed’ – by introducing sample-specific
index sequences prior to pooling and sequencing.
Data produced using the BLR protocol requires additional processing so that both
random hexamer sequences are present at known positions in the first read, to allow
identified TCRs to be linked to the barcode sequence when analysing a single read file.
This pre-processing occurs at the same time as demultiplexing, in one of two ways. The
earliest samples were first subjected to the standard Illumina demultiplexing procedure
that occurs by default on the MiSeq during FASTQ generation, which deconvolutes
samples based on their P7-X-SP2 index sequence. This produces two FASTQ files (one
starting from each end of the amplicon) for every P7-X-SP2 index used. A custom
script (named AddAllR2Hex) then pastes the random hexamer sequence (and asso-
ciatd quality scores) from the second read to the start of the first. This produces a
read where the first twelve bases are made up of the two random hexamers, followed by
the rest of the read, which could contain V(D)J information. These reads can then be
further demultiplexed based on the presence of the relevant SP1-N6-I-α/βRC1 index
immediately downstream of the barcode, which was done using the grep command in
bash to pull out direct matches.
The second technique implemented (used on the majority of runs) involves simul-
taneously demultiplexing on both indexes, allowing complete control over index string
matching criteria. This method involves first obtaining FASTQ data for all three reads,
i.e. including the index read (which is not produced by default). This was achieved in
one of two ways, depending on which of the two MiSeq machines I had access to was
available. One of the machines had an altered configuration file which overrode various
default settings, making the MiSeq output the index read simultaneously with the two
sample reads. To obtain the index read for data from the other machine, the entire
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output run folder (containing the raw base-call data) was copied and reprocessed us-
ing the Illumina software CASAVA/bcl2fastq to produce all three FASTQ files. All
three reads could then be simultaneously processed to enable the production of reads
containing: both random hexamer sequences (to become the barcode), both hexamer
indexing sequences (to allow demultiplexing) and the rest of the read one sequence
(containing the V(D)J information). A single script (DualIndexDemultiplexing)
scrolls through all three FASTQs simultaneously, moving the relevant sequences to
known locations in one output read, which is then written to a specific file based on its
sample-specific index sequence.
Demultiplexed reads can then be analysed for TCR rearrangements, while still
retaining any barcode information without needing to refer to multiple files.
2.4.3 TCR assignment and error-correction
Our group has previously released software called Decombinator, which rapidly scans
HTS data for recombined TCR sequences (111). ‘Decombined’ data stores TCR rear-
rangements as a five-part classifier, where the fields detail which V and J genes were
used, how many deletions there were from each of these genes, and the nucleotide
sequence (or ‘insert’) between the remaining ends of the two genes. As described in
Chapter 5, a modified version of Decombinator called ‘verbose Decombinator’
(vDCR) was developed and employed in the work of this thesis. vDCR was built on
Decombinator version 1.4, and incorporates additional error-filtering capabilities and
outputs additional read information for downstream processes. Note that the most
recent release of Decombinator (v2.0) incorporates a number of the general improve-
ments made in vDCR, and thus can be considered broadly functionally equivalent (112).
An extended set of V and J gene tags (relative to the standard Decombinator tag
set) was used in this work.
Rearrangements detected by vDCR are output in ‘n12’ file format. If the libraries
were produced using either the BV or BLR protocols – which introduce hexamers
of random nucleotides to both ends of each cDNA molecule prior to amplification
– then the additional information contained in the n12 file can be used for further
data correction. By using the 12 random nucleotides as a barcode of unique cDNA
molecules, comparison of TCR sequences sharing barcodes allows removal of those
containing errors. Furthermore, counting the number of barcodes associated with an
error-corrected TCR (after clustering to remove probable errors in the barcode) provides
an estimate of cDNA frequency. Barcodes were clustered if they possessed an edit
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distance of three or fewer to all other sequences in that cluster. Error- and frequency-
corrected data is said to be ‘collapsed’, therefore the script that performs this function
is named CollapseTCRs. The development of this process is described in greater
detail later, in Chapter 5.
By default the ‘OmitN’ option in the vDCR code is set to ‘False’ (unlike in standard
Decombinator), thus allowing reads through even if they contain ambiguous base
calls. Reads that contain Ns in their inter-tag region (or barcode sequence, where ap-
plicable) are instead filtered after Decombining by using bash/awk commands. Reads
with erroneously long inter-tag distance greater than 130 nucleotides were removed at
the same time. If the data was not generated using a barcoded protocol, then the
following command was used, which only filters out reads with ambiguous base call in
the inter tag region (the seventh field of the n12 files):
awk ’{FS=`, `} {if ($7˜/N/){next} else{ if (length($7) < 130){print}}}’ \
FILE.n12 > temp && mv temp FILE.n12
If the data had been generated using a barcoded protocol, then the command was
altered to also filter out n12 entries containing an ambiguous base in their barcode field
as well (the ninth field), as this would impact upon the clustering process:
awk ’{FS=`, `} {if ($7˜/N/ || $9˜/N/){next} else{ if (length($7) < 130) \
{print}}}’ FILE.n12 > temp && mv temp FILE.n12
Note that in the BV analysis of the cord blood data, low-frequency rearrangements
found to not be using the primed V regions (as a result of off-target priming or misas-
signment) were similarly filtered out prior to further analysis.
2.4.4 TCR productivity and CDR3 amino acid determination
TCR productivity – i.e. the likelihood of producing polypeptide chains that could func-
tionally serve in a surface-expressed receptor complex – was determined for raw or
collapsed Decombinator identifier files. This is achieved by inferring the complete nu-
cleotide sequence, determining the reading frame, translating the sequence and search-
ing for the presence of particular TCR motifs in the appropriate locations. These
tasks are all performed by a single Python script (CDR3ulator), which makes use of
functions adapted from equivalent scripts written for similar purposes by other group
members Dr. Niclas Thomas and Katharine Best. In order to be considered productive
a TCR classifier must produce a sequence that meets the required criteria:
• Sequences must be in frame.
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– This is determined by the number of nucleotides from the first base of the
V region to the last base of the J region minus one being a multiple of three
(as the last nucleotide of the J region contributes to the first codon of the
constant region).
• Sequence must contain no stop codons.
– Using Biopython, this equates to discounting any translated sequences
that contain the ‘*’ character.
• Sequences must contain the conserved CDR3 cysteine residue.
– This is the second conserved cysteine residue that marks the start of the
CDR3 sequence (113).
• Sequences must contain the conserved FGXG motif.
– This is the motif that ends the CDR3 sequence (113). Note that in human
αβ TCR chains a number of germline J genes predicted to be functional
diverge from this motif by one residue; in order to be correctly assigned each
gene must contain the appropriate motif.
Productive and non-productive reads are then written into separate files. In this
thesis, I have used the standard CDR3 definition that runs inclusively from the second
conserved cysteine to the phenylalanine in the conserved FGXG motif. Note that
these statuses are predicted, and may not reflect the true productiveness of a given
cDNA. It is possible that transcripts assigned as productive contain non-sequenced post-
transcriptional modifications that prevent their function, or that some non-productive
sequences are able to contribute to some biological function.
2.4.5 Sorting of poly-T homopolymer containing reads
Data produced using the poly-T RACE protocol (described above in Section 2.3.3) were
sorted into reads that did or did not contain poly-T sequences in their 5’ (i.e. those which
were sequenced in the same orientation as transcription or not) through use of a cus-
tom Python script (SortToPolyTREGEX). This script makes use of the re package to
search for various regular expressions (regex) that look for the presence of poly-T tracts.
Regex analysis is required as polymerase slippage and homopolymer-induced error re-
sults in exact string matching of long homopolymers being unfeasible. Three regexes
were employed: ‘TTTTTTTT’, ‘TT+[ACGN]T+’ and ‘TT+[ACGN]T*[ACGN]T+’.
The search was configured to detect any poly-T tract of eight or more bases in the first
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70 basecalls of a read, making allowances for up to two non-T bases to be included.
Reads were sorted into one of two output files depending on the presence of poly-T
homopolymers being detected in their 5’.
2.4.6 Splicing analysis
2.4.6.1 Mapping of reads to TCR germline loci
Alternative splice events were detected by mapping reads to the germline genomic
TRA/D and TRB loci. The TRA/D germline sequence consisted of nucleotides 3080000-
4030000 from the GRCh37.p5 primary assembly of the Homo sapiens chromosome 14.
The TRB sequence used was the NG 001333.2 version of the curated locus sequence
from chromosome 7, which is 684973 bp long (accession number 114841177).
Reads were mapped against these references using the RNA sequence aligner STAR
(114). Bam files produced by STAR (v2.3.0) were sorted and indexed using SAMtools
(v0.1.19) (115), and visualised using the Broad Institute’s Integrative Genomics Viewer
(IGV, v2.3.32) (116). Mapped reads were visually compared against mapped germline
sequences for L-PART1, L-PART2 as well as V and J genes, downloaded from IMGT/GENE-
DB (19).
2.4.6.2 Quantification of intra-V gene splicing events
Having identified intra-V splice sites through manual inspection of one donor’s reads,
these sequences were searched for in a number of donors. Paired-end reads were first
merged using FLASH (117), which finds those which overlap in their 3’ sequences,
reverse complements one and combines them, producing reads with the longest possible
coverage over the V region. This process typically merged around one third of all reads
per file of data produced using the BLR protocol.
Merged reads were then analysed with a single Python script (SpliceAnalysis)
that performed a number of tasks, including: collapsing, to reduce errors; Decombining
and translation, to assess the presence and productive status of rearrangements, and
checking for the presence of previously identified intra-V splice events. Collapsing of
merged reads occurs slightly differently to collapsing barcoded Decombinator out-
put, as it is the whole read that is being collapsed, not just the section that has been
determined to cover the rearrangement. As before, the most common sequence within
a barcode is taken as the likely-actual sequence, and any others but error-containing
PCR-descendants. Only barcodes with a minimum of three separate reads are consid-
ered. If there is no sequence within a barcode that is more prevalent than the others,
then a consensus sequence is created by taking the most common nucleotide at each
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position of each equivalent read: if two or more nucleotides are equally present at a
position then that barcode is ignored. All barcode sequences shared by a particular
corrected sequence are then clustered as in CollapseTCRs to estimate the frequency
of sequences. Corrected sequences were then inspected for rearrangements using the
core functions of vDCR. The original, published V and J gene tag set was used, as these
tend to lie closer to the recombining edge. Corrected sequences with rearranged TCRs
are then translated by inference from the Decombinator classifier and predicted pro-
ductivity is recorded. Amino acid sequences are then also translated from the complete
actual sequence (not that inferred from the classifier). Correct reading frames were de-
duced by finding the frame that contains the amino acids of the constant region covered
by the RC1 primer used during amplification: ‘IQNPDPA’ for TRAC5, ‘DLKNVF’ for
TRBC1 and ‘DLNKVF’ for TRBC2. The productiveness of the transcript can therefore
be inferred from the whole sequence itself, i.e. whether there is an in-frame start codon
relative to the required constant region residues, and the absence of an interrupting
stop codon. Sequences were also searched for the exact string matches of splice events
as determined from the mapping described in Section 2.4.6.1. All findings are input
to a dictionary, recording for a given corrected transcript sequence: its frequency; the
presence of a rearranged TCR; the predicted CDR3 (or criteria for being deemed non-
productive); the actual open-reading frame of the complete sequence, and whether or
not it contains any identified intra-V splice events.
2.4.7 Calculation of diversity and sharing values
2.4.7.1 Gini index
The Gini index is a measure of inequality or dispersion of a distribution, often employed
in economics to represent the distribution of wealth in a system. Gini indexes are
calculated in reference to a Lorenz curve, where the proportion of resource allocation
is plotted as a function of the proportion of the population (Figure 2.1):
G =
A
A+B
Gini index values can range from zero, representing total equality or maximum
dispersion (e.g. all money is shared equally) to one, representing total inequality (e.g.
5This sequence actually starts from the second amino acid of the constant region: the last nucleotide
of the J gene starts the first codon of the constant region, and TRAJ genes do not all end in the same
nucleotide, thus after splicing the first codon of the constant region can encode one of four different
amino acids.
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Figure 2.1: Gini index calculation from the Lorenz curve. The Gini index is defined
as the ratio between the area under the Lorenz curve (LC) and the total area, under the line
of equality (LE, or perfect distribution line).
one entity has all of the money). Gini indexes were calculated using the ineq library
in R.
2.4.7.2 Shannon entropy
Shannon entropy is a measure borrowed from information theory, where it is used to
quantify the ‘entropy’ of a system. It can also be considered to be measuring either
the uncertainty or information content, where higher entropies correspond to more
uncertainty or information. Consider a comparison of a fair dice roll and a fair coin
toss: there is more uncertainty as to the output of the die than the coin, as there are
more options (more entropy). The greater array of possible values produced from an
equal number of rolls compared to tosses similarly could contain more information (X6
as opposed to X2). When Pi is the probability of instance i occurring in a distribution
(and b is the base of the logarithm), the Shannon entropy is defined as:
H = −
∑
i
Pi logb Pi
Shannon entropies were calculated using the entropy library in R, using the base
2 logarithm to produce output in bits.
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2.4.7.3 Jaccard index
The Jaccard index is a normalised measure of sharing between two sets of items. It is
defined as the size of the intersection of those two sets (i.e. how many unique items are
found in both) divided by the size of the union (how many different unique items are
found in total between the two sets):
J(A,B) =
|A ∩B|
|A ∪B|
In this thesis, Jaccard indexes were calculated using a custom function in R, using
the default functions intersect and unique.
2.4.7.4 Jensen-Shannon divergence
The Jensen-Shannon divergence (JSD) value is a modification of the Kullback-Leibler
divergence (KLD) – to make it symmetric and produce finite values – that relates to
the amount by which two distributions (P and Q) differ:
I(P ||Q) = 12
[
D
(
P || P +Q
2
)
+D
(
Q|| P +Q
2
)]
Here D represents the KLD using the base 2 logarithm, defined as:
D(P ||Q) =
∑
i
P (i)log
P (i)
Q(i)
The KLD is therefore the logged difference between distributions P and Q, using
P as the expected distribution. By taking the average of KLDs calculated in either
orientation, the measure becomes symmetric. In this work, JSD was calculated in
Python using a function written by Jonathan Friedman (118).
2.5 Commitment to open science
I adhere to the principles of open science, under the expectation that verification, re-
production and proper dissemination of research can only be properly achieved through
adequate sharing of the processes and results involved. Accordingly, the following com-
ponents of the content of this thesis have been made publicly available.
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2.5.1 Data deposition
The vast majority of the raw sequence data produced and analysed in this data has been
uploaded to the NCBI Sequence Read Archive (SRA). The SRA accession numbers of
these datasets are:
• Simple V amplification HiSeq data: SRP055031
• Poly-T RACE 454 data: SRP055040
• Barcoded V MiSeq data: SRP055080
• Barcoded ligation RACE MiSeq data: SRP045430
2.5.2 Source code
The scripts required for the standard analysis of TCRs from high-throughput sequenc-
ing data obtained using these protocols can be downloaded from a freely accessi-
ble GitHub repository at https://github.com/JamieHeather/tcr-analysis (119). This
repository contains vDCR, CDR3ulator, the extended tag sets as well as the associ-
ated demultiplexing and basic plotting scripts.
Another repository, available from https://github.com/JamieHeather/ThesisScripts
was generated to contain a sample of the more specific analyses that were used during
this thesis. In addition to the scripts listed in bold in preceding sections, this repository
also contains scripts that:
• Randomly draw a given number of sequences (either DCR classifiers or CDR3s)
from a larger file, for the purpose of size-matching data for fair comparison
(SizeMatch and CDRSizeMatch)
• Construct FASTQ files from the inter-tag region data contained in n12 files, and
assess the average quality score and converted error probabilities (FastqInterTag,
PrintTotalAvgQuals and PrintErrorProbabilities)
• Take two DCR index files and output a comma-delimited table, giving the propor-
tional frequency of each TCR sequence in both of the two files (ProportionPrePlot),
allowing for convenient correlation measurements
• Quantify and compare the presence of published TCRs sequence in multiple sam-
ples (HIVPublished CDR3s and InvariantTCR)
47
2.5 Commitment to open science
• Measure TCR repertoire population level differences across multiple samples,
such as publicness, translational convergence and similarity of TCR gene usage
(Publicness, HIVTranslational Convergence and LigRaceJSDs)
• Quantify the presence of certain genes or subsequences (GeneUsage and FindDs)
• Mix TCR classifiers from multiple subsets to generate in silico simulated reper-
toires of mixes populations (HIVCD4 CD8 Mixing CDR3s)
Note that the sequences of invariant and antigen specific TCRs harvested from the
literature are contained within the HIVPublished CDR3s code.
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3Exploring healthy T-cell receptor
repertoires
3.1 The global TCR repertoire at steady state
In this section I explore the data generated from sequencing ten healthy donors’ whole
peripheral blood repertoires using the barcoded ligation RACE strategy (or ‘BLR’)1.
In these experiments a fraction of RNA extracted from a 2.5 ml sample of whole blood
served as the template for reverse transcription, TCR amplification and sequencing.
Sequences produced were analysed using Decombinator, the TCR analysis software
developed in our group, and further error-corrected using CollapseTCR. The error-
corrected TCR classifiers produced by Decombinator (‘DCRs’) – which are equivalent
to unique nucleotide sequences – are the basis for the following analyses.
3.1.1 Clonal distribution of the healthy TCR repertoire
The first aspect of the repertoire considered is its basic clonal composition. The dis-
tribution of TCR rearrangement frequencies is an intrinsically difficult property to
visualise, as the vast majority of unique DNA recombinations – 50 to 80% – only occur
once in a given sample, while a small fraction of sequences are found repeated tens,
hundreds, or even thousands of times (Figure 3.1A). This produces a characteristic ‘L’
shaped distribution, which makes the data somewhat difficult to interpret. By plot-
ting the logged rank (with the most common rearrangement as rank one) against the
logged frequency (Figure 3.1B) we observe an approximately linear relationship be-
tween the two (at least for sequences with more than five copies), indicating that a
given sequence will be more frequent than the next most common sequence by a fixed
proportion. Thus there are a small number of highly frequent rearrangements, and a
large number of sequences that only occur very rarely in these samples.
The frequency distribution of different TCR chains relates to another property
of a repertoire, that of diversity. This is thought to be a very important repertoire
characteristic, as the number of different types of antigen receptor in a system should
1The development of this protocol, and all others, is covered in detail later in Chapter 5.
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relate to how many antigens that system can respond to. TCR receptor diversity can
be measured in many different ways (120); in this thesis I make use of two indexes
of diversity borrowed from other fields. The Gini index is a measure of inequality (or
unevenness) frequently used in economics, as it permits an overview of the distribution
of a resource such as wealth. For example, a Gini index value of one represents total
inequality, in which all of the wealth belongs to one entity, while a Gini index of zero
represents total equality, in which all entities possess an equal share of wealth (121).
With respect to TCRs, Gini index values of zero would correspond to all rearrangements
being equally present in a sample, and as oligoclonality increases – i.e. as subsets of
sequences began to become more common and dominate the repertoire – values would
tend towards one. Figure 3.1C shows that the α and β repertoires of healthy donors have
Gini indexes towards the low end of the scale, indicative of a generally even distribution
structure. The other measure employed is Shannon entropy, borrowed from information
theory. Shannon entropy is a more complicated measure that incorporates both aspects
of diversity – the number and frequency of different species – to produce a value that can
be interpreted as the information content or complexity of a system (122). More species
(or TCRs) being present increases the total information content, as does increasing the
evenness. Thus the higher the Shannon entropy the more information content a system
has, and the harder it is to predict to what species additional observations are likely
to belong. Conversely, a distribution where all species are the same has no information
Figure 3.1 (preceding page): Clonal composition of the healthy human αβ TCR
repertoire. A: Percentages of each of the ten donor’s repertoires that are accounted for by
rearrangements of different frequencies (i.e. how many times that rearrangements appears).
B: Logged rearrangement rank versus logged frequency reveals a linear distribution for all but
the lowest frequency sequences. C: Gini indexes of the distribution of unique rearrangements
of healthy donor repertoires; dotted lines connect the α and β values of the same donor.
There is no significant difference between the paired α and β Gini index values (p-value
= 0.38, Wilcoxon signed rank test). D: Shannon entropies of the healthy donor samples.
There is no significant change between the αβ paired Shannon entropy values (p-value =
0.08), although the majority of donors tend to have greater values in their β chains. E: The
proportion of unique rearrangements (i.e. ignoring the frequency of each) that are predicted
to be productive (P) or non-productive (NP). F: The proportions of the criteria by which
the NP rearrangements shown in E were determined to be so. OOF = out-of-frame; OOF*
= out-of-frame, also containing a stop codon; IF* = in-frame but containing a stop codon; C
= lacking the conserved cysteine residue at the start of the CDR3. Note that the translation
software only generates sequence up until the end of the J region, thus OOF transcripts
without stop codons in this analysis could contain stop codons further downstream in the
sequence. All error bars indicate standard deviation around the mean value calculated using
all ten donors.
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per se, and thus would have a Shannon entropy of zero. Figure 3.1D shows the Shannon
entropies of the healthy donor repertoires, showing that typical healthy repertoires (of
these sample sizes) possess in excess of twelve bits of information.
V(D)J recombination will not always produce a recombined gene that is capable
of being translated into a functional polypeptide. Due to the random nature of the
recombination process, rearrangements may fail to be in the correct frame downstream
of the junction, or contain premature stop codons, preventing translation of valid TCR
chains. When developing the software to translate TCR nucleotide sequences and
extract CDR3 regions, I counted TCR sequences that are expected to fail to produce
a valid CDR3, and are thus considered non-productive. When considering unique
rearrangements (i.e. ignoring how prevalent each rearrangement is) I observed that on
average 16% of all α chain rearrangements and 2.6% of β were non-productive (Figure
3.1E). Examination of these non-productive sequences reveals that the majority of them
are out-of-frame and contain stop codons (Figure 3.1F). A small number are in-frame
yet contain a stop codon, and a similar number lack the conserved cysteine residue
in the V gene which marks the N-terminal end of the CDR3 region. Note that there
was a similar requirement for detection of the FGXG-based motif in the J gene that
marks the C-terminal CDR3 end, however no sequences were deemed non-productive
due to lacking this sequence. This difference is likely due to the fact that the conserved
cysteine in the V is much closer to the recombining edge than the FGXG is in the J,
and thus is more likely to be lost through base deletion during recombination.
3.1.2 V and J gene usage
Another important feature that will define a given repertoire is the frequency with
which different V and J genes are used. Figure 3.2A-D shows the mean proportional
usage of all the different TRAV, TRAJ, TRBV and TRBJ genes in our ten healthy
donor repertoires respectively. The distributions are non-uniform; some genes are used
in a far higher proportion of rearrangements than others. Figure 3.2E shows that the
more a given V or J gene is used, the more deviation there is between how much
different individuals use it.
During this analysis I observed a large number of unexpected recombination events.
The first class of unexpected rearrangements involved detection of supposedly TCR
δ chain specific V genes rearranged onto α chains, using the α constant region in
combination with α chain J genes. Despite α and δ V genes sharing a common pool of V
genes (Figure 1.2) it is currently reported that not all genes can be used by either chain:
of the eight V regions known to contribute to δ chain receptors, five are also known
52
3.1 The global TCR repertoire at steady state
A
B
D E
C
53
3.1 The global TCR repertoire at steady state
to participate in α chain production (termed ‘TRAV/DV’ genes) (123). According to
IMGT, the three remaining genes – TRDV1, TRDV2 and TRDV3 – are supposedly
exclusively limited to δ chain rearrangements. However as Figure 3.2 demonstrates, all
three can be found in α chain recombinations, even present at greater amounts than
some of the officially-recognised TRAV genes. In order to confirm these findings, I also
looked for such sequences in the only other publicly available high-throughput α chain
data set: Figure A.1 in Appendix A shows that rearrangements using all three genes
can also be found among these independently generated sequences.
The second class of unexpected TCRs are those that do not use genes designated
as functional. For various reasons, several of the genes in the germline receptor gene
loci are predicted to either not participate in rearrangements, or not be able to encode
working polypeptides if they do (124). These non-functional germline genes come in
two varieties: open-reading frame genes (ORFs), or pseudogenes. ORFs are predicted
to not participate in rearrangements due to alterations in regulatory sequences, such
as splice sites or recombination signal sequences, or in conserved amino acid sequences
(such as the cysteine and phenylalanine residues that bound the CDR3 region), while
pseudogenes are those that contain stop codons or frameshift mutations. However ex-
amples of both V and J ORFs and pseudogenes can be found for both TCR chains in the
healthy donor data, with the exception TRBJ (which only has one such gene, a pseudo-
gene). Some of these genes account for a considerable proportion of the repertoire, such
as TRAJ35 and TRAJ58 (Figure 3.2C) or TRBV21-1 and TRBV23-1 (Figure 3.2D),
approximately occurring more frequently than one in every 500 sequences.
In addition to monitoring how frequently each V and J gene appears, I also measured
how frequently each combination of V and J gets used across our healthy donors. The
mean frequencies and standard deviations are shown for α and β in Figures 3.3 and
3.4 respectively. In terms of average α chain rearrangements (Figure 3.3A) most V-
J combinations account for small, roughly equivalent proportions of the repertoire,
with one particular V-J pair – TRAV1-2 - TRAJ33 – being far more prevalent than
any other. However comparison with the standard deviation of those averages (Figure
3.3B) reveals an increased number of mid-level hot-spots, indicating that at least in
some donors certain V-J combinations are used preferentially. β chain VJ pairing shows
Figure 3.2 (preceding page): V and J gene usage in healthy human αβ TCR
rearrangements. Mean proportional usage of the different genes for TRAV (A), TRAJ
(B), TRBV (C) and TRBJ (D) in the ten healthy donors. F, ORF and P stand for func-
tional, open-reading frame and pseudogene genes respectively, as described above. Error bars
indicate standard deviation.
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Figure 3.3: V and J gene pairing in healthy human α TCR rearrangements.
A: Heat-map showing the mean frequency with which the different α chain V and J genes
appear together in rearrangements, averaged across our ten healthy donor samples (taking
the frequency of each rearrangement in each donor into account). B: Heat-map showing the
standard deviation of the averages in A.
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Figure 3.4: V and J gene pairing in healthy human β TCR rearrangements.
A: Heat-map showing the mean frequency with which the different β chain V and J genes
appear together in rearrangements, averaged across our ten healthy donor samples (taking
the frequency of each rearrangement in each donor into account). B: Heat-map showing the
standard deviation of the averages in A.
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a number of hotspots in usage, particularly at the convergence of specific V and J genes
which appear to be highly expressed relative to the others (e.g. TRBV20-1 - TRBJ2-
1), while standard deviations appear relatively lesser in comparison. The upper limit
of the scale for the α chain average proportions is more than twice as much as that
in β, indicating that the TRAV1-2 - TRAJ33 rearrangements account for a greater
proportion of the α repertoire than the most frequent β V-J pairs do in theirs.
3.1.3 TRBD detection and usage
The two human TRBD genes are both very short and highly similar (Table A.1, Ap-
pendix A) and subject to nucleolytic degradation from both ends, making their assig-
nation by the tag-based gene identification system of Decombinator2 not feasible.
I developed additional methods to ascertain what the measurable contribution of the
different D genes to β chain recombinations was, by searching the Decombinator
classifier insert string – the nucleotides sequence found between the end of the V gene
and the start of the J gene – for residual TRBD sequences. Figure 3.5A shows what
percentage of total rearrangements contain detectable sequences from either TRBD
gene. This search was performed multiple times, each time with an increased minimum
length of matching sequence required. By applying the same search to the inserts of
α chain rearrangements (which should not contain TRBD sequences except by chance)
we can get an estimate of the false positive rate. For example, if we look in β chain
data for matches of only five nucleotides or longer we observe that seemingly 70% of
reads contain TRBD sequences; however by the same criteria, almost 8% of α reads
appear to as well. As the threshold increases the rate of detection falls – as you would
expect, given that there will be fewer sequences of the required length due to nucleolytic
‘nibbling’ – along with the false positive α assignation rate. This method represents an
improvement in measuring TRBD usage over existing techniques, both in the inclusion
of false positive detection as well as the separation of different length matching; existing
published analyses often just use thresholds of five (125) or six (126, 127) nucleotides.
One previous study additionally reported the presence of low-frequency tandem
TRBD gene usage, producing VDDJ transcripts, which were detected both in their
own data (127) and a previously published dataset (77). Figure 3.5B shows the extent
of such rearrangements in our data. We see at least an order of magnitude less fusion
D-D usage than in the Liu et al report (an average 0.38% of rearrangements using a
threshold of six nucleotides, as opposed to the lower bound of 1.73% stated in their
2This system is discussed in detail later in Section 5.3.1.
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publication). This is likely due to the current analysis requiring exact sequence matches,
while that previously published allowed mismatches.
I also assessed the extent to which each TRBD gene associated with different TRBV
and TRBJ genes. Figure 3.5C and D show that despite large deviations, there are both
V and J genes which significantly pair more frequently with a particular β D gene. Of
particular note is the separation of TRBD-TRBJ gene pairing between the two different
TRBDJ gene clusters (Figure 3.5D). Despite pairing far less frequently with the TRBD1
cluster (TRBJ1-1 to TRBJ1-6, see Figure 1.1), TRBD2 does indeed pair with each of
the TRBJ genes at some level. Extending this analysis, Figure 3.5E quantifies the
contribution that each of the individual TRBD genes makes to the rearrangements
that have detectable D regions, and how long the sequence match is. The majority
of rearrangements with shorter D regions used TRBD1, while TRBD2 accounts for
a greater proportion of the longer matches. This is not unexpected: the germline
TRBD2 sequence is longer than TRBD1 (16 versus 12 nucleotides). Across all ten
donors we note that TRBD1 is cumulatively used more frequently, accounting for 64%
of all detectable TRBD usage. This is in contrast with a previous report of a more
equitable distribution (75). This value is likely to be extremely cohort-specific, given
that there is some evidence to suggest such patterns are influenced by both age and
sex (128).
Figure 3.5 (preceding page): TRBD detection and usage in healthy human TCR
β rearrangements. A: Mean percentages of total healthy volunteer β chain rearrange-
ments that contain exact contiguous matches to any TRBD gene sequences (see Table A.1,
Appendix A). TRBD search was performing using an increasing threshold for the shortest
sequence match to be counted. Each search was repeated using the α chain Decombinator
rearrangements of the same donors as a specificity control, as these should only contain
TRBD sequences as a result of non-templated nucleotide insertions and deletions. B: Mean
percentages of total β chain rearrangements that contain tandem TRBD sequences, i.e. both
a TRBD1 and TRBD2 sequence. C and D: Proportions of TRBV and TRBJ genes, respec-
tively, that are found in combination with particular TRBD genes, for those rearrangements
where one D gene was unambiguously assigned. E: The length distribution profiles for all
of the TRBD matches given a particular match length threshold. C, D and E were all
performed using a TRBD search with a minimum match length of six nucleotides. TRBD2
results include sequences that map to either allele (TRBD2*01 and TRBD2*02). All error
bars show standard deviation. Asterisks indicate significance by Wilcoxon rank sum tests: *
for p-values ≤ 0.05, ** for ≤ 0.01 and *** for ≤ 0.001.
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3.1.4 TCR sharing and publicness
An emerging aspect of TCR repertoire research is the extent to which different TCR
receptor sequences are shared between individuals. This phenomena is manifest at
multiple levels, from any two individuals sharing a certain proportion of their sequences,
up to so-called ‘public’ sequences, that are found across multiple individuals (129, 130,
131). I assessed the extent of such sequences in my healthy donor repertoire data using
several techniques.
I first adopted a TCR-centric view, and measured how many productive sequences
appear in what number of donors. This analysis was repeated at three levels of TCR se-
quence, considering: the nucleotide sequence level, represented by the Decombinator
classifier (or ‘DCR’); the CDR3 alone, and finally the CDR3 in combination with the
V and J genes used in that rearrangement (‘VJ-CDR3’). Figure 3.6A shows what we
might expect; as we increase the number of donors we find fewer sequences that are
shared across that many (for example, there are approximately 1 × 105 β chain DCR
sequences that appear exclusively in one donor, but only one sequence that is shared
by five donors). Therefore it may be more useful to consider ‘publicness’ as a scalar
rather than a binary property. There is a general trend among the different types of
sequence, where VJ-CDR3s are more public than DCR classifiers, and CDR3s are yet
still more public. This may be explained by the possible convergence between these
levels: multiple nucleotide sequences (DCRs) can encode the same VJ-CDR3, and the
same CDR3 can be made in multiple V-J gene contexts.
I next took a donor-centric view, by performing pairwise comparisons of every
combination of two donors and measuring by how much their repertoires overlap, using
the Jaccard index (Figure 3.6B). This was performed both on complete repertoire
Figure 3.6 (preceding page): TCR sharing and publicness of productive rear-
rangements. A: Publicness of productive TCR sequences in healthy human donor reper-
toires, i.e. how many unique sequences were found only in one donor, or two donors, or three
and so on. DCR = Decombinator classifier, which is representative of unique nucleotide
sequences. VJ-CDR3 = a CDR3 amino acid sequence in combination with the V and J genes
with which that CDR3 was found. CDR3 = the CDR3 region alone, from the conserved
cysteine in the V region to the conserved phenylalanine in the J region. B: Sharing of unique
sequences between pairwise comparisons of all donors, measured using the Jaccard index,for
both complete and subsampled repertoires. Subsampling involves randomly selecting a fixed
number of samples from each donor’s repertoire before comparison. α chain repertoires were
subsampled to 6000 unique sequences, β chain repertoires to 9000 (reflecting the lower bounds
of number of sequences found in these groups). C: Frequencies of the CDR3s summarised in
A. Horizontal dashes indicate group means.
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samples and on subsamples, where a fixed and equal number of rearrangements were
randomly selected from each donor before comparison, in order to control for differences
in sequencing depth. We again see the sharing increase as we consider the different
sequence types (CDR3 > VJ-CDR3 > DCR). As with Figure 3.6A, we also see that
α chains are also far more shared than β chains. This probably reflects both the
relative decrease in α chain diversity (Figure 3.1D) and the fact that there exist T-cell
subpopulations that make use of so-called ‘invariant’ TCR α chains (discussed in more
detail later in Section 3.1.5).
Shared and public clones are also reported to be present in higher frequencies in the
repertoire (129). I investigated this in my data by plotting the proportional frequency
of each CDR3 that was found shared among each number of donors (Figure 3.6C). Av-
erage values remain low in both chains up until the highest possible number of donors,
indicating that the more public clonotypes are indeed more likely to be higher frequency
than those that are less shared. However by looking at the underlying distributions
we do see that there are equally high private clones (found in one or two donors), but
these are just outweighed by the relative surplus of private clones that only occur at
very low frequencies.
This analysis also revealed that there are non-productive nucleotide rearrangements
(those expected to not translate correctly) that are also shared among multiple indi-
viduals (Figure 3.7A). Despite only a fraction of unique rearrangements being non-
productive, there were still α chain sequences that were shared among all ten individ-
uals, and β sequences that were found in four different donors. Pairwise comparisons
revealed that between any two donors, non-productive sequences are actually signifi-
cantly more shared than productive sequences, in either chain (Figure 3.7B). As with
productive α chains, non-productive α sequences that were shared among more people
showed larger mean frequencies than those shared among fewer (Figure 3.7C). Remark-
ably, for those rearrangements that were common to either nine or ten individuals, the
non-productive recombinations averaged larger clone sizes than the productive.
Inspection of the overlap in repertoires between individuals (intra-donor) provides
us information on TCR sharing and publicness. By taking multiple bleeds from one
individual and comparing these (inter-donor), we are able to obtain information about
the dynamics of the repertoire within a person. Four of our healthy donors were bled
twice, three months apart, and processed. As before, I then calculated the Jaccard
indexes of intra- and inter-donor pairwise repertoire comparisons (Figure 3.8A). As
might be expected, two repertoires from the same donor share more TCR sequences
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than repertoires from two different donors. I did not observe non-productive rearrange-
ments being more shared than productive for intra-donor as we do for inter-individual
comparisons.
By plotting the proportional frequencies of rearrangements in the first bleed against
those in the second we can see how stable the clonotypic hierarchy is within individ-
uals. The examples shown in Figure 3.8B demonstrate the donors that had the best
and worst correlation by R2 value. Even for the samples with a poorer fit by linear
regression show a clear pattern; low-frequency sequences (below 1× 10−3, or one in ev-
ery 1000 recombinations) display little correlation and are often simply not present in
the other bleed, while higher-frequency sequences match exceedingly well. This might
be explained by lower frequency clones being less likely to be captured by sequential
sampling events.
3.1.5 Invariant TCR detection
There exist various subpopulations of phenotypically distinct αβ T-cells that make
use of so-called ‘invariant’ TCRs, which are composed of near-identical α chains and
a small pool of β V genes. Currently, we know of three such cell types, which use
these restricted diversity receptors to recognise non-canonical ligands bound to various
MHC-like molecules. Discovered first, invariant natural killer T-cells (NKT) respond
to glycolipid antigens bound to CD1d, using a TRAV10 - TRAJ18 containing TCR
(132, 133, 134). Mucosal-associated invariant T-cells (MAIT) are MR-1 restricted and
recognise microbial vitamin metabolites with TCRs using TRAV1-2 primarily in com-
bination with TRAJ33, although variants using TRAJ12 and TRAJ20 have recently
been described (135, 136, 137, 138). The most recently categorised population are the
germline-encoded mycolyl lipid-reactive (GEM) T-cells, which use TCRs containing a
TRAV1-2 - TRAJ9 α chain, and recognise mycobacterial lipids presented by CD1b
(139, 140). Having noticed that two types of invariant TCR-bearing cells make use
Figure 3.7 (preceding page): Non-productive TCR sharing and publicness. A:
Publicness of non-productive TCR rearrangements, inferred from Decombinator indexes
(or DCRs) that are not expected to encode a productive TCR polypeptide. P = productive,
NP = non-productive. B: Sharing of DCRs that describe either productive or non-productive
rearrangements, for either whole or subsampled repertoires. Samples were subsampled down
to the lower bound of NP samples, which were 1000 for α chains and 260 for beta chains. Note
that there are no subsampled P DCR results for beta, as all of these comparisons resulted in
no shared clones. C: Frequencies of P and NP DCRs summarised in A. Horizontal dashes
indicate group means.
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Figure 3.8: Intra-donor TCR sharing. A: Overlap in DCR repertoires of the four healty
donors from whom we took two peripheral blood RNA samples, three months apart, measured
by Jaccard index. Both productive and non-productive (P and NP) DCR were compared, for
both complete and subsampled repertoires. ‘Intra’ indicates comparisons of the two bleeds
from one individual, while ‘inter’ indicates comparison of two bleeds from different individuals
(but taken at the same time). α repertoires were sampled down to 1,300 rearrangements,
while β repertoires were subsampled to 300. B: Example plots demonstrating the intra-
individual concordance of rearrangement frequencies. α and β repertoires are shown for the
individuals with the highest and lowest degrees of correlation by R2 value (HV01 and HV03;
higher and lower two plots respectively). Note that the first and second sample bleeds were
all taken at the same times of the year for each donor.
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Figure 3.9: Detection of known and putative invariant α chain TCRs. A: Number
of published invariant TCR VJ-CDR3s that were found in our healthy donor peripheral
blood repertoires. The sources of these sequences are listed in Table A.2. B: The size of the
published CDR3s and VJ-CDR3s searched for in our donors, as proportions of the repertoires
that they were found in. Note that the ‘Putative’ group shown in A does not include the
putative sequences derived from the healthy donors presented later in this chapter.
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of the same α V gene (TRAV1-2), the group that discovered GEM cells have recently
performed targeted deep-sequencing of α chains that specifically use this gene (141).
This process has generated a number of novel sequences that are shared among multiple
individuals, which they claim represent potential invariant T-cell subpopulations. I har-
vested published sequences for these invariant TCRs and the putative invariant shared
TRAV1-2 sequences (referenced in Table A.2), and looked for them in the healthy donor
repertoires in the context of the correct V and J genes.
As Figure 3.9A shows, we are able to detect invariant α chains belonging to each
population at the VJ-CDR3 level to some extent. Most of these TCRs are only de-
tectable in a small subset of donors. Only two of the five described GEM VJ-CDR3
sequences were found in this data, in different donors, with a slightly greater number
of NKT and putative TRAV1-2 invariant sequences in more donors. This is likely due
the prevalence of these cell types: human NKT cells account for approximately 0.2%
of T-cells in blood (142), while GEM are two orders of magnitude less frequent (140).
However, far more sequences derived from MAIT cells are found, with at least ten
VJ-CDR3s being detected in each of the donors. While this search was repeated for
β chains, this search yielded almost no results; only two MAIT β CDR3 sequences
(lacking V and J gene context) were detectable, at low frequency.
Figure 3.9B shows how prevalent each detected invariant TCR sequence was in the
repertoire file in which it was found. GEM sequences were only identified close to the
limit of detection for this assay, with NKT and the putative sequences from Van Schaik
et al being slightly more frequent. MAIT cell sequences are detected far more often
and at higher frequency, with one sequence making up 3% of all sequences in the α
repertoire it was found in. MAIT cell sequences reach such high proportions in blood
that the contribution of their invariant α chain is readily apparent even by looking at
V-J gene pairing frequencies, as was was shown earlier in Figure 3.3 (the most frequent
pairing is TRAV1-2 - TRAJ33, the canonical MAIT combination). This is consistent
with existing flow cytometry data showing that MAIT cells can be exceedingly common
in blood, sometimes accounting for upwards of 10% of CD8+ T-cells (143).
I also used my data to identity potential invariant TCRs based on degree of public-
ness. We have already observed that there are a number of α chain VJ-CDR3 sequences
shared among the majority of the healthy cohort (Figure 3.6A). I took the sequences
that were found in seven or more donors, and subtracted any that matched a pre-
existing known or potential invariant population. This left 40 sequences (listed in
Table A.3, Appendix A). One sequence was found in all ten donors, using TRAV13-1
and TRAJ6, bearing the CDR3 CAASKGGSYIPTF. This does not appear to be any
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kind of contamination, as this same sequence is generated using different nucleotide se-
quences in different donors. Searching for these sequences in the data produced a large
number of hits, at greater frequencies than all other groups apart from MAIT (which
might be expected, seeing as this list was defined by being common in this dataset).
3.1.6 Section discussion
TCR repertoires have a number of properties by which they may be characterised.
Perhaps the simplest attribute to measure is the spread of frequencies of different
rearrangements. The resultant distribution is characterised by an abundance of very low
frequency sequences, and a small number of more common recombinations. Description
of the frequency landscape of recombinations in healthy donors may function as a
benchmark against which to assess samples with expected repertoire perturbations.
When doing so, we must bear in mind that approaches that start with an RNA substrate
(such as the one used in this thesis) do not allow one to infer a direct correlation between
sequence frequency and cell counts, as different cells may express different amounts.
The presence of non-productive (NP) rearrangements detected in this RNA-derived
data may initially seem surprising, given that mechanisms exist to downregulate such
sequences. Various epigenetic systems mediate allelic exclusion of chromosomes that
do not contain productively rearranged alleles (144, 145, 146, 147), and any transcripts
that are made from such rearrangements are thought to be efficiently downregulated
by nonsense-mediated decay (NMD) (148, 149). Therefore NP reads potentially just
represent the ‘leakiness’ of the system, which seems fairly considerable in the α chain
data. Allelic exclusion has been reported to be stronger at the TRB locus, a fact which
can be inferred from the relative ability to find cells transcribing two productively
rearranged α chains (72, 150). The majority of observed NP sequences from either
chain contain premature stop codons, which are thought to be the strongest signal for
downregulation by NMD (151). These two findings might seem incongruent, but likely
reflect that the majority of NP reads would be expected to contain stop codons.
These data also demonstrate that some supposedly non-functional germline TCR
genes contribute to relatively high frequency rearrangements. This does not necessarily
correspond to their involvement in functioning TCR heterodimers: indeed some of the
pseudogenes would be expected to not be able to produce any peptide at all. However
I believe that there is a strong case for the official status of several of these genes to
at least be reconsidered, if not reclassified. For instance, the frequently-found gene
TRAJ58 is classified as an ORF as it contains an in-frame stop codon (152); however
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as this resides towards the very 5’ of the gene it can very easily be removed by nucle-
olytic nibbling during recombination. This allows it to produce perfectly theoretically
functional rearrangements as appear in this data, as well as in several published reports
that selected T-cells based on TCR binding (153, 154, 155). Another oft-detected ORF
in our data was TRAJ35 (which is classified as such due to the presence of a cysteine
in place of the phenylalanine in its FGXG motif) is found in valid rearrangements in
several papers (156, 157, 158). TRDV1 particularly, which is shown to be consistently
used at reasonably high frequencies in this data, has been found to be rearranged to
a variety of TRAJ genes by a number of groups, some of whom detected surface ex-
pressed protein (127, 159, 160, 161, 162, 163, 164, 165, 166). The most recent paper
to make note of this claims that TRDV1 is used with sufficient frequency and breadth
of TRAJ genes that it merits a change of name to TRAV42/DV1 (127) (although this
would not fit current IMGT numbering conventions). It even appears that IMGT is
aware of TRDV1 recombining with at least one TRAJ gene (167), but does not count
this as a dual TRAV/DV usage V gene (168), stating:
“Although the TRDV1 gene was also found rearranged to a TRAJ gene and
therefore expressed with the TRAC gene ... it is considered as a TRDV
gene.”
Even recombinations using genes which would prevent translation still contain in-
formation, even if they arise due to some basal transcriptional noise of the system,
and thus are worthy of inclusion at the primary stages of TCR analysis. For instance,
to the best of my knowledge this thesis is the first report of recombination between
TRDV2 and TRDV3 with any TRAJ genes in a healthy donor’s repertoire3. I predict
that comparably high-resolution investigation of δ chain TCR repertoires would find V
genes currently considered to be purely involved in α chain recombination contributing
to TRDJ- and TRDC-containing δ chain rearrangements.
I have also demonstrated that β chain Decombinator classifier insert sequences
can be searched to permit detection of TRBD genes. Due to the nature of these genes,
they are often impossible to detect or assign reliably. One gains most sensitivity by
using shorter match length thresholds, but this reduces the specificity of the search
as shorter sequences are more readily produced by chance. This is evidenced by the
presence of false positive TRBD hits in α chain sequences. Even taking these limitations
3The only papers I have found to describe TRDV2-TRAJ recombinations – which remarkably even
included TRDD genes – did so in cells derived from leukaemia patients, and were predicted to not
produce functional protein (169, 170).
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into account, these results demonstrate that one is able to extract some information
regarding the recombination of TRBD genes in data generated using the pipeline in
this thesis. Doing so I have repeated some notable findings from other studies, such
as the pairing of TRBD2 with TRBJ genes from the TRBD1 cluster, and preferential
pairing between TRBV and TRBD genes. The presence of VDDJ rearrangements is
particularly interesting, as among T-cells these are often thought to be the sole province
of δ chains, due to the configuration of the RSS around the D genes (171, 172). This
raises the possibility of there also being direct VJ β chain rearrangements existing
(173). Such rearrangements would however be hard to distinguish from genuine VDJ
sequences that just had heavily deleted TRBD genes. While assignation of residual
D gene nucleotides is not a requirement for the majority of analyses I describe in
this thesis, such efforts would be of great importance in experiments inferring the
mechanisms of recombination from sequence data.
There is a growing body of work describing sharing, ‘publicness’ and bias in TCR
repertoires. Since the first descriptions of public TCRs recognising specific influenza,
lysozyme and Epstein-Barr virus antigens (174, 175, 176), such responses have been
discovered in many reactions across all species studied, prompting a great deal of dis-
cussion (177, 178, 179, 180). Turner et al have proposed a system of classification for
the different types of bias observed in a response to an antigen (177). Type I bias
describes responses that deploy multiple TCRs all using the same V gene, type II bias
involves TCRs that share common amino acid motifs or features in their CDR3s, and
type III bias denotes the sharing of actual nucleotide sequences. Miles et al later pro-
posed an additional class, type IV bias, which describes those TCRs that fall between
types II and III; such sequences share V gene identity and a significant proportion of
matching CDR3 sequence, but differ in a small number of residues (179). While I am
not presenting any antigen-specific data in this thesis, we can still infer the existence
of each of these levels of bias in this global repertoire data by merit of the shared TCR
features and sequences.
One surprising result from the publicness analyses described in this chapter is the
extent to which non-productive (NP) rearrangements are shared between people. While
infrequently detected (for reasons discussed in Section 3.1.1), on a per-TCR basis NP
sequences were more likely to be shared between people than those that were produc-
tively rearranged. I propose that these data are consistent with the hypothesis that
TCR sharing occurs as a function of generation probability, i.e. these TCRs are for some
reason more likely to be made in multiple individuals (131). In this model, TCRs are
produced at different efficiencies, therefore those that are generated most easily or most
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often are those most likely to be shared. Productively rearranged receptors, regardless
of potential publicness, will be subject to thymic selection, thus a portion of these will
not be detected in the periphery. Non-productively rearranged receptors however do
not contribute to ligand recognition and therefore cannot be selected against, therefore
it is reasonable to assume they will exist in different individuals at some rate more
proportional to their production. NP sequences are therefore more shared than pro-
ductive as they have not had some potential public sequences removed. This higher
level of sharing is only manifest between individuals; NP TCRs were not more likely to
be found in two bleeds of the same person taken several months apart. This is consis-
tent with the idea that we are observing NP TCRs at some rate proportional to their
production; those we see at relatively high-frequencies being retained have likely been
generated in thymocytes whose functional TCR chains have promoted their expansion.
These data do not however provide information as to the mechanism of unequal
TCR production frequencies. One of the leading models for explaining public TCR
responses is that of convergent recombination, which postulates that such sequences
arise by merit of multiple recombination events producing the same nucleotide sequence
(178, 181, 182). However one group has applied various statistical analyses to a selection
of NP TCR sequences (obtained by sequencing from genomic DNA) and found that
convergent recombination does not explain sharing, lending weight to the possibility
that biases in the recombination machinery are instead responsible for production of
public sequences (183, 184).
Related to measuring publicness is the detection of sequences known to exist in the
non-pMHC-restricted T-cell subsets that express relatively invariant TCRs4. In this
study, working from a fraction of RNA extracted from a 2-3ml sample of peripheral
blood, the sequences we can most readily detect are those belonging to MAIT cells,
which are highly prevalent cells in human blood5. However if other populations were
a focus of research one could increase their detection through sequencing RNA either
from larger volumes of blood, sorting cells, or by isolating RNA from other tissues in
which these cells reside.
One exciting possibility offered by repertoire sequencing is the identification of po-
tential unknown invariant populations. Van Schaik et al recently reported just such an
exercise, looking for sequences that were highly shared in TRAV1-2+ cells from three
4However seeing as each so-called ‘invariant’ TCR is actually a pool of several similar but non-
identical sequences, the field may at some point wish to address this choice of word.
5Note that NKT cells are more prevalent in mice than in humans (185), while MAIT cells are more
prevalent in humans than in mice (135), so this finding is likely species-specific.
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or more donors (141). They found a number of sequences, some of which were iden-
tifiable in this data, with more regularity than seen for iNKT or GEM cell sequences.
An analogous search for highly shared sequences in my data, found a variety of highly
shared sequences, one of which was present in all ten donors. Without any evidence
of a phenotypically unique cell subset possessed of non-pMHC restriction we cannot
differentiate these sequences from just highly shared clonotypes, perhaps representing
public responses against common antigens. The line between invariance and type IV
TCR bias will be a technologically difficult one to draw. Characterisation of cells us-
ing single-cell RNA sequencing data, permitting both identification of TCR chains and
expression of lineage-specific markers, could represent a sequencing based solution to
more confidently assert the existance of such cells. As for presentation, there are a
great many MHC and MHC-like genes that could be responsible for displaying anti-
gens to such hypothetical subsets. The original draft of the human MHC predicted 128
different protein-coding genes (186), while later work – which counted a larger portion
of chromosome 6 – raised this estimate to 252, of which roughly 70 are predicted to
have immune functions (187). A number of class I-like genes additionally exist outside
of the MHC (188) which might serve in such a role. Indeed, all of the molecules that
we currently know to display antigens to invariant T-cell populations – CD1 and MR1
– fall into this category, with their genes located on chromosome 1 (189, 190).
High-throughput sequencing is therefore able to extract and quantitate a number
of diverse inter- and intra-individual TCR repertoire features, working from a small
sample of blood.
3.2 Subset-specific TCR repertoire findings
In addition to investigating the global repertoire of peripheral blood, I also undertook
a number of trial experiments to assess features of TCR repertoires of particular cell
subsets. Herein I additionally explore data produced using different protocols, which
only amplify rearrangements using a limited selection of V genes.
3.2.1 CD4 and CD8 TCR repertoires
T-cells can be divided into two major functional subsets – T helper cells or cytotoxic T-
lymphocytes (CTLs) – based on the expression of either the CD8 or CD4 glycoprotein
TCR co-receptor. As these molecules associate with T-cells that recognise peptides
bound to different families of MHC molecules – class I or II – we hypothesised that
their TCR repertoires would differ substantially, reflecting the significant structural
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differences in ligands. In collaboration with Dr Theres Oakes, PBMC from two healthy
donors were sorted into CD4+ and CD8+ populations and their TCR repertoires were
sequenced. Cell purities are displayed in Appendix A in Figure A.2.
Overlap analysis revealed that there is very little sharing between the CD4 and CD8
compartments within a donor (Figure 3.10A). The CD4 and CD8 compartments of the
two different individuals actually share more sequences with one another than do the
separate populations within each individual. One of the healthy volunteers who donated
blood for sorting was also one of the donors who provided two samples for previous
analyses (HV01, see Figure 3.8). The blood to be sorted was drawn approximately two
years after the two previous whole blood samples, yet still shares a large number of
sequences with both CD4 and CD8 populations. The overlap between the two whole
blood samples of this sample taken three months apart was included in Figure 3.10A
for reference.
I also inspected the inequality of the sorted repertoires. CD8 repertoires display a far
more unequal distribution than CD4, representative of a more oligoclonal distribution
(Figure 3.10B). The whole blood samples from the same donor display intermediate
equalities, being a combination of both populations. This difference in inequality is
apparent even when viewing the VJ gene pairing frequencies of each population (Figure
A.3 to A.6, Appendix A). CD4 populations in both chains clearly display a more even
spread of gene usage compared to CD8, which is typified by a combination of hotspots
and many infrequently used combinations.
Another feature that was apparent from viewing the VJ pairing of one of our sorted
repertoires (HV01) was the segregation of large amounts of TRAJ1-2 - TRAJ33 rear-
rangements (the gene pair that contributes to canonical MAIT cell invariant TCRs)
to the CD8 repertoire (Figure A.3). Donor HVD4’s CD8 repertoire does not promi-
nently display this pairing (Figure A.4, although there are indeed a number of MAIT
Figure 3.10 (preceding page): Clonal composition of the sorted CD4 and CD8
TCR repertoires. A: Heatmap showing the overlap between sorted CD4 and CD8 subsets
of two donors, HV01 and HVD4 (D4), by Jaccard index. Sorted samples from HV01 were
taken approximately two years after the two HV01 bleeds (v1 and v2) that were used in
Section 3.1. Upper-left hand triangle shows comparisons of α chain rearrangements, lower-
right triangle shows beta. B: Clonal inequality of CD4 and CD8 compartments by Gini
index. Unsorted whole blood samples from HV01 from two years before were included for
reference. Plots A and B were both generated using subsampled repertoires to control for
different sample sizes; 10,000 DCRs were used for alpha, while 20,000 were used for beta. C:
Proportional frequencies of the VJ-CDR3 sequences of invariant α chain TCRs (discussed in
Section 3.1.5) as found in either file of CD4 and CD8 sorted TCR data.
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cell sequences present). Instead this population is dominated by large expansions of
clonotypes made using TRAV12-2 and TRAJ18, which account for 16.4% of all rear-
rangements. Within this VJ combination, 88.5% produce CDR3s that fit the pattern
CAVXXDRGSTLGRLYF (where X represents any amino acid). This raised the pos-
sibility that we might be able to confirm and/or determine the CD4/CD8 expression
patterns of different invariant TCR clonotypes. I searched for the presence of known
and potential invariant α chain sequences in the sorted repertoire data (Figure 3.10C).
As with previous analyses, very few GEM and iNKT sequences were detected, however
those that were found were predominantly in the CD4 compartment. MAIT sequences
were present in both populations, but only reached the large populations sizes observed
previously in the CD8 subset. The putative rearrangements from Van Schaik’s and my
own data are found distributed approximately evenly between both populations. Of
particular note is the sequence that was earlier found to be present in all ten healthy
donor whole blood samples (TRAV13-1 - TRAJ6, CAASKGGSYIPTF). Not only was
it found exclusively within the CD4+ compartment of both sorted samples, but it was
highly prevalent in each, being the most frequent non-MAIT invariant sequence found in
the CD4 data (from HVD4). The CD8 VJ-CDR3 sequence with the highest frequency
was TRAV12-2 - TRAJ5, CAVNNTGRRALTF (also in HVD4), one of the sequences
that was earlier identified in eight of ten of our whole blood healthy samples, although
this sequence was found at low frequency in the CD4 population of both donors. Of
those 40 sequences, the majority were found in both CD4 and CD8 repertoires; ten
were found exclusively in CD4, while only one was found exclusively in CD8 (Table
A.3).
3.2.2 Clonality distribution differences using targeted V amplification
protocols
In the process of developing the error-correcting pan-TCR amplification protocol used
in the rest of this thesis (the process of which is covered in Chapter 5), I tested various
intermediate protocols which specifically target a limited number of V genes. These
intermediate protocols were used to compare the repertoires of two pairs of cell subsets:
na¨ıve versus memory, and cord blood versus adult peripheral blood.
3.2.2.1 CD4+ CD45RA+ versus CD45RO+ clonal distributions
The first such experiment targeted rearrangements using the α and β V genes TRAV8-4
and TRBV12-3 (see Section 5.2.2 for details). Three healthy donors were bled and
PBMC extracted. One donor’s PBMC were processed and sequenced, while the other
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A B
Figure 3.11: Clonal composition of CD4+ CD45RA+ or CD45RO+ TRAV8-4+
and TRBV12-3+ repertoires. A: Logged rearrangement rank versus logged frequency
for the five samples sequenced using the simple V amplification protocol, targeting specific
V genes. Thus α results are exclusively those that are shown by Decombinator to be
using TRAV8-2 or TRAV8-4 genes (which are highly similar in their 3’ regions, and are
thus indistinguishable). β samples shown use TRBV12-3. D2 samples were whole, unsorted
PBMC. D3 and D4 were sorted into CD4+CD45RA+ (‘na¨ıve’ or ‘n’) and CD4+CD45RO+
(‘memory’ or ‘m’). B: Gini indexes for the repertoires shown in A.
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two donors’ cells were sorted into CD4+ populations expressing either CD45RA or
CD45RO, using magnetic assisted cell sorting (MACS), before sequencing. These
populations have been used to enrich for na¨ıve and memory populations respectively
(191, 192). It must however be noted that using differential CD45 isoform expres-
sion does not provide true na¨ıve-memory separation, as there is a subset of antigen-
experienced memory cells that lose CD45RO and re-express CD45RA; such highly dif-
ferentiated cells are called TEMRA (T effector memory RA
+) (193), and will be included
in our ‘na¨ıve’ sorted population.
Figure 3.11A shows that the pattern of rearrangement frequencies by rank are
broadly analogous between the groups. This implies that there are both expanded
clones in the na¨ıve population and a large number of memory clonotypes that are
not expanded. Examination of the Gini indexes of these populations (Figure 3.11B)
does however reveal that within a donor, the CD4+CD45RO+ population does display
greater inequality, indicative of a greater proportion of the memory repertoire being
occupied by relatively expanded clones.
3.2.2.2 Cord blood versus adult whole blood clonal distributions
The next subset experiment used a more refined experiment: while still priming from
specific V genes in the PCR, the requisite sequences were introduced to allow error-
and frequency-correction (described later in Sections 5.2.5 and 5.3.2), analogous to
the approach used to correct the majority of the data in this thesis. This ‘barcoded
V’ (BV) protocol targeted two additional V genes to the previous V-primed strategy
– TRAV21 and TRBV20-1 – which had consistently appeared at high frequencies in
our preliminary pan-V experiments. This protocol was used to explore the clonotypic
structure of TCR rearrangements in cord blood relative to whole peripheral adult blood,
focusing on this small number of genes.
Analysis of the specific-V data revealed that both adult and cord blood display the
typical linear log-rank pattern, in which each rearrangement is a certain proportion
bigger than the previous one (Figure 3.12A and B). Thus both populations contain
a small number of relatively expanded and a large number of very-low frequency se-
quences; however sequences in adult blood reach greater frequencies than cord blood.
This feature is recapitulated in their diversity indexes: cord blood repertoires display
lower Gini indexes and greater Shannon entropies, indicative of more evenly distributed
diverse repertoires (Figure 3.12C and D).
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Figure 3.12: Clonal distributions and diversity indices of adult and cord blood
V-specific repertoires. Logged rank-frequency distributions for whole peripheral adult
blood (A) and neonatal cord blood (B). C: Gini indexes for adult and cord blood samples.
D: Shannon entropies for adult and cord blood samples. Cord blood samples displayed
significantly lower Gini indexes (p = 5.746e-05) and higher Shannon entropies (p = 0.03458),
by one-sided Wilcoxon rank sum tests. All data in this section was produced using the BV
protocol, and therefore only contains rearrangements using TRAV8-2/TRAV8-4, TRAV21,
TRBV12-3 and TRBV20-1.
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I investigated the distributions of the lengths of the inserts6 and CDR3s of the two
groups. Interestingly, despite adult donors’ rearrangements tending to contain a greater
number of non-templated nucleotides than cord blood (Figure 3.13A), CDR3s from both
groups contain a median of 14 amino acids (Figure 3.13B). Despite the confounding
presence of residual TRBD gene nucleotides this pattern was also observed in β chains,
producing the same median length CDR3s (Figure A.7A and B). Pairwise comparisons
of either length distribution between all donors reveals that inter-group pairs are more
significantly different than intra-group pairs (Figure 3.13C), i.e. any given repertoire
from one group is likely to have a length distribution more similar to another member
of that group than the other. Within groups CDR3 length profiles also differ less than
insert length profiles. We can infer two main findings from these data. First, that there
exists a greater level of heterogeneity in how many inserted nucleotides one finds in TCR
repertoires than in the lengths of the resultant CDR3s of those rearrangements. The
second finding is that that both these length distributions differ significantly between
neonatal cord and peripheral adult blood.
Sharing analyses that were first performed on the pan-V healthy data (presented
earlier in Section 3.1.4) were applied to the BV data of this Section. While only
considering a limited number of V genes, there are sequences from both chains that
are present in the majority of donors (Figure 3.14A). These groups also share similar
numbers of sequences with one another, although the variation is greater among adult
samples (Figure 3.14B). This data thus provides another resource to look for highly
public α chain sequences. Table A.4 in Appendix A details those VJ-CDR3s that were
present in seven or more of the BV-processed samples. One of the V genes targeted –
TRAV21 – was also found to be used by some of the highly public sequences discovered
6The fifth field of the Decombinator classifier that contains the nucleotide sequence between the
recognisable ends of the V and J genes.
Figure 3.13 (preceding page): Adult and cord blood α chain TCR length distri-
butions. A: Box plot of α chain rearrangement insert lengths, i.e. the number of nucleotides
between the recognisable ends of the V and J genes, for adult (HV) and cord blood (CB)
samples. B: Box plot of α chain CDR3 lengths (running inclusively from the conserved cys-
teine contributed by the V gene to the conserved phenylalanine in the J gene). C: P-values
obtained from running two-sided Wilcoxon rank sum tests on all the insert and CDR3 length
distributions of pairs of donors shown in A, B and Figure A.7 in Appendix A. ‘Intra’ indi-
cates comparisons within a group (e.g. cord blood versus cord blood) while ‘Inter’ indicates
one distribution from each group. Dashed horizontal lines indicate levels of significance: 0.05
(*), 0.01 (**) and 0.001 (***). Note that despite a similar nomenclature, the adult healthy
volunteers were not the same as those used in the pan-V gene results in Section 3.1.
80
3.2 Subset-specific TCR repertoire findings
A
B
Figure 3.14: TCR publicness and sharing in the BV data. A: Publicness of nucleotide
(DCR) and VJ-CDR3 sequences in the data produced using the barcoded V protocol, i.e.
how many sequences were there found in a given number of donors. Both healthy adult and
cord blood samples were pooled. Note that CDR3 sequences alone are not plotted as they
exactly matched the VJ-CDR3 data, possibly as a result of targeting specific V genes in
the amplification process. B: Sharing between the different groups amplified with the BV
protocol, measured by Jaccard index. α repertoires were subsampled to 400 sequences, β
repertoires to 1,200.
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previously in data produced with the BLR protocol (Table A.3); cross-referencing these
results showed that a number of sequences are found in both analyses. Thus we find
sequences that are shared among up to fifteen different donors in our data alone.
3.2.3 Section discussion
In this section I report results from preliminary analyses made using combinations
of specific cell populations and V gene repertoires. Most notable are the differences
between the TCR repertoires of CD4+ and CD8+ T-cell populations. The most strik-
ing difference is the disparity of evenness of repertoires between the two groups, in
agreement with previous findings (194), including deep-sequencing reports (99). This
separation of polyclonality between CD4+ and CD8+ might be explained by differ-
ences in their proliferative programs; upon stimulation, CD8 cells undergo a greater
amount of division, achieving larger burst sizes, that are more persistent than clonal
exansions in CD4 cells (69, 195). Serendipitously, one of the donors bled for cell sorting
was also one of the donors for whom there were data for the two whole blood sam-
ples (discussed in Section 3.1, which were taken approximately two years apart from
the sorted samples), revealing a slightly higher long-term retention of sequences in the
CD8 compartment.
The other notable finding is one replicating an observation from a previous TCR
repertoire paper, that an individual’s CD4+ and CD8+ populations do not show much
overlap in TCR usage (83). In fact the CD4 and CD8 populations of the different
donors shared more sequences than did the two populations within the same donor,
highlighting the relationship between TCR identity and T-cell subtype. This makes
intuitive sense, as CD4 and CD8 cells are recognising different pools of peptides (or
‘peptidomes’) in the context of different classes of MHC molecules, therefore one might
expect a separation in their TCR repertoires. It was shown as early as the late 1980s
that TCR sequences were in some way deterministic of the fate of that cell, as T-cells
in mice expressing transgenic TCR sequences derived from a CD8 cell line were found
to preferentially develop into CD8+ cells (196). According to a current model of lineage
commitment, this repertoire property is likely enforced by the signal strength of the
TCR-pMHC reaction during development: stronger, longer signals produce CD8 cells,
and short, weaker signals lead to CD4, while any cells assigned the incorrect fate are
later deleted (40). Note that this if effectively a combination of the ‘instructive’ and
‘stochastic’ models originally proposed (197).
Data produced from MACS sorted cells underwent the initial pilot TCR amplifica-
tion and library preparation protocol featured in this thesis. As this protocol lacks the
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ability to apply barcode-based error correction, the data are somewhat rudimentary
and are likely to be less robust quantitatively. Comparison of Figure 3.11 with similar
data (e.g. Figure 3.1B and C) suggests the effect of PCR amplification and errors are
skewing the results. The broad findings however – that low frequency clones occur in
memory populations, and expanded clones could well exist in na¨ıve populations – agree
with those found in previous deep-sequencing efforts (83, 198).
A more refined protocol that also only targets specific V genes for amplification
was applied to cord and adult whole blood samples. Cord blood is of particular med-
ical interest due to the combination of large numbers of haematopoietic stem cells
and relatively na¨ıve T-cell populations possessed of lesser cytotoxic abilities, making
it an attractive source of material for stem cell transplants (199). It also presents an
interesting research opportunity to immunologists, as it allows inspection of T-cells
arguably at their most na¨ıve, having been shielded from microbial antigens whilst in
utero. This likely explains the clonal distribution we observe in the cord blood, which
is far more evenly distributed than adult blood, without so many clonal expansions,
confirming previous spectratyping results (200). However there are some expanded se-
quences, which may reflect sequences that were produced frequently, perhaps as a result
of convergent recombination or recombination bias as discussed above. I also demon-
strate that despite producing the same median length CDR3s, adults’ repertoires tend
use TCRs with more inserted nucleotides (either N or P nucleotides) to encode them.
Again, this supports previous published reports that describe foetal rearrangements
tending towards shorter CDR3s than infants’ (201), or adult blood tending towards
longer CDR3s than cord blood (202). We know that in human embryos, Tdt – the
enzyme responsible for the non-templated addition of nucleotides during recombina-
tion – is expressed before the 22nd week of gestation7 (204). Therefore the difference
between the degree of non-templated nucleotide addition between cord and adult blood
cannot be explained by lacking the enzyme. Instead, I hypothesise this difference is a
result of two features; the lack of expanded clones in cord blood and the probability
distribution of producing TCRs with different numbers of insertions. Probabilistically
speaking, the formation of TCRs with increasing numbers of nucleotides is less likely
with each addition, therefore the longer the insert sequence the rarer that sequence
can be expected to be produced by recombination. Adult repertoires have had both
more chances to make such sequences and to increase their frequency by cell division
7Note that is not the case in mice, as they do not express Tdt until three to five days after birth
(203).
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(as some cells bearing many insertions can be expected to expand in response to their
cognate antigen), thus such sequences should be more frequent in adults.
3.3 Intra-gene splicing of TCR transcripts
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Figure 3.15: Examples of intra-V gene splicing. Examples of genes that display non-
canonical splice events that interrupt V gene sequences, for TRAV1-1 (A), TRBV7-8 (B),
TRBV7-3 (C) and TRBV2 (D). Chromosomal germline (GL) sequences for each sequence
are included for comparison. Schematics are to scale: vertical dashed lines indicate 100 bp
intervals.
Detecting rearrangements using non-functional TCR genes (as was shown in Figure
3.2) required the design a new set of V and J gene tag sequences, which are used to
bioinformatically determine which specific genes are used in a TCR rearrangement8.
8Discussed later in Section 5.3.1.1
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During the course of testing this new ‘extended’ tag set, the frequency of one particular
TRAV gene dropped significantly relative to its use in the original tag set. By inspecting
the nucleotide sequences of reads that were assigned recombinations using the original
tag set but not with the new, it was revealed that a number of transcripts using TRAV1-
1 were subject to alternative splicing, to an splice acceptor site that lies within the new
tag sequence.
In order to more systemically assess the extent of splicing within V genes I first
needed to obtain nucleotide sequences that spanned the complete V gene. The se-
quencing protocol used in this thesis produces paired-end reads (i.e. one read from
both ends of the template molecule), each 250 base pairs long9. By using the program
FLASH (117) I was able to merge all of the reads that overlap in their 3’s for one donor
to obtain sequences which should contain whole transcript sequences. I then made
use of the molecular barcodes introduced uniquely to each cDNA during the amplifi-
cation process to error-correct our data. This differs to the error-correction employed
in assigning the recombined TCR sequence: this splicing analysis requires accurate
base calls across the entire length of the sequence, whereas the standard analyses are
more tolerant of inaccuracies that would not affect calling the identity of a rearrange-
ment. Accordingly more stringent filtering criteria were applied: in short, only those
amplicons which were covered by more than three high-quality sequencing reads were
considered, and then the most common base at each position was calculated to obtain
a consensus for each transcript. These error-corrected transcripts were then processed
using Decombinator, giving us rearrangement information. Recombined sequences
up to the 3’ of the V gene were then mapped onto the appropriate germline locus using
the RNA alignment software STAR (114), and inspected for alternative splicing (AS).
A number of V genes in both chains were found to be subject to alternative splicing
at some frequency: 30 distinct splice events were recorded divided across the 17 genes
listed in Table A.5. Figure 3.15 shows scaled schematic representations of four example
genes that between them demonstrate the breadth of different splice events taking place.
These alternative spliceoforms often employ the standard splice event required to add
the first exon (which contains the majority of the leader sequence, termed L-PART1
under IMGT nomenclature (19)) but then also splice out a downstream section of V
sequence (e.g. Figure 3.15A i to iii). Some transcripts do however display other splicing
profiles, such as splicing the L-PART1 sequence directly into the middle of the V gene
(Figure 3.15A iv), making use of a splice donor upstream of L-PART1 (3.15C i), or
failing to remove the leader sequence intron (Figure 3.15D i).
9This process is detailed later in Section 5.2.6.
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Figure 3.16: Extent of intra-V gene splicing. A: Number of merged, paired-end indi-
vidual transcript consensus sequences that were successfully produced per healthy volunteer
(HV). B: Proportions of transcripts that made it through each step of the analysis. DCR =
those transcripts in which Decombinator successfully assigned a rearranged TCR, using the
original tag set. DCR:P = of those assigned a rearrangement, how many appear to contain a
valid productive rearrangement based solely on the Decombinator classifier, performed as
in Figure 3.1. P/NP: AS = Of the reads determined to be productive (P) or non-productive
(NP) based on their DCR, those that were shown to contain one of the alternative splicing
(AS) events listed in Table A.5. C: Assessment of what proportion of reads predicted to be
productive based on their Decombinator classifiers stand to theoretically translate based
on the presence of start and stop codons in their complete transcript sequence. Categories
are: those transcripts that contain only start codons (+ start - stop); those that contain
both with the last start codon being downstream of the last stop codon (and thus might be
translated, + start > + stop); those with both but stop codons after the last start codon
(+ start < + stop), and those that contain no start codons at all (-start +/- stop). D: The
proportions of different criteria found among the NP transcripts preventing their productivity
based on Decombinator classifiers. OOF = out-of-frame but lacking a stop codon (at least
upstream of where the constant region would start); OOF* = out-of-frame, also containing
a stop codon; IF* = in-frame but containing a stop codon; FGXG = lacking the conserved
motif at the end of the CDR3; C = lacking the conserved cysteine residue at the start of the
CDR3. α chain results are shown in green, β chain in purple, with any transcripts found
to contain splice events (as listed in Table A.5) hatched. All error bars indicate standard
deviation.
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I then quantified how frequently these splice events occurred in each of the ten
healthy donors sequenced, after equivalent processing. Figure 3.16A shows how many
overlapped and error-corrected transcripts were obtained using the high stringency
pipeline. Of those transcripts produced, the majority are successfully assigned rear-
rangements and seem to encode productive polypeptides (Figure 3.16B). By looking for
the splice sites identified above in either the productive (P) or non-productive (NP) we
can see that splicing is proportionally enriched among the NP. In order to assess what
effect AS might be having on seemingly-productively rearranged receptors, such tran-
scripts were searched for the presence of start and stop codons (Figure 3.16C). In order
to feasibly be productive, a transcript must contain a start codon that is followed by
no stop codons (as these transcripts were reverse transcribed upstream of their proper
stop codon). We can see that AS-transcripts show a large reduction in the proportion
of transcripts that contain a start codon without a stop codon present. Instead they
possess a far larger proportion of transcripts that contain stop codons but might still
yet be productive as the last stop codon precedes the 3’-most start codon. Interestingly
there is an increased tendency among α chain transcripts to fall in this category relative
to β chains, even in unspliced transcripts. There does not appear to be any considerable
difference between unspliced and AS transcripts in terms of the profiles of transcripts
that would not be expected to translate, i.e. those that lack a start codon or have one
followed by a stop codon. Note that this analysis is limited in two respects. One, we
can only obtain full-length sequences for those transcript that are short enough to be
overlapped, and two, these sequences may not actually correspond to the actual 5’ end
of mRNA sequences, rather just where the reverse transcriptase molecule dissociated. I
also looked to see whether there was a difference in the reasons why different unspliced
and AS transcripts were classified as NP (Figure 3.16D). As there are so few sequences
that are NP, of which only a fraction are spliced (with averages of 60 and 8 NP/AS
transcripts per donor) this analysis is limited. However there does appear to be at the
very least an increase in the frequency of in-frame sequences that contain stop codons
(i.e. as a result of non-templated nucleotide deletion or addition) in AS-transcripts.
3.3.1 Section discussion
There are a number of insights that can be drawn from this analysis. The first is
that alternative splicing at the TCR loci appears to consist of a far more diverse series
of splice events than has previously been recogised. In addition to describing a vari-
ety of novel cryptic splice donor sites, I believe this to be the first report of human
TCR pre-mRNAs undergoing alternative splicing to cryptic acceptor sites within the
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sequence of the V gene itself. There is one report that I can find of an equivalent
phenomenon, in which a non-productively rearranged α chain in a clonal murine hy-
bridoma was shown to have undergone inter-V gene splicing (205). This analysis finds
over 10,000 transcripts that undergo this intra-V gene AS, allowing one to quantita-
tively and qualitatively probe the properties of such sequences. These splice events
should theoretically be able to dramatically regulate a transcript’s expression. That
they are enriched among TCRs that should not be able to produce a valid polypep-
tide based on their rearrangement (‘recombinatorially non-productive’) suggests that
it might be employed as a mechanism in these cases to further regulate message that
will not be contributing towards surface receptors. The different profiles in criteria for
non-productivity between spliced and unspliced transcripts might reflect AS preferen-
tially being employed against particular subsets of transcripts. For instance it known
that AS-mediated incorporation of stop codons can lead to degradation of message by
nonsense-mediated decay (206). However the possibility remains that these transcripts
just represent some low-level errors of the transcription and splicing machinery, and
the tremendous depth of high-throughput sequencing has brought them above the level
of detection; functional experiments would be required to settle the matter.
Perhaps more interesting is the small fraction of sequences which we would de-
termine to be productive, based on their recombined hypervariable region, but which
contain upstream intra-V splicing events. It is probable that this would either prevent
translation entirely, or at least alter the protein structure so much that the product
would no longer be able to contribute to a valid surface-expressed receptor (‘transcrip-
tionally non-productive’). This raises the possibility that AS might be able to function
to suppress the expression of valid TCR rearrangements, perhaps to prevent the ex-
pression of autoreactive receptors.
These findings could also impact on the design of repertoire sequencing experi-
ments. All protocols of which I am aware (including the one I developed and employed
in this thesis) involve targeted sequencing around the recombination junction to extract
clonotypic information. Many even use V-gene specific primers to amplify just this re-
gion. While it is not important for this work, it is feasible other groups may be trying
to extract specific rearrangements to use functionally downstream; researchers should
remain aware of the fact that just because the cDNA describing the CDR3 appears
productive, alternative splicing events upstream could be preventing that rearrange-
ment from being expressed as working protein. Sequencing technologies permitting
longer reads than are currently available would be required to ensure transcripts are
functional based on their entire lengths. Similarly, construction of TCR sequences for
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gene-therapy purposes might benefit from modulation of cryptic splice sites to prevent
unwanted alternative splicing of transgenes.
3.4 Chapter discussion
High-throughput sequencing of TCR repertoires effectively consists of the application
of novel disruptive technologies to a relatively new field. It is clearly a very powerful
tool for research, yet as a field we are still in the early stages of exploring what we might
accomplish using these methods. In this chapter, I have displayed an overview of some
of the kinds of experiments and analyses one can employ in repertoire sequencing efforts,
indicating the range of research questions that we might begin to address. Working from
small samples of peripheral blood from healthy individuals, I have shown it is possible
to extract a great deal of information about various aspects of TCR biology. At the
most simple level, I have described the basic clonotypic and germline gene distributions
in my data. These findings recapitulate those of the earliest TCR repertoire sequencing
efforts, particularly with respect to the striking nature of the relative abundances of
the lowest and highest frequency sequences and the differential usage of different V and
J genes (75, 76). This provides us an impression of the ‘shape’ of the repertoire, which
allows us the chance to use this as a reference point when looking for perturbations to
the repertoire, such as in disease. An important related aspect of this appreciation of
repertoire configuration is how to score and interpret diversity.
I have also looked in my data for the presence of shared or public sequences, as
well as those belonging to the so-called ‘invariant’ TCR T-cell subpopulations. Even
without focusing on antigen-specific cell populations I can readily show the presence
of a large number of sequences that are shared between multiple donors. Some of
these sequences are even found in all donors: while these mostly consist of sequences
known to be found in MAIT cells, at least one other sequence was found to be equally
public, with several others not far behind. As more donors and cell compartments
are sequenced, I anticipate that we will find a far larger number of shared sequences,
blurring the lines between what we currently consider to be public and private, a
prediction supported by the observation of yet more low-frequency but highly shared
sequences even when only priming off a small number of V genes. I also expect that in
line with current findings (138), cells matching the phenotypic profiles of the non-pMHC
restricted TCR populations but with increasing deviation from the exact canonical
sequences will be found, which might eventually necessitate the need to reassess usage
of the word ‘invariant’. I also demonstrated how by sorting cells into subpopulations
prior to sequencing one can not only gain information about those sorted samples,
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but apply sequence-matching analyses to infer properties about unsorted populations.
Finally I have shown how we might use repertoire sequencing data to learn about aspects
of TCR biology unrelated to the clonal composition of the repertoire in revealing the
presence of multiple novel splice events that occur within the TCR V gene sequences,
which might represent an under-appreciated level of TCR regulation.
Several themes that emerge from this chapter are worthy of particular note. The
first is how these experiments speak to the richness of the data produced by repertoire
sequencing. However – due to the age of the technique – there is still little consensus
about what information is most important and how best to present it, which presents
a challenge for both analysis and interpretation. Indeed, as is the case for all HTS,
with decreasing costs and greater access to sequencers we could be heading towards a
scenario in which data analysis instead of generation becomes the limiting step (207).
Another important aspect of this data is the frequency with which we find uncom-
mon phenomena (such as alternative-splicing or use of unexpected V-genes) that might
not be detected or be more readily overlooked from studies using lower-throughput or
-resolution repertoire methods. It is probable that as the field investigates increasing
numbers of large, multi-dimensional datasets more thoroughly we will discover increas-
ing numbers of such novel events or contradictions to existing rules, and we should be
prepared to obtain and assimilate such information. For example, the IMGT databases
contain a great deal of well-annotated and easily accessible information regarding vari-
able lymphocyte receptors from a number of species, and their classification and num-
bering systems allow sensible interpretation of data between studies (19, 101, 102).
This has made it in invaluable resource for repertoire studies, demonstrable by the fact
that almost every high-throughput repertoire paper either cites the resource or makes
use of its nomenclature. However, as we have seen in this chapter, it certainly contains
incorrect classification of some genes, therefore – at least in some small way – experi-
ments which are based exclusively upon their annotations are flawed from the outset.
One could imagine a scenario in which looking for a particular specific TCR clone could
be important, such as tracking minimum residual disease in a leukaemia patient: if this
clone happens to be using a V gene that was not included in the multiplex primer
panel or rearrangement analysis software then it unlikely to feature or be detected in
the data. This chapter serves as a reminder that we must remain open-minded in our
approach, and that even the most well-curated databases are still subject to errors. I
imagine that IMGT must soon adopt a system whereby the findings of such repertoire
sequencing experiments can be incorporated. Another area where this might be useful
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is the identification of new alleles of different germline genes, which has already been
reported in one RepSeq analysis (183).
There are a number of caveats and limitations both to repertoire sequencing gen-
erally and the analyses presented here specifically. One of the major issues is that of
sampling: in any one experiment we can only observe a fraction of total cells taken
typically from one tissue, usually blood10. These tissues are themselves subject to sam-
pling processes as cells enter and leave, divide and die. This will affect the nature of
the questions that can be answered using repertoire sequencing. One is only able to
reliably study cells which appear frequently appear above the rate of detection of the
experiment: one would not be able to study say GEM cells at the depth of sampling
used in this study without great cost. Given the conservation between samples, it is
however probable that the general TCR repertoire features and population structures
obtained from a small but random sample are indeed likely to be representative of
the whole tissue. In a similar vein, Eugster et al were able to detect antigen-specific
T-cell responses from sequential small blood samples, however the exact clones used
were often different between samples (208). It must also be stressed that in this thesis
I was only making use of a fraction of RNA derived from just two to three millilitres
of blood, yet was still able to generate this wealth of data: if greater depth is required
one could easily take more blood, process more RNA or sequence more of the library.
Sampling leads on to another important consideration for repertoire sequencing,
that of diversity. Diversity is a key parameter of the T-cell response – arguably even
the ‘purpose’ of TCRs – as it corresponds on some level to the number and nature of
antigens that can be responded to (209). However we cannot compare sample diversity
in its purest sense (i.e. number of different sequences, or richness) due to the sampling
effect. Instead, in this thesis I have adopted two diversity indices to measure different
aspects of TCR repertoire diversity, which can then be compared between samples
without knowing the true size of the repertoire. Being able to measure repertoire
diversity in healthy individuals provides a baseline against which to compare repertoires
from patients who we might expect to display altered T-cell populations.
The final major consideration is that of expression. With the exception of Harlan
Robins’ group, and anyone who makes use of data generated either in collaboration with
them or through the company he helped found, the majority of groups currently using
deep-sequencing to study TCR repertoires use RNA as their starting material. This has
a number of technical benefits, such as the downregulation of non-productive sequences
10This problem affects mouse studies to a lesser extent, as more T-cells can be sampled, i.e. a greater
proportion of a given mouse’s total T-cells can be sampled by splenectomy than can be obtained from
a human by phlebotomy.
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and the ability to perform unbiased pan-TCR amplification (discussed in detail in
Section 5.1.2 in Chapter 5), yet also brings some caveats, the foremost being that mRNA
expression levels are mutable. TCR expression has a further complication, as not only
can mRNA levels change through modulation of transcription or turnover as with any
transcript, but such processes could theoretically differentially affect TCRs as each V
gene brings its own promoter and regulatory regions to a rearrangement (210, 211).
Therefore we must not confuse sequence frequencies with cell frequencies. However,
the two are related, if not linearly. While not extensively studied, TCR expression has
been shown in several in vitro model systems to increase upon T-cell stimulation prior
to cell division (212, 213, 214, 215), even as TCR molecules are internalised from the
cell surface (216, 217). This implies that there are two forces driving the frequency of
TCR mRNA molecules in a blood sample (and thus the probability of their detection by
sequencing): the number of cells of that clonotype, and their activation status, which
could be advantageous in certain experiments. Using gDNA should allow description
of relative abundance of cells, assuming an unbiased amplification protocol. However,
if one requires absolute quantitation of cells from repertoire sequencing data, it would
require using a barcoded amplification approach analogous to the one described in this
thesis, but using gDNA as a substrate, a strategy that to my knowledge has not yet
been employed.
In spite of these limitations, in this chapter I have demonstrated how one can apply
TCR repertoire sequencing to even small samples of peripheral blood and extract a
great deal of diverse information relating to T-cell biology.
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4Perturbations to the T-cell
receptor repertoire during HIV
infection
4.1 Introduction
4.1.1 HIV and AIDS
June 1981 saw the beginnings of the Western outbreak of acquired immunodeficiency
syndrome (AIDS) in the United States of America, which made it to the United
Kingdom by the end of that year (218, 219). The syndrome consists of increased like-
lihood of pathology from opportunistic infections, often from typically non-pathogenic
microbes, as well as certain uncommon malignancies and autoimmune conditions, in
patients with no history of immunodeficiency (220). Pneumonia from Pneumocystis
jiroveci (then called Pneumocystis carinii) and Kaposi’s sarcoma (later found to be
caused by the eponymous herpesvirus (221, 222)) were particularly common forms of
AIDS associated disease (223, 224). Moreover the syndrome was initially enriched
among certain demographics, particularly men that have sex with other men, intra-
venous drug users, haemophiliacs and Haitians (220). In the following years, several
groups – notably those headed by Luc Montagnier and Robert Gallo – isolated cyto-
pathic T-cell tropic retroviruses from patients with AIDS (225, 226, 227). These were
later discovered to all be the same virus and the causative agent of AIDS, which was
eventually renamed human immunodeficiency virus (HIV) (228, 229, 230).
HIV has been the subject of a great deal of research, thus much is now known about
it and its life cycle. It belongs to the lentivirus family of retroviruses (231). Primary
infection can often be asymptomatic or produce mononucleosis symptoms, and initial
peak viraemia will typically be contained as the cellular and humoral responses to the
virus develops (232, 233). Patients usually then enter a phase of seeming good health
with minimal viraemia, which can last from months to years, although the virus remains
highly active in lymphoid tissues (234, 235). As the disease progresses, patients suffer
from a gradual loss of CD4+ T-cells, which prompted research that identified CD4 itself
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as HIV’s primary receptor for cell entry (236, 237). This CD4 cell death was previously
thought to be the result of apoptosis of uninfected bystander T-cells, likely as a result
of activation-induced cell death or by action of some viral component (238). However
recent evidence suggests that the bulk of CD4 cell loss in lymphoid tissues may be due
to unsuccessfully infected cells undergoing pyroptosis in response to aborted reverse
transcription products, creating an inflammatory focus that in turn could recruit more
T-cells to the site of infection (239, 240). This loss of CD4 cells and the chronic
systemic inflammation seen during HIV are thus considered the driving forces of the
immunodeficiency that causes AIDS, making CD4 count a useful clinical marker of
disease progression (241).
HIV also perturbs the CD8+ compartment, both through driving antigen-specific
clonal expansion as well as the general bystander activation and exhaustion observed
during infection (242, 243). CD8+ cytotoxic T-cells (CTL) are important mediators of
anti-HIV immunity. Strong CD8 responses correlate with control of initial viraemia,
while subsequent loss of or escape from viral-specific CTLs associates with increasing
viral titres and clinical progression (244, 245, 246, 247). Qualitative differences in the
CD8 T-cells of individuals who achieve good virological control correlate with a delay
in progression to AIDS (248, 249, 250). Furthermore certain HLA class haplotypes
associate with either greater or lesser ability to control disease progression (251).
3’-azido-3’-deoxythymidine (AZT), a thymidine analogue that inhibits HIV reverse
transcriptase (RT) by chain termination, was shown to possess antiviral activity both
in vitro and in vivo, providing the first antiretroviral therapy (ART) for HIV (252,
253). Inspection of viral sequences from treated patients with decreasing sensitivity
to treatment however revealed that the RT gene could acquire resistance mutations
(254). The development of additional drugs, and particularly new classes of drugs that
target different stages of the HIV life cycle, allowed the development of combination
ART (cART, also called highly active antiretroviral therapy, HAART) drug regimens
(255). HAART reduces viral loads, improves CD4 cell levels and reduces the risk of
opportunistic infections, while reducing the risk of resistance as the virus would need
to mutate multiple residues simultaneously (256). Accordingly cART has become the
standard of care for patients with HIV (257).
Current therapeutic options are however unable to completely remove virus from
an individual as HIV integrates its genome into that of the host, allowing it to persist
in the face of treatment, necessitating constant medicating (233). Moreover patients
on HAART still remain at greater risk of certain non-AIDS related diseases, which are
typically those often associated with aging, displaying increased rates of cardiovascular,
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kidney, liver and bone disease, cancer and various neurological syndromes (reviewed
in (241)). Despite increasing life expectancy of HIV+ individuals substantially, these
treated patients still have lower life expectancies than HIV- people (258). This suggests
that HIV is able to cause some physiological damage (either before or during therapy)
that treatment is unable to fully rectify, or that the drugs themselves have off-target
effects. At the end of 2013 there were 35 million people estimated to be infected with
HIV globally, of whom approximately 12.9 million were receiving ART (259), therefore
the burden both of the disease and any therapy-associated pathology remain important
subjects of research.
4.1.2 HIV TCR repertoire analysis
There have been a number of studies using various techniques investigating TCRs in
HIV-infected individuals. Flow cytometry, DNA hybridisation and quantitative PCR
have shown decreased expression of certain V genes, with certain families being de-
pleted to variable extents in different individuals (260, 261, 262, 263). Furthermore
spectratyping analysis revealed a skewing of CDR3 length distributions in certain V
families, indicative of clonal expansions (264, 265, 266). A decrease in TCR diversity
associated with HIV infection has also been measured using a number of experimental
approaches (267, 268, 269), although such observations have typically been limited to
either antigen- or T-cell subset-specific populations. The overall impact on the clonal
structure of the T-cell population of the virus depleting CD4+ T-cells while simultane-
ously being targeted by (and eventually escaping from) CD8 cells remains incompletely
understood.
As discussed in Chapter 3, the introduction of high-throughput DNA sequencing
(HTS) allows analysis of the TCR repertoire at much greater depth than was previously
possible. The wide ranging T-cell effects and large global disease burden make HIV-
infection an eminently suitable testing ground for such analysis. Therefore in this
chapter I describe the sequencing of TCR repertoires from a cohort of ART-na¨ıve
HIV patients. RNA was extracted from the peripheral blood of 16 adult HIV-positive
patients due to start ART at two time-points, both immediately prior to (‘v1’) and three
months after commencing therapy (‘v2’). Patients were excluded if they were currently
showing symptoms for AIDS related illness, or if they had been recently vaccinated.
Each RNA sample was processed using the error-correcting barcoded-cDNA protocol
that was used in Chapter 3 (detailed later in Section 5.2.6). The patient data was
compared to the healthy repertoires of the ten healthy donors explored in Chapter 3,
four of whom were also sampled twice after a three month interval.
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4.2 HIV infection associates with a dramatic loss of TCR
diversity
Given the variety of reports of reduced diversity in the CDR3 repertoires of HIV patients
I used the indexes employed in Chapter 3 to assess the diversity in the pre-treatment
patient samples. Figure 4.1A and B display a significant difference between the Gini
index and Shannon entropy of healthy and HIV-positive repertoires respectively. The
reduced diversity reflected by the difference in these indexes was manifest in both
α and β chains, although the complexity of α chain repertoires was less than those
of β (Figure 4.1B), consistent with the lack of a diversity region and consequently
less junctional diversity (78). The high inequality and low complexity of repertoires
from HIV patients could be considered equivalent to a relatively oligoclonal population
in comparison to healthy individuals. In order to assess whether this was the case I
measured the average proportional frequency of the 50 largest CDR3s in each donor: in
patients these common sequences accounted for approximately ten times the proportion
of their respective donors than in healthy donors (Figure 4.1C). I performed a number
of linear regressions to see whether any clinical scores correlated with the repertoire
diversity metrics. Surprisingly, the most significant correlation was between the CD8
cell count and the Gini index (Figure 4.1D), suggesting that particularly unevenly
distributed repertoires might be produced in part by large clonal expansions in the
CD8 pool. Despite the low CD4 T-cell counts in these patients, CD4 values did not
correlate with Gini index (see Figure B.1A in Appendix B). Multiple regressions of
both indexes against various clinical scores (performed by my colleague Katharine Best)
confirmed that CD8 cell count and Gini index were the two parameters that correlated
best (Figure B.1B).
These findings seemed to run in opposition to the simplest potential explanation,
that the decrease of diversity was solely attributable to the loss of CD4 T-cells as a
result of viral infection. I wished to further explore the hypothesis of CD8 expansions
being a pressure driving down diversity, however we did not have access to fresh or
sorted blood samples from these patients. In order to overcome this limitation, an
alternative assay was devised that requires neither access to patient samples nor sorting
of HIV-positive cells. TCR sequences were randomly sampled from the CD4+ and
CD8+ repertoires sorted from healthy donors (discussed earlier in Section 3.2.1) in
silico, and combined in different amounts to simulate mixed repertoires from donors
with different CD4:CD8 ratios. The diversity indexes of these simulated repertoires are
shown in Figure 4.2. As the proportion of CD8 cells increases, so does the repertoire
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A B
C D
Figure 4.1: TCR-repertoires of HIV-infected patients are typified by lower clonal
diversity and higher inequality than healthy donors. A: Evenness of healthy and HIV-
infected whole, unsampled CDR3 repertoires as measured by Gini index. HIV+ Gini indexes
were significantly greater than healthy donors’ (p = 7.937e-15, the lower bound for this test
in R, the statistical software used). B: Information content (as a diversity index) measured
by Shannon entropy of CDR3 repertoires. HIV+ Shannon entropies were significantly lower
than healthy donors’ (p = 7.937e-15). Between both healthy donors and HIV patients, alpha
repertoires have significantly lower Shannon entropies (p = 2.582e-05). C: Mean proportional
frequencies of the 50 most common CDR3s for healthy (blue) and HIV-infected (red) donors:
HIV+ mean frequencies are significantly higher than healthy donors (p = 7.937e-15). P-values
in A, B and C are all Wilcoxon rank sum tests. D: Linear regression of CD8 T-cell count
during the v1 bleed versus Gini index (R2 = 0.51, p = 4.30e-6).
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B
Figure 4.2: Simulating TCR repertoires with different CD4:CD8 ratios. CD4+
and CD8+ T-cells were sorted from PBMC extracted from two healthy donors (HV01 and
HVD4) and sequenced. Fixed numbers of TCR classifiers were randomly sampled from each
population and mixed in different ratios to simulate populations with different ratios, and
then Gini index (A) and Shannon entropy (B) were calculated. Horizontal lines indicate the
mean index values of the healthy (blue) and HIV-infected (red) repertoires in our dataset ±
standard deviation. The mean ratio observed in our patient clinical data (0.31:1) is denoted
by x¯ (vertical red line, ± standard deviation)
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inequality (Figure 4.2A), while the complexity falls (Figure 4.2B). The diversity indices
of the simulated repertoires intersect the mean values observed in the sequenced data
of the healthy repertoires at ratios of 2.5:1 to 2:1, within typical expected ranges for
a healthy population (270). However, when we reconstitute simulated repertoires with
a ratio of 0.31 – the average CD4:CD8 ratio seen in the HIV patient’s clinical data –
we see that the reconstituted repertoires are still yet more diverse, showing both lower
Gini indexes and higher Shannon entropies. These findings demonstrate that the low
diversity observed in the HIV+ samples does not appear to solely be due to a decreasing
CD4:CD8 ratio; instead, CD8 expansions as well as CD4 cell loss must be driving the
inequality and low complexity in HIV+ patients.
4.3 TCR repertoire population structures are perturbed
in HIV patients
In spite of the stochastic nature of V(D)J recombination, there are a number of reper-
toire features that are reported shared between individuals, potentially reflecting con-
straints of the recombination machinery (77, 179, 271). These properties are character-
istic of, and potentially contributory towards, what we consider to be ‘healthy’ TCR
repertoires. Therefore I wished to establish whether these features were altered during
HIV infection.
One such property is the sharing of TCR clonotypes across multiple individuals
(discussed above in Section 3.1.4), possibly as a result of convergent or biased recombi-
nation processes (130, 131, 181, 184, 271). Given the dramatic loss of diversity observed
in HIV patients, I hypothesised that we should expect to see less sharing. I calculated
the publicness of those CDR3s that were only found either in healthy or HIV-infected
patients; those that were limited to HIV patients were far less public, occurring less
often and in fewer donors for both α (Figure 4.3A) and β chains (Figure B.2A). Cal-
culation of the Jaccard index – a normalised measure of sharing – between pairs of
different donors revealed that any two HIV patients share fewer CDR3s than do any
two uninfected controls (Figure 4.3B). I also observed that the largest CDR3s in the
healthy donors are also encoded by a greater number of nucleotide rearrangements than
those in HIV-infected donors (Figures 4.3C and B.2B). This loss in translational con-
vergence occurs even though the most common CDR3s in HIV patients account for a
far greater proportion of their respective repertoires, reflecting the extreme expansions
of individual rearrangements.
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Figure 4.3: HIV+ TCR repertories are less shared, public, and translationally
convergent than healthy controls, and are highly divergent in their V and J
gene use. A: α chain CDR3s are less public in HIV-infected than healthy repertoires. The
number of CDR3s shared by different numbers of individuals is shown, considering only those
CDR3s that were found exclusively in either healthy (blue) or HIV+ (red) donor repertoires.
This analysis was applied to whole samples (solid lines) and a random subsample of 5000
CDR3s (dotted lines). To account for the greater number of patients than controls, ten
HIV+ samples were randomly selected and publicness measured: this was repeated 100 times,
shaded areas represent standard deviation. B: Inter-donor Jaccard index measuring sharing
between pairwise combinations of healthy control (HC) or HIV-infected CDR3 repertoires,
for 5000 randomly chosen CDR3s. Horizontal lines indicate medians. Inter-donor Jaccard
scores were significantly higher in healthy donors than HIV+ patients for both chains (p =
2.2e-16 and 1.147e-13 respectively, unpaired Wilcoxon rank sum test). C: α CDR3s display
a lower mean translational convergence in HIV+ donors than healthy, i.e. were encoded by
fewer nucleotide sequences, determined by counting the number of unique Decombinator
identifiers that produce the same CDR3. Blue and red lines indicate the mean translational
convergence for each group (healthy/HIV respectively) for each CDR3 rank; green and purple
lines show a sliding window averaging across 100 ranks. D: Barplot showing the difference in
TRAV usage, by Jensen-Shannon Divergence (JSD). Donor-specific proportional gene usage
matrices, before each pair of healthy or HIV+ donors was compared. Only interquartile
ranges and medians are shown.
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I also assessed the differences between the V and J gene expression profiles of the
two groups, by comparing frequency distributions of pairs of donors using the Jensen-
Shannon measure of divergence (JSD). Values for α V genes are shown in Figure 4.3C,
while the remaining genes’ divergence values are in Appendix B, Figure B.3. Healthy
donors’ repertoires diverge from one another by a relatively small, consistent amount,
while any two HIV+ patients differ by greater, more variable amounts. Comparing
healthy donor to HIV-patient distributions reveals an intermediate level of divergence
(data not shown for clarity). These data suggest a scenario in which there exists a
healthy core of gene usage, where any two individuals can differ from one another by
a small amount. HIV infection then drives an individual’s usage profiles away from
this healthy core, but it does so in a different direction in different people, producing
idiosyncratic profiles that differ somewhat from typical values, but greater from other
patients. I also note that there is no difference between infected and uninfected donor
profiles for TRBJ (Figure B.3C), perhaps due to the smaller number of genes or the con-
founding effect of the D region. Examination of the raw gene usage profiles themselves
(Figure B.4) reveals that most genes on average are used an equivalent amount, just
with greater variance among patients; a small number of genes in each locus, however,
show a consistent difference in frequency between healthy controls and HIV-infected
individuals (e.g. TRAJ33 and TRBV6-1, Figure B.4B and C).
4.4 Effect of antiretroviral therapy on TCR repertoires of
HIV+ individuals
By comparing the treatment-na¨ıve samples with those taken after an average of 14
weeks of therapy I was able to assess the impact of short-term ART upon the TCR
repertoires of HIV patients. The four healthy donors who were also sampled after a
comparable time period act as controls of typical repertoire variation over time and
between samples.
By inspecting the clinical parameters we can infer that the ART had the expected
effects: viral loads drop in all patients, typically beneath the limits of detection, while
absolute CD4 cell levels and CD4:CD8 ratios increase significantly (Figure B.5). The
only major lymphocytic parameter to not significantly change over the course of the
treatment is the CD8 T-cell count (Figure B.5B), which could indicate that the CD8
expansions hypothesised above are persistent in the face of treatment. This analysis
also revealed an interesting caveat of our patient data: the length of time elapsed before
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Figure 4.4: ART partially reduces repertoire inequality, but general diversity
and idiosyncratic gene usage do not recover. A: Intra-donor Jaccard indices, describ-
ing overlap between v1 and v2 bleeds for both healthy control (HC) and HIV+ donors for
5000 CDR3s subsampled from whole repertoires. Horizontal lines indicate medians. Healthy
controls have significantly lower α and β chain intra-donor sharing by Jaccard (p = 0.02912
and 0.01367 respectively, one-sided unpaired Wilcoxon signed rank test). B: Log2 fold change
in median TRAV Jensen-Shannon Divergence (JSD) from v1 to v2 (red). Blue bars indicate
the log2 change in median JSD that would be required for that patient to reach the mean
value of the median JSDs for the ten healthy controls, i.e. return them to the average level
of divergence healthy controls display in Figure 4.3D. C: Gini indexes of whole CDR3 reper-
toires of healthy donors, and both v1 and v2 bleeds of HIV+ patient repertoires. Horizontal
lines indicate medians. Pre-ART bleeds have significantly higher Gini indexes than post-
ART (p = 0.0001673, paired one-sided Wilcoxon test). D: Shannon entropies of whole CDR3
repertoires of healthy donors, and both v1 and v2 bleeds of HIV+ patients. Horizontal lines
indicate medians. There is no significant difference between pre- and post-ART Shannon
entropies (p = 0.1609, paired one-sided Wilcoxon test). Fold changes are shown in Figure
B.8.
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each patient began therapy correlated with their CD4:CD8 cell ratio at time of the pre-
treatment bleed (Figure B.6). This might be explained by differences in viral control
influencing the likelihood of patients seeking rapid treatment.
In contrast to the inter-donor Jaccard indexes shown in Figure 4.3B, calculation of
intra-donor CDR3 repertoires revealed that the overlap between two samples from the
same donor is greater for the HIV patients than the healthy donors (Figure 4.4A), i.e.
more sequenced are retained within an HIV-patient over the same time period. Given
the various levels of subsampling in such sequencing efforts – including cells sampled
during phlebotomy, mRNAs processed during amplification and amplicons recorded
in the sequencer – it is only ever possible to obtain data for a fraction of the entire
TCR repertoire. That these HIV patients have far fewer unique CDR3s at both time
points but still retain more sequences over therapy suggests that clonal expansions
are persistent, even in the face of therapy. However there are two patients that have
exceedingly low Jaccard indexes in both chains, indicating that they have undergone
dramatic repertoire remodelling events. Post-treatment gene usage divergence values
were calculated as before: not only did divergence not return to healthy ranges, in
the majority of patients it actually increased (Figures 4.4B and B.7). The majority
of patient repertoires (11 out of 16) did observe a decrease in Gini index on ART,
indicating a partial recovery in repertoire equality (Figures 4.4C and B.8A). However,
the information content as measured by Shannon entropy did not significantly change
over the course of treatment (Figures 4.4D and B.8B). Thus three months of ART
is sufficient to reduce viral load to undetectable levels and begin to replenish CD4
cell numbers, but does not restore the properties of the TCR repertoire to the ranges
observed in healthy donors.
4.5 Tracking sequence-specific CDR3s on ART
It is not yet possible to infer the quaternary structure of TCRs from primary sequence,
much less their binding specificities. Moreover most high-throughput experiments,
including this one, do not yet routinely obtain paired α and β chain sequence and
MHC haplotype information. However there are a number of reports that CDR3s from
T-cells reactive against the same antigens often share sequence identity or features,
and some TCRs can recognise the same peptide in different HLA backgrounds (272,
273, 274, 275). There are also reports from several groups of public TCR sequences
reactive against HIV antigens (276, 277, 278), sometimes even finding the same CDR3
in combination with different V and J genes (249). This lead me to question whether our
data contains any CDR3 sequences of known specificity, as a proxy for such specificities
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Figure 4.5: Dynamics of viral-associated and invariant MAIT cell CDR3s. A:
Proportional frequencies of the published, antigen specific CDR3s that were also found in
the whole CDR3 repertoires pre- and post-treatment. CDR3s were only included if they
appeared twice or more in both of a patient’s bleeds. Horizontal lines indicate medians.
HIV-related CDR3s significantly decreased after three month of therapy, while CMV CDR3s
increased (p = 0.01799 and 0.04919 respectively, paired Wilcoxon signed rank test). HIV-
associated CDR3s were only found in six of the 16 HIV+ patients, with the majority (7/13)
all found in one donor (P017). The two HIV-associated CDR3s found in healthy volunteers
were from the same donor (HV04). CMV-associated CDR3s were found across nine HIV+
donors (with four, the most, being contributed by P027), while the single healthy response
was found in HV03. B: Proportional frequencies of α chain sequences that match published
MAIT cell VJ-CDR3 sequences, for healthy control (left) and HIV donors (right). Horizontal
lines indicate medians. Healthy donors’ median MAIT CDR3 frequencies are significantly
higher than those of HIV patients at both time points (p = 0.006366 and 0.03558, unpaired
one-sided Wilcoxon signed rank test). There is no significant change in frequency for either
healthy or HIV+ results from bleed v1 to v2 (p = 0.2929 and 0.1403 respectively, paired
one-sided Wilcoxon signed rank test).
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potentially existing in the patients. I therefore harvested the amino acid sequences of
published CDR3s known to be specific to HIV antigens from the literature (referenced
in Appendix Table B.1). These were typically obtained through isolating HIV-specific
pMHC-tetramer positive T-cells from infected patients. A comparable set of sequences
were also collected for CMV- and EBV-specific CDR3s was also collected, as these are
other well-studied, widespread chronic viruses known to drive large oligoclonal T-cell
expansions (81, 279, 280).
The relative change and raw frequency values for those published viral-associated
CDR3s that were found in our data (present at least twice in both of an individual’s
bleeds) are shown in Figures 4.5A and B.9. Thirteen HIV-associated CDR3s were
present in the HIV patients’ sequence data, coming from six of the 16 individuals
sampled. These sequences included three α chain CDR3s, one of which was present
in two donors while the third differed by only a single amino acid. Seventeen CMV-
associated CDR3s were detected from nine patients, while six EBV-associated sequences
were found across five patients. Interestingly, the frequency of HIV-associated CDR3s
decreased in frequency over the course of therapy, while the majority of CMV- and
EBV-associated sequences grew more frequent. These viral-associated sequences were
almost completely absent from the healthy controls, with only one or two low-frequency
responses identified per virus (although this will partially reflect the greater number of
HIV patients sequenced). If we assume that these viral-associated sequences may indeed
represent T-cells playing a role in specific antiviral responses, this data would suggest
that during ART anti-HIV clones are able to contract as viral load falls, which would
leave ‘space’ in the repertoire into which clones of other specificities could expand. The
nature of this ‘space’ would likely be decreased competition for some shared or limiting
resource. The extent of the herpesvirus response is particularly noteworthy. The rate of
return for this analysis was much greater than for HIV – despite finding more sequences,
I only searched for 265 published CMV CDR3s compared with 871 specific for HIV –
and the resultant CDR3s account for greater proportions of their repertoires (Figure
B.9A). This is consistent with observations that CMV- and EBV-specific TCRs often
belong to very large and highly shared clones (81, 275).
I also looked for the presence of the invariant α chain TCRs of the non-pMHC re-
stricted T-cell subsets discussed in Section 3.1.5. MAIT cell VJ-CDR3 sequences had
been highly prevalent in the healthy controls (see Figure 3.9), and are still often de-
tectable in the HIV-patient repertoires (Figure 4.5B). However there was a significant
reduction in the proportional frequency of MAIT cell TCR sequences detected in un-
treated HIV patients, that did not significantly change after three months of treatment.
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This depletion of MAIT cell sequences is so profound that we can see it at the gene
level: the V and J genes for the canonical MAIT alpha chain (TRAV1-2 and TRAJ33)
as well as the V genes known to contribute to their beta chains (TRBV6-1, TRBV6-4
and TRBV20-1 (281)) were among the minority of genes that were used significantly
less in the HIV patient data (Figure B.4A-C). Similarly, despite there being no pub-
lished iNKT VJ-CDR3 sequences observed in this analysis, the genes encoding their
invariant TCRs (TRAV10 and TRAJ18 (282)) were also less common in the reper-
toires from HIV-infected samples. NKT cells are known to be reduced in HIV patients
(283, 284, 285); it is possible that a far wider range of iNKT CDR3s exists than is
currently known and some are being depleted in these patients, which would explain a
decrease in the associated V genes. No GEM sequences were found using these critera,
consistent with their low detection even in healthy individuals.
4.6 Discussion
Through application of the unbiased, error-correcting TCR amplification and sequenc-
ing protocol developed in the course of my PhD, I have explored the effect of HIV
infection and subsequent antiretroviral treatment upon TCR repertoires. HIV pa-
tients’ repertoires differ from those of healthy individuals in every regard examined.
They are typified by marked clonal inequality, wherein a relatively small number of
highly expanded, private rearrangements occupy a large proportion of the repertoire.
Furthermore this inequality correlated with the patients’ CD8+ cell counts. However
neither Gini index values nor CD8 counts correlated with CD4 counts, suggesting that
the two compartments are being altered by different processes. Cell counts of both
populations failed to correlate with the length of time individuals remained infected
but untreated, which varied widely in this cohort. These correlations, combined with
the fact that in silico simulation of repertoires of decreasing CD4:CD8 ratios failed
to reproduce the low inequality observed in the patients, speak to a model in which
CD8+ clonal expansions help drive the loss of repertoire evenness, independent of CD4
cell death. These two components of T-cell perturbation drive reductions in repertoire
diversity, translational convergence and inter-donor TCR sharing, endowing patients
with highly idiosyncratic gene usage profiles that lie far outside the ranges observed in
healthy uninfected individuals.
A current weakness of TCR sequencing approaches is the inability to assign speci-
ficity, as predicting protein structures and behaviours of large multi-protein complexes
remains extremely challenging in general, and particularly difficult for TCR-pMHC
interactions (reviewed in (286)). Even were there mechanisms to infer TCR antigens
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from sequence, this current study would not be geared towards this end as we ob-
tained neither paired αβ chain information nor patient HLA haplotypes. I nevertheless
identified a small number of CDR3s in the HIV patients’ repertoires that have pre-
viously been reported as belonging to viral-specific T-cell clones. The frequency of
these CDR3s undergo changes that we might expect if they were reactive against their
associated viruses: HIV-associated CDR3s got rarer while CMV- and EBV-associated
CDR3s became more prevalent. This matches a variety of reports that found a de-
crease in HIV-reactive clone frequency during ART while CMV-reactive clones increased
(268, 287, 288), which is in turn reinforced by the frequent loss of CMV viraemia during
treatment for HIV (289, 290). These findings lend weight to the possibility that the
viral-associated CDR3s in this data might actually be derived from TCRs which share
those specificities, and the changes observed in Figure 4.5A represent the contraction
of HIV-reactive clones as ART depletes the source of antigen, allowing re-emergence
of protective responses and pathogen control. If so, it is possible these shared viral-
associated CDR3s could represent members of a subset of receptors in which antigenic
specificity is concentrated in one of the two chains (291, 292).
Questions as to the nature of the expanded sequences remain. These could represent
CD8+ clones that are yet to contract in response to diminished antigen levels, or still be
responding to residual infection. These need not consist exclusively or even primarily
of HIV-reactive clones. For example, of the viral-associated CDR3s I found, those
associated with CMV were found at much higher frequencies than those associated
with HIV. Indeed, Betts et al reported that only an average 6.31% of total CD8 cells
from treatment-na¨ıve HIV-patients were specific for HIV antigens (293). The rest of
the expanded clones may be driven to proliferate in an antigen-independent manner, or
by exposure to other non-HIV pathogens as a result of increasing immunosuppression
(294, 295). For instance it has been shown that HIV induces gastrointestinal damage
that leads to increased translation of gut microbial antigens to the circulation (296, 297),
which stands to act as a substantial source of persistent antigens for T-cells to react
against. Another potential explanation for such prevalent, persistent clones is the more
recent discovery that the integration of HIV at different genomic sites associates with
clonal expansion and retention (298), even when the integration consists of defective
provirus (299), presumably as a result of interacting with the expression of neighbouring
host genes. However due to the lack of correlation between CD4 count and either
diversity index it seems unlikely that this phenomena causes widespread effects in this
data.
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Not only does this data describe a profound perturbation to the normal TCR reper-
toire in the context of chronic HIV infection, these abnormal population structures per-
sist despite otherwise effective ART. Three months of ART is often associated with a
reversal of AIDS-associated pathology, clinical improvement and decreased risk of mor-
bidity, even though CD4+ T-cell counts may remain well below normal levels (300, 301).
Nevertheless, it is apparent that the recovery of the CD8+ T-cell repertoire remains in-
complete despite effective treatment. Large CD8+ clonal expansions are often found to
persist after years of therapy (reviewed in (302)), and significant ‘holes’ in the repertoire
may remain. Insufficient epitope coverage as a result of profound CD8 clonal inequal-
ity may also explain why HIV patients with low CD4:CD8 ratios are at a greater risk
of developing non-HIV related morbidity and mortality (270, 303), even when viral
replication is controlled.
In this data I have described that the invariant alpha chain TCRs of MAIT cells –
which can comprise in excess of 10% of the circulating CD8 T-cell pool under normal
circumstances (304) – are profoundly depleted in this HIV+ cohort, and remain so over
the course of treatment. This is in agreement with similar findings from recent efforts
that described the same phenotype using multiparameter flow cytometry (143, 304,
305). It is unclear whether the under-representation of these cells in the blood occurs
as a result of increased cell death or trafficking to another tissue, although they do not
appear to be preferentially targeted by the virus (143), consistent with their primarily
CD8+ or double negative profile (306). However, given their contribution to bacterial
ligand recognition at mucosal sites, their absence in even treated HIV+ patients may
represent gaps in the immune protection from certain microbes. Invariant TCR chain
NKT cells have also been reported to be selectively depleted early during HIV infection
(284, 285, 307), which may similarly lead to gaps in viral protection, although these
sequences remain below the thresholds of consistent detection in this study. The loss
of these non-pMHC restricted T-cell subsets are thus prime examples of potential holes
in the repertoires of HIV patients.
Further longitudinal samples from the patients in this and other cohorts at later
time-points after starting therapy will be instructive in assessing the extent and reper-
toire correlates of long-term immunological recovery. Sequencing RNA from a larger
blood sample would also increase the range of detection in these assays. Sorting of
patient blood into different populations – particularly CD4+ and CD8+ – before se-
quencing would allow much greater resolution in the descriptive and predictive power of
the experiment, although handling and cell sorting of blood from HIV patients presents
its own technical and safety challenges. In this vein, an ideal experiment would likely
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involve high-throughput single-cell whole transcriptome sequencing, from which one
could extract both paired TCR information and expression of T-cell subset markers.
There is obviously more to T-cell immunity than just which clonotypes are present
at what frequencies. In the case of HIV, particular clonotypes may be present but
exhausted as a result of chronic stimulation (243), and remain unable to offer fur-
ther protection. Thus transcriptomic profiling of cells with known TCRs would allow
qualitative descriptions from which we might estimate phenotype.
In conclusion, my data contribute to the field by describing in detail how HIV
infection profoundly alters the TCR repertoire. Partial reversal of inequality may be
rapid and lead to improved immune function, coinciding with the first more rapid
phase of T-cell recovery (308). Long-term damage to the repertoire may be much
more difficult to repair, particularly in adults where naive peripheral T-cell pools are
maintained by homeostatic cell division as opposed to thymic production of new cells,
which may contribute to long-term morbidity (309, 310). TCR sequencing and similar
approaches offer a chance to gain new insight into such processes, which in larger studies
may provide useful biomarkers for patient stratification.
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5.1 Introduction
High-throughput DNA sequencing (HTS) of variable antigen receptor repertoires (or
‘Rep-Seq’ (74)) represents a tremendous opportunity to dissect immunological phe-
nomena with the utmost breadth and accuracy. However, while the transition to such
platforms offers great throughput and resolution, it also introduces a number of techni-
cal hurdles which must be overcome in order to produce valid, good quality data. This
chapter deals with the nature of these hurdles, and how I have addressed them during
my PhD. Herein I detail the amplification procedures and sequence-based metrics that
were used to judge efficacy and appropriateness of different strategies. The biological
interpretation of the data output from these protocols was covered above in Chapters
3 and 4.
5.1.1 DNA sequencing technologies
In order to fully appreciate the development of protocols for sequencing TCR reper-
toires, we must first understand how sequencing technologies work, and how high-
throughput sequencers are different to earlier generation machines.
5.1.1.1 First-generation DNA sequencing
Despite Watson and Crick solving the three-dimensional structure of DNA in 1953
(311)1, the ability to ‘read’ or sequence DNA did not follow for some time. Initial
efforts focused on sequencing the genomes of single-stranded RNA bacteriophages and
bacterial ribosomal RNA subunits – which were the most readily available pure popu-
lations of single RNA species at the time – through what we would now consider to be
extremely arduous techniques, involving a great deal of radioactive labelling and two-
dimensional fractionation (313, 314, 315). It was by using such techniques that Walter
Fiers’ laboratory was able to produce the first complete sequence of a gene encoding
a protein, that of the coat protein of bacteriophage MS2 (316), followed four years
1Notably working from crystallographic data produced by Rosalind Franklin and Maurice Wilkins
(312).
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later by the complete genome (317). Around this time various researchers2 began to
develop methods for sequencing DNA, again making use of radiolabelled nucleotides.
Original observations that one could make use of DNA polymerase to incorporate nu-
cleotides at the ends of bacteriophage genomes that possessed 5’ overhangs (318) lead
researchers to create their own partially double-stranded DNA molecules through the
addition of synthetic oligonucleotides, enabling sequencing by incubating with mixtures
of variably-labelled nucleotides (319, 320, 321, 322). A notable alternative technique
involved using a number of different chemical techniques to cleave DNA preferentially
at different bases, allowing inference of the original sequence by comparison of the resul-
tant molecule lengths (323). However the major breakthrough that forever altered the
progress of DNA sequencing technology came in 1977, with the development of Sanger’s
‘chain-termination’ or dideoxy technique, in the same year that his group sequenced
the first DNA genome, that of bacteriophage φX174 (or ‘PhiX’) (324, 325). The chain-
termination technique makes use of chemical analogues of the deoxyribonucleotides
(dNTPs) that are the monomers of DNA strands; dideoxynucleotides (ddNTPs) lack
the 3’ hydroxyl group that is required for extension of DNA chains (as it forms the bond
with the 5’ phosphate of the next dNTP) (326). Radiolabelled ddNTPs mixed into a
DNA extension reaction at a fraction of the concentration of standard dNTPs results
in DNA strands of each possible length being produced, as the dideoxy nucleotides get
randomly incorporated as the strand extends, halting further progression. By perform-
ing four parallel reactions containing individual ddNTP bases and running the results
on four lanes of a polyacrylamide gel, one is able to use autoradiography to infer what
the nucleotide sequence in the original template was, as there will a radioactive band
in the corresponding lane at that position of the gel. While working on the same prin-
ciple as other techniques (that of producing all possible incremental length sequences
and labelling the ultimate nucleotide), the accuracy, robustness and ease of use led to
the dideoxy chain-termination method – or simply, Sanger sequencing – to become the
most common technology used to sequence DNA for years to come.
A number of improvements were made to Sanger sequencing in the following years,
which primarily involved the replacement of phospho- or tritrium-radiolabelling with
fluorometric based detection (allowing the reaction to occur in one vessel instead of
four) and improved detection through capillary based electrophoresis, both of which
contributing to the development of increasingly automated DNA sequencing machines
(327, 328, 329, 330, 331, 332, 333). These sequential alterations produced the first
2Principally Ray Wu, Walter Gilbert and Fred Sanger, the latter of whom had been very instrumental
in the earlier development of RNA sequencing techniques.
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crop of commercial DNA sequencing machines (334) which were used to sequence the
genomes of increasingly complex species. These ‘first-generation’ DNA sequencing ma-
chines produce reads slightly less than one kilobase (kb) in length: in order to analyse
longer fragments researchers made use of techniques such as ‘shotgun sequencing’ where
overlapping DNA fragments were cloned and sequenced separately, and then stitched
together in silico (335, 336). The development of techniques such as polymerase chain
reaction (PCR) (61, 62) and recombinant DNA technologies (337, 338) further aided
the genomics revolution by providing means of generating the high concentrations of
pure DNA species required for sequencing. These advances also aided sequencing by
less direct routes. For instance, the Klenow fragment DNA polymerase3 had originally
been used for sequencing due to its ability to incorporate ddNTPs efficiently; however
more sequenced genomes and tools for genetic manipulation provided the resources to
find polymerases that were better able to cope with the additional chemical moeities of
the increasingly modified dNTPs used for sequencing (340). Eventually, newer dideoxy
sequencers – such as the ABI PRISM range developed from Leroy Hood’s research, pro-
duced by Applied Biosystems (341), which allowed simultaneous sequencing of hundreds
of samples (342) – came to be used in the Human Genome Project, helping to produce
the first draft of that mammoth undertaking years ahead of schedule (343, 344).
5.1.1.2 Second-generation DNA sequencing
Concurrent to the development of large-scale dideoxy sequencing efforts, another tech-
nique appeared that set the stage for the first wave in the next generation of DNA
sequencers. This method markedly differed from existing methods in that it did not in-
fer nucleotide identity through using radio- or fluorescently-labelled dNTPs or oligonu-
cleotides before visualising with electrophoresis. Instead researchers utilised a recently
discovered luminescent method for measuring pyrophosphate synthesis4 to infer se-
quence by measuring dNTP incorporation when each nucleotide is washed through the
system in turn, over the template DNA which was affixed to a solid phase (346). Note
that despite the differences, both Sanger’s dideoxy and this pyrosequencing method
are ‘sequence-by-synthesis’ (SBS) techniques, as they both require the direct action of
DNA polymerase to produce the observable output (in contrast to say the Maxam-
Gilbert technique, which uses chemical degradation to produce different sized radi-
3A fragment of the E. coli DNA polymerase that lacks 5’ to 3’ exonuclease activity, produced through
protease digestion of the native enzyme (339).
4This consisted of a two-enzyme process in which ATP sulphurylase is used to convert pyrophosphate
into ATP, which is then used as the substrate for luciferase, thus producing light proportional to the
amount of pyrophosphate (345).
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olabelled fragments). This pyrosequencing technique, pioneered by P˚al Nyre´n and
colleagues, possessed a number of features that were considered beneficial: it could be
performed using natural nucleotides (instead of the heavily-modified dNTPs used in the
chain-termination protocols), and observed in real time (instead of requiring lengthy
electrophoreses) (347, 348, 349). Later improvements included attaching the DNA to
paramagnetic beads, and enzymatically degrading unincorporated dNTPs to remove
the need for lengthy washing steps. The major difficulty posed by this technique is
finding out how many of the same nucleotide there are in a row at a given position:
the intensity of light released corresponds to the length of the homopolymer, but noise
produced a non-linear readout above four or five identical nucleotides (349). Pyrose-
quencing was later licensed to 454 Life Sciences, a biotechnology company founded by
Jonathan Rothburg, where it evolved into the first major successful ‘next-generation
sequencing’ (NGS) technology.
The sequencing machines produced by 454 (which was later purchased by Roche)
were a paradigm shift in that they allowed the mass parallelisation of sequencing re-
actions, greatly increasing the amount of DNA that can be sequenced in any one run
(350). Libraries of DNA molecules are first attached to beads via adapter sequences,
which then undergo a water-in-oil emulsion PCR (emPCR) (351) to coat each bead in
a clonal DNA population (where ideally on average one DNA molecule ends up on one
bead which amplifies in its own droplet in the emulsion). These DNA-coated beads
are then washed over a plate with picoliter reaction wells that only fit one bead each;
pyrosequencing then occurs as smaller bead-linked enzymes and dNTPs are washed
over the plate, and pyrophosphate release is measured using a charged couple device
(CCD) sensor beneath the wells. This set up was capable of producing reads around
400-500 base pairs (bp) long, for up to the million or so wells that contained suitably
clonally-coated beads (350). This parallelisation increased the yield of sequencing ef-
forts by orders of magnitudes, for instance allowing researchers to completely sequence
a single human’s genome – that belonging to DNA structure pioneer, James Watson
– far quicker and cheaper than a similar effort by DNA-sequencing entrepreneur Craig
Venter’s team using Sanger sequencing the preceding year (352, 353). The original 454
machine (and first HTS option widely available to consumers), the GS 20, was later
superceded by the 454 GS FLX, which offered a greater number of reads (by having
more wells in the ‘picotiter’ plate) as well as better quality data (354). This principle
of performing huge numbers of parallel sequencing reactions on a micrometer scale is
what came to define the second-generation of DNA sequencing, often made possible as
a result of improvements in microfabrication and high-resolution imaging (355).
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A number of technologies sprung up following the success of 454, however the most
important among them is arguably the Solexa method of sequencing, later acquired
by Illumina (354). Instead of parallelising by performing bead-based emPCR, adapter-
bracketed DNA molecules are passed over a lawn of complementary oligonucleotides
bound to a flowcell; a following solid phase PCR produces neighbouring clusters of
clonal populations from each of the individual original flow-cell binding DNA strands
(356, 357). This process has been dubbed ‘bridge amplification’, due to replicating
DNA strands having to arch over to prime the subsequent round of polymerisation
off neighbouring surface-bound oligonucleotides (354). Sequencing itself is achieved in
a SBS manner using fluorescent ‘reversible-terminator’ dNTPs, which cannot imme-
diately bind further nucleotides as the fluorophore occupies the 3’ hydroxyl position;
this must be cleaved away before polymerisation can continue (358). These modified
dNTPs and DNA polymerase are washed over the primed, single-stranded flow-cell
bound clusters in cycles; each cluster incorporates the reverse complement of the base
at the position of the cycle number – which can be monitored with a CCD by exciting
the fluorophores with appropriate lasers – before enzymatic removal of the blocking
fluorescent moieties and continuation to the next cycle and hence next position in the
sequencing template. While the first Genome Analyzer machines were initially only
capable of producing very short reads (up to 35 bp long) they had an advantage in that
they could produce paired-end (PE) data, in which the orientation of the molecules
could be reversed, allowing observation of the sequence at both ends of each DNA clus-
ter. The standard Genome Analyzer version (GAIIx) was later followed by the HiSeq,
a machine capable of even greater read length and depth, and then the MiSeq, which
was a lower-throughput (but lower cost) machine with faster turnaround (359, 360).
A number of other sequencing companies, each hosting their own novel method-
ologies, have also appeared and had variable impacts upon both what experiments are
feasible and the market at large. In the early years of second-generation sequencing
perhaps the third major option (alongside 454 and Solexa/Illumina sequencing) (361)
was the sequencing by oligonucleotide ligation and detection (SOLiD) system from Ap-
plied Biosystems (which became Life Technologies following a merger with Invitrogen)
(362). As its name suggests, SOLiD sequenced not by synthesis (i.e. catalysed with a
polymerase), but by ligation, using a DNA ligase, building on principles established pre-
viously with the open-source ‘polony’ sequencing developed in George Church’s group
(363). In brief, following a bead emPCR, clonal DNA populations are interrogated us-
ing cycles of hybridising and ligating short degenerate, labelled oligonucleotides: each
fluorescent colour corresponds to a particular dinucleotide at a given position in the
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template, which can be observed (giving ‘2 base encoding’) before cleaving the fluores-
cent moeity off and continuing the ligation cycle. Capable of producing paired-end reads
– highly accurately, due to measuring pairs of nucleotides rather than single monomers,
meaning an error would have to occur on both observations – the SOLiD platform is
not able to produce the read length and depth of Illumina machines (364), although it
remains competitive on a cost per base basis (365). Another notable technology based
on sequence-by-ligation was Complete Genomic’s ‘DNA nanoballs’ technique, where
sequences are obtained similarly from probe-ligation but the clonal DNA population
generation is novel: instead of a bead or bridge amplification, rolling circle amplifica-
tion is used to generate long DNA chains consisting of repeating units of the template
sequence bordered by adapters, which then self assemble into nanoballs, which are
affixed to a slide to be sequenced (366). The last remarkable second-generation se-
quencing platform is that developed by Jonathan Rothburg after leaving 454. Ion
Torrent (another Life Technologies product) is the first ‘post-light sequencing’ technol-
ogy, as it uses neither fluorescence nor luminescence (367). In a manner analogous to
454 sequencing, beads bearing clonal populations of DNA fragments (produced via an
emPCR) are washed over a picowell plate, followed by each nucleotide in turn; however
nucleotide incorporation is measured not by pyrophosphate release, but the difference
in pH caused by the release of protons (H+ ions) during polymerisation, made possible
using the complementary metal-oxide-semiconductor (CMOS) technology used in the
manufacture of microprocessor chips (367). This technology allows for very rapid se-
quencing during the actual detection phase (365), although as with 454 (and all other
pyrosequencing technologies) it is less able to readily interpret homopolymer sequences
due to the loss of signal as multiple matching dNTPs incorporate (368).
This oft-described ‘genomics revolution’ has drastically altered the cost and ease
associated with DNA sequencing. This growth occurs in excess of that seen in the
computing revolution described by Moore’s law – that the complexity of microchips
(measured by number of transitors per unit cost) doubles approximately every two
years – as sequencing capabilities between 2004 and 2010 doubled every five months
(369). The various offshoot technologies are diverse in their chemistries, capabilities
and specifications, providing researchers with a diverse toolbox from which to design
experiments. However in recent years the Illumina sequencing platform has been the
most successful, to the point of near monopoly (370)5 and thus can probably considered
to have made the greatest contribution to the second-generation of DNA sequencers.
5In 2012 the board of Illumina claimed that approximately 90% of the world’s total sequencing
output is produced using their machines (371).
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5.1.1.3 Third-generation DNA sequencing
There is some discussion about what defines the generations of DNA sequencing tech-
nology, particularly regarding the division from second to third (372, 373, 374, 375).
Arguments are made that single molecule sequencing (SMS), real-time sequencing, and
simple divergence (from what are currently accepted as second-generation technologies)
should be the defining characteristics of third-generation; it is also feasible that a par-
ticular technology might straddle the boundary. For the purposes of this discussion, I
am taking the most consistently agreed upon characteristic, in which third-generation
technologies are those capable of sequencing single molecules, negating the need for
the clonal amplification techniques that typify the previous generation. The first SMS
technology was developed in the lab of Stephen Quake (376, 377), later commercialised
by Helicos BioSciences, and worked broadly in the same manner that Illumina does,
but without any bridge amplification; DNA templates become attached to a planar
surface, and then propriety fluorescent reversible terminator dNTPs (so-called ‘virtual
terminators’ (378)) are washed over one base a time and imaged, before cleavage and
cycling the next base over. While relatively slow and expensive (and producing rela-
tively short reads), this was the first technology to allow sequencing of non-amplified
DNA, thus avoiding all associated biases and errors (372, 374). As Helicos filed for
bankruptcy early in 2012 (379) other companies took up the third-generation baton.
At the time of writing, the most widely used third-generation technology is the
single molecule real time platform (SMRT) from Pacific Biosciences (380), available on
the PacBio range of machines. During SMRT runs DNA polymerisation occurs in arrays
of microfabricated nanostructures called zero-mode waveguides (ZMWs) – essentially
tiny holes in a metallic film over a chip – which exploit the decay properties of light
passing through very small apertures to allow visualisation of single fluorophores (due
to the zone of laser excitation being so small), even over the background of neighbouring
molecules in solution (381). By depositing single DNA polymerase molecules inside the
ZMWs and washing over the DNA library of interest along with fluorescent dNTPs,
the extension of DNA chains by single nucleotides can be monitored in real time; after
incorporation the fluorescent dye is cleaved away, ending the signal for that position
(382). In addition to the benefits of sequencing single molecules in a very short amount
of time (additionally producing kinetic data, allowing for detection of modified bases
(383)), PacBio machines are capable of producing incredibly long reads, up to and
exceeding 10 kb in length, which are ideal for de novo genome assemblies (372, 380).
Perhaps the most anticipated arena for third-generation DNA sequencing devel-
opment is the promise of nanopore sequencing, an offshoot of the larger field of using
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nanopores for the detection and quantification of all manner of chemicals and molecules,
beyond the scope of just biology (384). The potential for nanopore sequencing was first
established even before second-generation sequencing had emerged, when researchers
demonstrated that single-stranded RNA or DNA could be driven across a lipid bi-
layer through α-hemolysin molecules6 by electrophoresis; moreover, passage through
the channel blocks ion flow, decreasing the current for a length of time proportional to
the length of the nucleic acid (385). There is also the potential to use non-biological,
solid-state technology to generate suitable nanopores, which might also provide the
ability to sequence double stranded DNA molecules (386, 387). Oxford Nanopore
Technologies, the first company offering nanopore sequencers, has generated a great
deal of excitement over their nanopore platforms GridION and MinION (388, 389), the
latter of which is a small (mobile phone sized) USB device which was released to end
users in an early access trial in 2014 (390). Despite the admittedly poor quality profiles
currently observed, it is hoped that such sequencers represent a genuinely disruptive
technology in the DNA sequencing field, producing incredibly long read (non-amplified)
sequence data far cheaper and faster than we ever could before (384, 389, 391).
5.1.2 Considerations for repertoire sequencing
Sequencing variable immune receptor repertoires presents different technological and
scientific challenges to more typical sequencing efforts, such as genome sequencing or
RNA-seq, which must be addressed.
The region of interest and target of the sequencing will most often be that encoding
the complementarity determining region 3 (CDR3), due to its hypervariability and its
role in antigen determination. By targeting the CDR3 and its flanking sequences one is
able to obtain information about both the non-templated sequence and germline genes
used in a particular rearrangement. While there may indeed be biological information
located outside of this region – such as polymorphisms further towards the gene termini
– this is usually less sought after, and would require a different sequencing approach.
Having selected the target, there are two further considerations: choice of nucleic
acid substrate, and method of amplification. The latter consideration is required as the
current generation of commercial DNA sequencing platforms (discussed in Section 5.1.1)
require higher concentrations of nucleic acid than is easily obtained from appropriate
biological samples.
6Large ion channels from Staphylococcus aureus, that can remain open for extended periods.
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TCR sequences differ markedly between its genomic DNA (gDNA) and messenger
RNA (mRNA) forms (Figure 5.1A). Primarily, gDNA contains introns, the most sig-
nificant of which resides between the splice donor site at the end of the J gene and
the splice donor at the start of the constant region: depending on the TCR chain and
genes involved, this sequence spans anything from 2.5 to 70 kb (inferred from IMGT
LocusView (104)). After removal of introns by splicing during transcript maturation,
the constant region forms a contiguous sequence with the end of the rearranged J gene.
There will also be differences in copy number; the gDNA version will be present once
per cell, while the RNA could be present at greater amounts (or even be absent). Indeed
a number of papers have reported both temporary up- and down-regulation of TCR
mRNA in T-cell cultures following treatment with different strength activation signals7
(212, 213, 392, 393). As V(D)J recombination is predicted to only produce in-frame se-
quences one third of the time (due to the random addition and removal of nucleotides),
sequencing gDNA would be expected to sequence more non-productive rearrangements
than sequencing RNA, since mechanisms exist to prevent or downregulate expression
of such failed rearrangements (discussed in Section 3.1.1). Therefore we would expect
strategies that target mRNA as opposed to gDNA to be relatively enriched in produc-
tive TCR rearrangements. There are additional practical considerations to the choice
of nucleic acid, such as the relative increased stability of DNA compared to RNA, or
the availability of banked biological and clinical samples.
The challenge with amplifying TCRs lies in the fact that the different V genes can
differ substantially in their sequence, thus providing no shared region from which to
prime. There are two typical solutions. The first is to generate panels of different
primers targeting each of the V genes in one direction, and either all of the J genes
(Figure 5.1B, arrows) or the constant region (Figure 5.1B and C) in the other direc-
tion. These primers would then be pooled to run a multiplex PCR, in which multiple
oligonucleotide pairs prime multiple targets in one reaction. The alternative option is
to add a known adapter sequence to the 5’ end of all cDNA molecules (with respect
to the TCR coding sequence). This allows amplification of all rearrangements with a
single primer pair complementary to both the adapter and the constant region (Figure
5.1C). The addition of a known adapter sequence can be achieved using a number of
molecular biochemical techniques; such reactions are generally termed rapid amplifica-
tion of cDNA ends, or RACE (394). Both techniques have merits and disadvantages.
By targeting the J genes instead of the constant region in a multiplex PCR one is able
7Although it is difficult to know what impact changes in cell size and number have had on these
data.
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Figure 5.1: How the choice of nucleic acid impacts on choice of TCR amplification
protocol. A: Schematic of a rearranged TCR genetic locus, indicating the panels of V and J
genes, the site of interest (CDR3) and introns (dotted lines indicate splicing events), including
the large J-C intron, which can reach up to 68 kb (the distance from the furthest functional
alpha chain J gene (TRAJ57) splice donor site to the splice acceptor site of the constant
region (TRAC). B: Schematic of a multiplex PCR reaction to amplify rearranged TCR chains
from gDNA, using a panel of V gene and J gene specific primers (green and yellow arrows
respectively). C: Schematic of amplifying TCRs from cDNA (reverse transcribed either from
constant region specific or poly-T primers), either in a multiplex PCR from V primers to
J or constant region primers (green, yellow and blue primers) or using a single primer pair
targeting the constant region and a RACE adapter added to the 5’ end of all rearrangements
(blue and purple arrows).
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to amplify directly from gDNA (avoiding the large J-C intron). A multiplex PCR also
allows more control over how long PCR products (or ‘amplicons’) will be, which is
important as different sequencing technologies have different sequence length require-
ments and capabilities. However when mixtures of primers are used there is potential
for ‘primer bias’, wherein different primer pairs can amplify with different efficiencies,
which would lead to bias in the output data (395, 396). There can be no primer bias in
the a RACE approach, as each polymerisation event uses the same primers. Multiplex
PCR approaches could additionally fail to capture the full spectrum of rearrangements
of a given chain depending on whether or not all V genes have been included in the
primer panel.
5.1.3 Published TCR methodologies
In the few years in which adaptive immune repertoires have been explored using HTS
both approaches have been applied to TCRs. Interestingly, despite the capability of
multiplex PCRs to start with gDNA templates, a large number of groups with pub-
lished protocols use RNA (83, 126, 130, 198, 271, 397). There is one notable exception
to this, the protocol developed in the laboratory of Dr Harlan Robins, whose TCR
repertoire sequencing papers using gDNA templates make up a substantial proportion
of the literature in the field to date (398). They have additionally performed a num-
ber of experiments in a model TCRγ multiplex system using synthetic DNA libraries
covering all possible V-J combinations, allowing measurement and minimisation of the
effect of primer bias by altering primer concentrations (399). As for 5’ RACE tech-
niques, the vast majority of published techniques make use of the ‘template switching’
effect (75, 77, 88, 97, 99, 127, 400). A template switch reaction exploits the termi-
nal deoxynucleotidyl transferase activity of certain reverse transciptase (RT) enzymes,
which under certain conditions will add short non-templated homopolymers to the end
of the nascent cDNA chain (401, 402). Addition of oligonucleotides that contains a
complementary 3’ homopolymer sequence can then bind act as a primer, allowing the
RT to swap strands and produce a DNA strand in the same orientation as the original
mRNA8 (404).
When I began developing the TCR sequencing protocols used in this thesis there
were very few published TCR repertoire papers, with even fewer publicly accessible
datasets. The few publications that provided both protocol and data have been ex-
tremely useful, both as illustrations of how different groups have addressed the chal-
8This is analogous to how the retrovirus from which the RT is derived replicates its own RNA
genome (403).
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lenges of repertoire sequencing, and as a source of data to use in benchmarking my own
protocols. Accordingly I have described the process by which three such datasets were
produced in Section C.1 of Appendix C.
5.1.3.1 Our protocol; initial decisions
Our group elected to work towards developing a RACE protocol, i.e. extracting RNA
from some source of T-cells, adding a known sequence to the V-proximal end of TCR
cDNAs and then amplifying between that adapter and the constant region. The main
justification for this was a desire to minimise all potential sources of technical bias.
Additionally, as we are interested in the effects of infection upon the repertoire – rather
than say studying the process of V(D)J recombination itself – we do not expect to need
the non-productively rearranged sequences that will not be contributing to binding.
There were a number of other criteria for our eventual protocol to fulfil. It should
be sensitive, in that it permits the detection of low-frequency clonotypes. It should be
robust, and able to avoid or overcome error, which will always be produced at some level
in a high-throughput system; an early paper that sequenced transgenic mice bearing
single TCRs detected numerous sequences produced from through the accumulation of
errors (405). Furthermore, if such a technology is ever to be of clinical use, it should
also be as rapid and cost-effective as possible.
5.1.4 A note on FASTQ quality scores
The analyses presented in this chapter deal with investigating and comparing differ-
ent sets of high-throughput DNA sequencing data. A necessary component of such
comparisons involves considering sequence quality scores. These are values that give
an estimate as to the veracity of the individual DNA base calls. Although different
sequencing platforms calculate their quality scores differently, the values produced are
theoretically variants on the same principle established by the program Phred9. In
this scheme, the quality (Q) of a given base call is a value logarithmically related to
the probability (P) of that base call being correct, so that Q = −10 × log10(P ) (407).
In this framework, a quality score of 10 (Q10) means the probability of that base call
being incorrect is 1 in 10, while Q20 corresponds to 1 in 100 and so on, allowing pre-
dicted accuracies to be calculated from quality scores. While different platforms still
9Phred was developed alongside automated base-calling during the Human Genome Project, before
even the invention of second-generation sequencing platforms (406, 407).
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use this basic premise, due to the differences in error profiles calculation by the respec-
tive base-calling softwares, quality scores are not always directly comparable between
technologies.
5.2 Sequencing development
In the course of my PhD I performed a number of iterations of sequencing protocol
development, which informed and culminated in the protocol I used to produce the
data described in Chapters 3 and 4.
5.2.1 Comparison results from published datasets
A B
C D
Figure 5.2: Example V-J usage plots for the previously published datasets Pro-
duced by PlotDCR (a modified version of the plotting modules from Decombinator v1.4).
A and B: Alpha and beta distributions from the Wang et al paper (SRR030416). C and D:
Beta VJ distributions from the Warren et al (SRR060699) and Bolotin et al (SRR494403)
papers respectively.
I analysed three existing, published TCR-HTS datasets (described in Section C.1)
using the bioinformatic pipeline I applied to the data I generated, in order to provide
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controls. Table C.1 in Section C.2 of Appendix C shows the raw read and analysis
numbers for three FASTQ files downloaded from each dataset, and example V-J usage
information is shown in Figure 5.2.
5.2.2 Simple V amplification
5.2.2.1 Protocol
AA
B
F
D
C
G
E
SP1
SP2
Index
P5/P7
RNA
Poly-A
DNA
V region
D region
J region
C region
A
Figure 5.3: Schematic detailing the amplification and library preparation steps
involved in our initial simple V amplification experiment. A: TCR mRNA molecule
schematic, with different regions approximately to scale. Rearrangements are reverse-
transcribed using oligonucleotides directed against the J-region proximal (5’) end of the
constant region (blue arrow). B: Rearrangements that make us of particular V regions are
specifically targeted with specific V gene primers (green arrow) and relatively nested constant
region primers (blue arrow). Partially double-stranded ‘Y-adapters’ for adapter-ligation li-
brary preparation also shown (right): each consists of two oligonucleotides which are only
complementary at one end (red), which makes up the ligation interface. C to G: Standard
adapter-ligation library preparation. Y-adapters are ligated to both ends of the now double-
stranded amplicons (C and D), which results in different adapter sequences being present
at either end of the resultant molecules (E), permitting paired-end sequencing from either
end. Indexing and flow-cell binding adapter sequences can then be added by PCR (F), before
paired-end sequencing of final libraries (arrows, G).
My initial HTS experiment was kept relatively simple. One TCRα and one TCRβ
V gene – TRAV8-4 and TRBV12-3 – were selected, and amplified with specific V-region
primers. These genes were chosen as they are found in the TCR chains of the Jurkat
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cell line10. Jurkat is a widely used, well-studied and easily grown leukaemic cell-line
(410, 411), providing a ready supply of clonal TCRs with which I could validate the
developing protocol. I therefore designed a multiplex PCR that would amplify all TCR
rearrangements that use the Jurkat V regions (Figure 5.3A and B). After amplifica-
tion, purified TCR amplicons underwent standard adapter-ligation library preparation
(Figure 5.3B to G).
I also trialled using magnetic assisted cell sorting (MACS) to isolate different T-cell
subsets. This technique relies on attaching paramagnetic beads to specific cell types via
antibodies specific for particular cell surface markers, allowing retention of known cell
types in a magnetic field (412, 413). I performed negative selection MACS on peripheral
blood mononuclear cells (PBMC), whereby all cell types aside from those of interest
are bound by antibodies and retained in the magnetic field, providing the sorted cell
population in the eluate. Two donors’ PBMC were sorted into CD4+CD45RA+ and
CD4+CDR45R0+ populations, broadly representative of na¨ıve and memory phenotypes
(see Section 3.2.2.1). Two rounds of magnetic sorting were required to achieve the
enrichment shown in Figure 5.4A, wherein CD45RA+ cells were sorted to 87.5% purity,
and CD45RO+ cells to 98.2%. In addition to the two sorted donors, an additional
donor’s unsorted PBMC underwent the multiplex PCR. Figure 5.4B shows the products
of the specific-V RT-PCR by agarose gel electrophoresis. Amplified bands were excised,
purified, and sent to Professor Paul Kellam’s group at the Wellcome Trust Sanger
Institute, where the adapter-ligation was performed. Fully processed libraries were
then sequenced on the Illumina HiSeq platform, producing two 100bp paired end (PE)
reads.
5.2.2.2 Sequencing results
Sequences produced were tested for the presence of recombined TCRs (explained later
in Section 5.3). As Table C.2 shows, this protocol produced a wealth of data, averaging
almost 13 million reads per sample, or approximately 1.4 gigabases (gB) of data per
sample. I was however only able to detect rearranged TCRs in a very small proportion
of those reads: on average only 0.32% of TCRα and 0.77% of TCRβ input reads seemed
to contain TCRs, far below the observed assignment rate for the existing published data
sets (Table C.1). Closer examination of the reads revealed that the read length of the
data (100bp) is simply too short to detect the majority of rearrangements. In order to
try and salvage as many reads as possible, I ran the data through FLASH, a program
that merges overlapping reads in paired-end FASTQ data (117). This should allow
10GenBank accession numbers X02592 (408) and K02885 (409) respectively.
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TCR assignation for those clones whose V region could not be identified in 100bp, but
whose total amplicon length is short enough to overlap enough to merge, giving enough
sequence to make the assignation. While the rates of reads that merged was not large
(approximately 15% on average, see Table C.2), they were greater than expected. These
libraries were produced from gel-purified amplicons whose migration through agarose
suggested sizes of approximately 300bp (Figure 5.4B). Given that the sequencing pro-
duced PE reads of 100bp each (and factoring in the 10bp minimum overlap that FLASH
requires by default) the upper bound read length we should expect to see should be
190bp, significantly shorter than the apparent size of our bands and outside the area
of the gel-purification. Plotting the distribution of the lengths in the overlapped reads
reveals that 190bp is indeed the maximum length observed (Figure 5.4C). Due to the
nature of this distribution, I would conjecture that either some nucleolytic process is
occurring in between gel purification and library preparation, truncating amplicons at
some low rate, or a fraction of shorter amplicons are migrating at faster than expected
rates so as to be included in the gel purification, allowing them to be included in this
analysis.
Whatever the cause of the short sequences, the rate of TCR assignation in the
merged reads is greater than those reads that did not overlap, by at least two orders
Figure 5.4 (preceding page): Results of simple V amplification and HiSeq se-
quencing experiment. A: Example purities of ‘na¨ıve’ and ‘memory’ MACS-sorted T-cell
populations, by flow cytometry. Cell populations were first gated on CD3 and CD4. B:
Agarose gels showing the PCR products that were excised and purified for sequencing. D =
donor; N = na¨ıve, M = memory. Left-hand lane in each gel shows Hyperladder I (Bioline):
blue and green triangles indicate 600bp and 400bp bands respectively. Red arrows indicate
the α and β amplicons that were gel excised for purification (based on Jurkat sequences, ap-
proximate expected band sizes were 360bp and 300bp for α and β respectively). C: Length
distributions of extended reads merged by FLASH. D: Representative quality score barplot
for the D2 raw FASTQ file, as produced by FastQC. E: Representative quality score barplot
for the D2 α inter-tag FASTQ file, i.e. the FASTQ data for the reads that contribute to
the Decombinator-assigned rearrangement, delimited by the outermost bases of the V and
J tag sequences. FastQC plot features are: central red line = median, blue line = mean,
upper and lower whiskers = 10% and 90% points, yellow box = 25-75% inter-quartile range.
Green, amber and red backgrounds represent typical values deemed as ‘good’, ‘passable’ or
‘poor’ quality. F and G: Frequency plots produced by PlotDCR (a modified version of the
plotting modules of Decombinator) showing the V-J pairing frequency for α and β chain
rearrangements respectively for a representative donor (D2). H: Example read indicating
mis-priming (off-target amplification as a result of the bF3 primer binding a non-targeted
site), resulting in presence of additional V genes in the HiSeq data. Green indicates V region
identity, grey indicates primer sequence identity and asterisks indicate exact matches.
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of magnitude (Table C.3). This corroborates the hypothesis that poor assignation in
this HiSeq data is a result of the short read length, as longer reads contained more
detectable rearrangements. I also observed that the overlapped reads displayed a lower
average predicted frequency of errors, when considering the quality of the basecalls
used to identify the hypervariable region (p-value = 0.0012, one-sided Wilcoxon rank
sum test)11. This will partially be due to the nature of the FLASH merging algorithm,
as lower quality scores can be discarded in favour of higher ones at positions covered by
both reads (117). Overall read statistics for combined samples are shown in Table C.4.
In order to assess the distribution of potential errors across the reads I visualised the
quality scores using FastQC (108), a widely used FASTQ data checking tool. Both raw
sequences and ‘inter-tag’ region FASTQ files – those that contain the sequence used by
Decombinator to assign a TCR – were processed (Figure 5.4D and E). The inter-tag
sequences show much higher and more evenly distributed quality scores. Illumina read
quality is known to fall towards the 3’ of the read (414), from a combination of loss of
phasing of molecules within the cluster, loss of fluorescent signal intensity over time and
changes in the cross-talk observed between fluorophores at later cycles (415, 416). The
increasing quality at the start of the read is due to the Illumina base-calling software
using the information from the first few cycles to calibrate the quality-determination
for later cycles. Thus part of the higher and more even quality seen in the inter-tag is
due to selecting from a higher quality internal subsequence, as well as the mitigation of
quality loss from merging reads. Additionally, low quality 3’ tails would be expected to
contain an increased proportion of errors; due to the read length this is the area where
the V tag for potential TCR arrangements would fall; we are thus selecting for higher
quality reads as those with errors are less likely to be detected by Decombinator.
Figure 5.4F and G show representation frequency distribution heatmaps of α and β
V-J gene usage to provide an overview of the spread of TCR clonotypes. As expected
we see a polyclonal response within the V genes targeted by the primers. Low frequency
clones that do not use the targeted V genes are presumed to largely represent instances
of mispriming. An example of such mispriming is shownin Figure 5.4H, which was
identified as a rearrangement using TRAV9-1 amplified from the primer directed against
TRBV12-3 (bF3). Mis-assignment by Decombinator could also produce such reads.
11Note that there is no significant difference between the mean quality scores of these different groups,
which is likely due to the fact that the Q score value is a linear representation of logged data.
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5.2.2.3 Verdict
While the Illumina HiSeq was able to produce in excess of ten million reads for each of
our samples, the read length prevents it from being useful for our purposes. However,
the quality of the data and the rate of assignation in merged (and therefore longer)
reads suggests that the Illumina technology shows promise as a suitable platform could
we but attain longer reads.
5.2.3 Poly-T RACE
5.2.3.1 Protocol
AAAAAAAA
TTTTTTTTVN
AAAAAAAA
TTTTTTTTVN
A
B
C
Figure 5.5: Poly-T RACE strategy schematic. A: TCR cDNA, produced by reverse
transcription as displayed in Figure 5.3A. B: Tdt supplied with dATP is used to polyadeny-
late the 3’ end of the cDNA, to which a primer bearing a 3’ poly-T sequence can anneal.
Amplification occurs between the poly-T RACE primer and a relatively nested constant re-
gion primer. A ‘VN-hook’ is used to ensure that the poly-T primer anneals at the V-region
end of the poly-A tract. C: Amplicons produced using poly-T RACE.
Having established various protocol parameters with the simple V amplification
technique, I next moved towards a protocol that would allow amplication of all possi-
ble TCR rearrangements in a non-biased manner. This involved switching to a rapid
amplification of cDNA ends (RACE) protocol, which allows amplification of a cDNA
molecule in which only a single priming site (e.g. a TCR constant region) needs to
be known through addition of another priming site to the appropriate terminus of the
cDNA (394). In the first RACE trial I performed this adapter was added through treat-
ment with Tdt12, supplied with a single deoxyribose nucleoside triphosphate (dNTP),
which results in the homopolymer ‘tailing’ of the 3’ end of the cDNA (and thus the
5’ end of the original transcript) (25, 417). All such labelled transcripts can then be
12This enzyme is coincidentally the same one required for non-templated addition of nucleotides
during the TCR recombination process.
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amplified using one primer against the original known sequence (the constant region)
and another that contains in its 3’ a homopolymer of the complement nucleotide to
that which was used in the tailing reaction, which in my case was dATP (Figure 5.5).
Initial attempts to translate the reaction conditions of the single V PCR to the
poly-T RACE PCR were unsuccessful, so I made a number of alterations. These in-
cluded purifying DNA products in between various stages of the reaction, and addition
of a ‘VN’ dinucleotide ‘hook’ to the 3 end of the poly-T primer – where V is any
nucleotide apart from T, and N is any nucleotide – encouraging the annealing of the
poly-T primer at the 3’ end of the poly-T tail. The most significant improvement was
seen in the switch to and subsequent optimisation of a reaction using Phusion DNA
polymerase (New England Biolabs), replacing the Taq polymerase variant used previ-
ously. Phusion is a ‘second generation’ recombinant polymerase, engineered to increase
processivity and speed through addition of a DNA binding protein domain (418). In
addition to this increased processivity (i.e. how many nucleotides a given polymerase
molecule incorporates before dissociation from the DNA) Phusion reportedly has higher
fidelity, making fewer mistakes (419), which should reduce sequence errors. Phusion has
even been reported to produce libraries which retain higher post-homopolymer quality
sequences (by Sanger sequencing) (420), making it a credible suitable polymerase.
5.2.3.1.1 Poly-T RACE cloning
α             β
-RT -Tdt D7α D7β D8α D8β W
A B
Figure 5.6: Agarose gel scans showing amplicons produced using the preliminary
poly-T RACE protocol. Original genetic substrate taken from either lysed Jurkat cells (A)
or two healthy donors’ PBMC (B). Left-hand lane in each gel shows 100bp Hyperladder IV
(Bioline); blue and green triangles indicate 600bp and 400bp bands respectively. Red arrows
in B indicate those bands that were excised and re-amplified before cloning into pUC19 for
Sanger sequencing (see Appendix Figure C.1). Control lanes were: −RT (minus reverse
transcriptase); −Tdt (minus homopolymer-tailing); W (PCR water control).
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In order to test the efficacy of the optimised Phusion protocol I first amplified
the TCR from RNA extracted from Jurkat cells. As Figure 5.6A shows, I obtained a
single band for each chain, representing the alpha and beta rearrangements: Sanger
sequencing of these PCR products corresponded to the published sequences for these
chains. Application of this protocol to PBMC samples from two healthy donors revealed
a ladder of bands, representing clonotypes of differing mRNA length and frequency
(Figure 5.6B). In order to test whether this protocol was reliably amplifying genuine
rearrangements, I excised bands from the gel shown in Figure 5.6B (red arrows), purified
the DNA, re-amplified and cloned into plasmids to allow Sanger sequencing.
All normally sized TCRβ chains cloned from donor 7 (D7) were legitimate, produc-
tive TCR sequences (Appendix Figure C.1A and B). However, the D7 and D8 alpha
chains (which had been chosen due to their aberrant band sizes) proved less typical.
D7α (Figure C.1C) produced the longest band from the poly-T RACE PCR, which
turned out to be due to the V region being used by this rearrangement possessing a
unexpectedly long 5 untranslated region (UTR)13. This sequence does not appear to
represent gDNA contamination, as the leader intron immediately upstream of the V
region has been correctly spliced. Conversely, the D8α amplicon (Figure C.1D) was
the smallest distinct band, which yielded another peculiarly primed but correctly re-
arranged receptor. In this instance a molecule of the TRAC primer aRC1 seems to
have lost the five 3’-most nucleotides (likely through the strong 3’ to 5’ exonucleolytic
activity of Phusion), allowing amplification between two aRC1 moleculs (Figure C.1E).
These results indicate that this protocol is capable of selectively amplifying TCR se-
quences. However they also indicate both the presence of unexpectedly long mRNA
species and erroneous priming events. I also observed that two of the cloned sequences –
Figure C.1B and another, non-productive rearranged clone (not shown) – contain more
thymidine residues in the RACE homopolymer than were present in the primer. This
is likely caused by polymerase slippage, a form of errors in which repetitive sequences
cause the enzyme to dissociate, allowing the newly produced strand to shift in place
before re-association, forming insertions and deletions (421).
5.2.3.2 Sequencing results
5.2.3.2.1 454
13Note that this sequence belongs to a canonical MAIT cell sequence, underlining how frequent these
cells are, as discussed in Section 3.1.5. Furthermore, this cDNA could potentially have been even
longer; it contains a poly-A tract 668bp upstream of the start of its V region to which the our poly-T
primer could bind, relatively nested to a potential more 5’ Tdt-added adenine tract.
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Figure 5.7: Summary data for the poly-T RACE amplification products as se-
quenced on the 454 GS FLX. A: Length distributions of the 454 data, for the α and β
read files pooled from all donors. The upper limit read length of 1600bp is the number of
different ‘flows’ performed by the machine (where each nucleotide is washed over the wells of
the plate in turn plate) (422). It is unlikely these rare sequences represent genuine TCR tran-
scripts. B: Quality score barplot for the raw FASTQ file of a representative donor (D10, α
file), produced by FastQC (see Figure 5.4 legend). C: Quality score for the reads (sorted from
all files) that contain the RACE homopolymer at the start of the read, showing the impact
of the homopolymer on the quality of the read. Red line indicates approximate position of
the homopolymer in the read (which is variable, due to the indels the homopolymer causes).
D: Quality score for the inter-tag FASTQ sequence for D10 α. E and F: Frequency plots
produced by PlotDCR showing the V-J pairing frequency for α and β chain rearrangements
respectively for D10.
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After the low rate of TCR assignment observed using the Illumina HiSeq, I next
opted to try Roche’s 454 sequencing platform, which has been used in a number of early
TCR repertoire sequencing strategies (83, 97, 129, 198). This technology is capable of
much longer read lengths (350). Purified amplicons were produced from four healthy
donors and again sent to collaborators at the Wellcome Trust Sanger Institute for
sequencing. Amplicons pools were randomly fragmentated by sonication and subjected
to standard library preparation (analogous to that illustrated in Figure 5.3B-G).
Read statistics from this run are displayed in Table C.5. The samples contained
an average 19,000 reads each, below the 25-30,000 expected given the capacity of the
plate14 and how many samples we multiplexed. Of these reads, an average 41% were
assigned TCRs by Decombinator. The 454 produces reads of differing lengths; the
length distributions are displayed in Figure 5.7A. The quality score distribution in 454
reads (Figure 5.7B) mirrors that of the HiSeq data (Figure 5.4D). 454 qualities are also
known to decrease towards the 3’ of the read, and for similar reasons (accumulation of
noise and loss of signal) (416, 423).
Due to the mechanism of the 454 base-calling software, its output is particularly
prone to insertion and deletion errors (‘indels’) following homopolymer tracts (361, 368),
therefore I assessed the impact of these sequences in this data. I pooled the reads from
all donors and divided them into either orientation, i.e. those that contain the RACE
homopolymer either in their 5’ or 3’ end. Despite theoretically having been produced in
equal proportions during the PCR, reads that contained a 5’ RACE homopolymer only
accounted for 19% of the total. These reads showed a distinctly poorer quality profile
than whole reads (Figure 5.7C), with quality scores declining precipitously after the
approximate location of the poly-T. As in the HiSeq data, the quality distribution for
the inter-tag FASTQ sequence is similarly improved relative to the whole read scores
(Figure 5.7D), again suggesting that Decombinator does indeed select out higher
quality reads. Figure 5.7E and F show the α and β VJ gene usages for a representative
donor; despite a spread of clonalities these distributions were different between donors,
and did not resemble those observed in published datasets (Figure 5.2).
5.2.3.2.2 MiSeq – adapter-ligation
In parallel to the 454, I also explored the then-newly available Illumina MiSeq
platform. This makes use of the same Illumina reversible-terminator chemistry as the
HiSeq, but with longer reads and a faster turnaround (424). TCRs were amplified with
14Each run can produce up to 1× 106 reads per run, of which we were allocated a quarter.
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the poly-T RACE amplification (Figure 5.5) followed by NEBNext adapter-ligation
(Figure 5.3B-G) and run on the MiSeq.
Table C.6 shows the summary data for these original MiSeq test samples. Initial
trials spiking small amounts of TCR library into runs again produced both fewer reads
than expected and a lower rate of Decombinator assignation than in the 454 data
(31% versus 41%). The read quality was also lower than the reported capabilities of the
machine, lower even than unrelated samples sequenced in the same run. This appears to
be due to the RACE homopolymer having a markedly deleterious effect on the quality of
a given read; post-RACE-homopolymer sequences rapidly fall to the lower limit (Figure
5.8A)15. The quality of reads that originate from the constant region of the amplicon
show greater quality scores (Figure 5.8B), but still below the reported accuracy of the
machine. The distribution of homopolymer tract length (Figure 5.8D) further indicates
polymerase slippage. V-J pairing frequency (Figure 5.8E and F) again revealed a
preference for the Jβ1 cluster, in contrast to previous published datasets (Figure 5.2B-
D). This lead to an alteration of the beta constant region primers: instead of the one
original primer (βRC1), which used two degenerate bases to cover the sequences of
both of the TRBC genes16, two primers exactly specific for each TRBC were designed
and mixed in equal concentrations.
5.2.3.2.3 MiSeq – PCR library preparation
Neither 454 nor Illumina platforms appear able to efficiently sequence libraries con-
taining the homopolymer introduced during the poly-T RACE protocol. However I
observed that reads starting from the constant region end of the amplicons – those that
contain the V(D)J information – tended to not suffer from this poor quality. There-
fore we theorised that by sequencing the libraries unidirectionally from the constant
region one could obtain all the clonal information without wasting reads by sequencing
through the RACE homopolymer. I modified the library preparation protocol to add
the Illumina sequencing and flowcell-binding elements specifically to both ends of TCR
cDNA via a stepwise PCR protocol (as opposed to the random addition of sequences
through ligation, as depicted in Figure 5.3B-G). This also offered the opportunity to
use the constant region primer itself as the sequencing primer, permitting sequencing
15The lower limit of Illumina quality scores is Q2, although this does not refer to a specific measured
error rate. Instead it is used if successive base calls towards the end of a read are consistently low
quality (e.g. Q15 or lower) to indicate that such sequences are probably not suitable for downstream
analysis (425).
16Accession numbers M12887 and M12888.
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Figure 5.8: Results for the first poly-T RACE amplicons being sequenced on
the MiSeq, having undergone NEBNext adapter-ligation library preparation. A:
Quality barplots of sorted reads that were found to contain the poly-T RACE homopoly-
mer, produced by FastQC (see Figure 5.4 legend). Red line indicates approximate location
of homopolymer. B: Quality distribution of the sorted reads that did not contain the ho-
mopolymer. C: Quality barplots for the inter-tag FASTQ sequence, i.e. the FASTQ data
that contributed to Decombinator-assigned TCRs. The quality of the inter-tag data in-
creases because the Decombinator-delimited TCR FASTQ data has been converted to the
correct orientation for transcription (i.e. V→ (D)→ J→ C). D: Frequency of different length
homopolymers of the sorted reads that made up the data summarised in A. The first 70
nucleotides of each read were searched for a ‘seed’ homopolymer consisting of eight matching
nucleotides (setting the lower bound), and then any additional identical bases were counted.
90113 out of the total 292096 reads (31%) contained homopolymers of equal length to that
of the primer. E and F: Frequency plots produced by PlotDCR showing the V-J pairing
frequency for alpha and beta chain rearrangements.
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Figure 5.9: Clustering on the MiSeq flowcells. A to C: Thumbnail images of DNA
clusters produced by bridge amplification during different MiSeq runs. Images are taken from
the adenosine channel for the first cycle of each respective run, but are representative of all
channels. Images are produced by the MiSeq software, and sample different sections of the tile
for an overview of cluster formation. A: An example of a successful run performed using the
same versions kits on the same MiSeq machine, with a mean raw cluster density of 964k/mm2.
B: The clustering of the first MiSeq run in which stepwise PCR was used to add the required
sequencing elements (158k/mm2). These clusters are diffuse and low-intensity, which likely
contributed to low levels of cluster detection. C: The second run had PhiX genome spiked
in to provide additional diversity produced greater density (391k/mm2). Given the poor
rate of TCR assignment many of these clusters likely correspond to PhiX reads. D: Average
raw cluster densities (black) and clusters that pass Illumina filters (e.g. chastity and phasing
filters, red) for each iteration of initial MiSeq runs. ‘AL’ = adapter-ligated, i.e. the runs
presented in Table C.6. TCR libraries constituted a minor proportion of these AL runs,
so the majority of the clusters should be formed from the unrelated libraries (which were
randomly sheared viral genomes). ‘PCR’ runs had Illumina adapter sequences introduced by
stepwise PCR. ‘PCRv1’ was the initial attempt (sequencing off the TCR constant regions
with custom primers), ‘PCRv2’ introduced PhiX spike-ins (and reverted to standard SP1
oligos) and ‘PCRv3’ introduced random nucleotides between SP1 and TCR constant regions,
to augment initial nucleotide diversity for every cluster. The image shown in A was kindly
provided by Anthony Brooks at UCL Genomics.
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further into the V gene. Initial attempts suffered from low cluster density, and only
a small proportion of those clusters passed all requisite filters. However visual inspec-
tion of images taken by the sequencer did not appear to show loss of clusters. Instead
there was a relative increase in low-intensity, more diffuse clusters (Figure 5.9A and
B), which might be less readily accepted by the detection software. Illumina base-
calling software calibrates cluster detection based on the results of the first few cycles
of imaging, assuming that there should be approximately equivalent proportions of
each nucleotide at each step. This has lead to reports of problems when sequencing
so-called ‘low-diversity’ libraries (426). In order to overcome such low nucleotide diver-
sity, six random nucleotides were added between the constant region and sequencing
primers, and highly diverse ‘PhiX’ libraries17 were spiked in. Cluster densities im-
proved following these alterations (Figure 5.9C and D), as did quality scores and rates
of TCR assignation, although all values remained far below the reported capabilities
of the machine. Binding sites for the primary Illumina sequencing primer (SP1) were
also reintroduced, so as to be able to sequence under the most controlled and tested
conditions. However even as number of raw reads per run increased, the proportion of
reads that Decombined remained low; large amounts of the data was made up of reads
that mapped to the PhiX genome, or were seemingly noise.
One hypothesis that could explain the lack of cluster generation is that the sequences
required for bridge PCR and Illumina sequencing were not being correctly incorporated
during library preparation. Individual amplicons were cloned from final sequenced
libraries, revealing that all requisite sequences were present in the appropriate locations
and orientations (Appendix Figure C.2). Therefore this method of library preparation
does not appear to be responsible for the low cluster density.
Consultation with Illumina sequencing experts lead us to the conclusion that the
most probable cause of the consistently low cluster density numbers (and hence poor
read depths) was the RACE homopolymer. One possible explanation posited is that
the RACE homopolymer might interact with the poly-T oligonucleotide sequences that
are used to attach the P5 and P7 binding elements to the flowcell. This issue is
seemingly separate from the poor quality in sequences downstream of homopolymers,
and is independent of library diversity, as the problem was maintained even after adding
leading random nucleotides and spiking in PhiX DNA. Thus the inclusion of such long
homopolymers in the libraries likely precludes one from achieving optimal output.
17Genomic libraries of the bacteriophage φX 174 – a common control library in the sequencing
industry – produced through random shearing and adapter ligation.
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5.2.3.2.4 Effect of native TCR homopolymers
Even without considering the RACE poly-T tract, we would expect there to be a cer-
tain number of homopolymer sequences occurring within TCR transcripts. Therefore
I also assessed the extent of the these ‘native’ homopolymers and whether they affect
the quality of our reads, for both the 454 and MiSeq data. I counted the number of
homopolymers of four bases or longer in the prototypical alleles of the IMGT-described
functional TCR genes, revealing that homopolymers occur in the majority of germline
genes: over 350 were found spread across 132 of the 155 germline genes (Figure 5.10A).
A similar search applied to a published, rearranged αβ TCR data set that did not use
homopolymer RACE – which would contain any additional homopolymers produced
during recombination – revealed that 88% of reads contained homopolymers of four
bases or longer, and that those reads typically contained at least two such sequences
(Figure 5.10B). This indicates that even without considering the effect of the RACE
homopolymer the majority of reads in a TCR library can be expected to contain ho-
mopolymer sequences. Any TCR sequencing approach must therefore be able to cope
with them. In order to assess whether these native homopolymers impacted upon
quality, I first combined all of the reads for all samples of a given run. For the 454
data, reads containing the RACE homopolymer in their 5’ were filtered out. A 200bp
window downstream of the sequencing primer – that should contain any V(D)J infor-
mation without reaching the poorest quality at the 3’ of reads – was then extracted
and searched for homopolymers of five nucleotides or longer. The last five nucleotides
of any such homopolymer, and the next 15 bases, were then extracted. Random se-
quences of comparable length were also extracted from the same window of the reads
for comparison. The median quality of 454 reads during a homopolymer are much lower
compared to random sequences, requiring almost ten subsequent base calls to return to
baseline (Figure 5.10C). In contrast, the median quality of the MiSeq data within and
following homopolymers is unperturbed relative to the random sequence control.
5.2.3.3 Verdict
The convenience of homopolymer-tailing 5’ RACE in studying TCRs was realised
shortly after its development (427), and was still being used for lower-throughput
analyses at the time of our adopting it as a possible protocol for high-throughput TCR
repertoire sequencing (428). Therefore in my PhD I trialled sequencing TCR libraries
amplified using this approach on both Roche’s 454 GS FLX platform, and Illumina’s
MiSeq platform.
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Position in 20-mer subsequence
A B
C
Figure 5.10: The extent and effect of ‘native’ homopolymers (HP) in TCR reper-
toire sequence data. A: The number of homopolymers of four nucleotides or longer in the
germ-line V and J genes of the human α and β chain TCR loci. Only the prototypical alleles
for functional genes have been included. 356 total homopolymers were detected, across 132
out of 155 germ-line genes. B: The number of homopolymers of four nucleotides or longer
in the pooled data from Wang et al (83) (see Section C.1), which was not produced using a
homopolymer approach, and sequenced using 454 technology. 1,634,849 homopolymers were
detected, across 747,829 of the total 847,610 reads. C: The effect of native TCR homopoly-
mers on the quality of the data. Homopolymers of five nucleotides or longer were detected,
and the last five nucleotides plus the next 15 bases were harvested into separate FASTQ files,
for both the pooled 454 data and that of the third, most productive MiSeq run (PCRv3).
Due to having more reads (and homopolymers), the post-homopolymer subsequences from
the MiSeq data were subsampled to match the number of detected 454 subsequences (31285
reads). An equal number of reads were then randomly subsampled from the initial pooled
FASTQ files, and then random 20-mers were subsampled from these (from between positions
40 and 240, thus only sampling the higher-quality section of the read that should contain any
V(D)J information while skipping the initial primer regions). Solid black lines represent me-
dian quality scores for each position, grey shaded areas represent median absolute diversity,
dotted black lines indicate the end of the homopolymer sequences.
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454 seems to be an inappropriate technology for the sequencing of TCR libraries,
primarily due to a propensity for quality scores to decline following homopolymer se-
quences – indicative of a lower probability of base calls being correct. Given the reg-
ularity with which homopolymers occur natively within the TCR transcriptome, this
represents a substantial source of potential error, theoretically producing a less accu-
rate assessment of a sample repertoire. While producing reads that are long enough
for our purposes, there are a number of other technical and practical reasons that
make 454 sequencing a less viable option. 454 sequencing requires more DNA per
library preparation than Illumina methods (several µgs as opposed to less than one
µg), necessitating either more PCR cycles (increasing risk of error) or more substrate
(which might be limiting in clinical samples). It is also consistently more expensive
than Illumina sequencing (355) and has a slower turnaround. In controlled compar-
isons, Illumina based technologies typically produce fewer errors than 454, partially
as a function of the greater depth afforded by Illumina18 (360, 361, 368). The 454
propensity towards indels makes it additionally less suitable for repertoire sequencing.
Such errors are less readily detected by Decombinator (which has mechanisms for
correcting substitution errors located in V or J tag sites) and are more likely to turn
a functional TCR sequence into a non-functional one (appearing as frameshift muta-
tions), as opposed to just a different TCR sequence (which might then still translate
to the same CDR3 sequence) (361, 368). This relative abundance of indel errors in
raw TCR sequence data from the 454 platform (as well as the Ion Torrent platform,
which operates in a similar pyrosequencing manner) has been noted previously, further
suggesting Illumina as a more appropriate technology (126). Finally, even had the 454
quality profile been better, the choice to not pursue this technology in our sequencing
program proved serendipitous, as in 2013 Roche revealed that it planned to stop sell-
ing and ultimately discontinue the technology, instead focusing on its later acquisition
PacBio (429).
Sequence data produced using the MiSeq lacked the post-homopolymer decline in
quality observed in the 454 results. It also possessed a number of features that are
highly suited to our needs: it produces reads that are long enough for us to capture
both V and J tags (permitting Decombinator assignation), doing so on runs that are
both very quick to run and relatively cost-effective. However reads originating from
the end of the amplicons that contain the RACE homopolymer – as in the 454 data –
were of very poor quality, and therefore of little practical use. Efforts to rectify this
18It is worth noting that the quality scores of the two technologies are not directly comparable due
to differences in how the respective softwares calculate error: each is designed to detect their major
source of errors, which is indels for 454 and substitutions for Illumina (354, 355, 416).
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problem through unidirectional sequencing from the constant region failed to produce
the volume of data that the machine should be capable of. In the case of the MiSeq, this
problem was not due to low diversity libraries, as it persisted even with the addition of
PhiX spike-ins and random nucleotides downstream of the sequencing primer.
Despite its ability to amplify a polyclonal population of sequences, TCR amplifi-
cation through homopolymer-RACE consistently produced libraries refractory to both
454 and Illumina sequencing, and thus is not a suitable amplification process for high
throughput repertoire analysis. This finding has implications for those groups who may
have employed such strategies in the past for lower throughput cDNA analyses and are
considering the transition to NGS.
5.2.4 Ligation RACE
5.2.4.1 Protocol
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Figure 5.11: Ligation RACE strategies. Starting with TCR mRNA (A), we explored a
number of ligation RACE strategies, including ligation of adapters to mRNA 5’ caps directly
(Ai and B), or reverse-transcription followed by adapter-ligation to cDNA 3’s (Aii and C).
Both produce equivalent adapter-labelled cDNA molecules (D).
In order to retain the ability of the poly-T PCR to amplify a wide range of V-
bearing TCR rearrangements whilst improving on the efficiency of clustering in the
bridge amplification, alternative 5’ RACE strategies were tested. A number of 5’ RACE
strategies employ some form of oligonucleotide ligation to add a known sequence, of-
fering an alternative to homopolymer tailing (430). The first such strategy we tried
used RNA-ligation, wherein RNA oligonucleotides bearing the PCR priming site are
ligated specifically onto fully processed mRNAs using an RNA ligase (431). Treatment
of whole RNA from a sample of lysed cells with phosphatase removes the 5’ phosphate
group from any RNA molecules that lack a 7-methylguanosine (m7G) cap. Tobacco
acid pyrophosphatase (TAP) is then used to ‘decap’ the fully-processed mRNAs, re-
moving the m7G while leaving a 5’ phosphate group, a requirement for ligation. Then
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addition of an RNA oligonucleotide adapter that contains a 3’ hydroxyl group (but it-
self lacking a 5’ phosphate) in the presence of an RNA ligase results in the attachment
of the adapter to the 5’ end of previously-capped mRNAs. Concurrent with the test-
ing of the RNA-ligation RACE, various members of the laboratory – Prof. Chain, Dr
Oakes and myself – also trialled several DNA ligation techniques, the most successful
of which involved using an RNA ligase to attach a DNA adapter to the 5’ UTR of our
cDNA molecules (432, 433). Both of the two major tested ligation-RACE strategies are
illustrated in Figure 5.11. Amplicons then underwent a comparable PCR-based library
preparation technique to the initial MiSeq attempts.
5.2.4.2 Sequencing results
Table C.7 shows the read statistics of the two major ligation protocols tested. Despite
very high rates of TCR assignation using the RNA ligase protocol, quality remained
relatively low. Moreover, the TCRs assigned displayed skewed V and J gene usage
and pairing, particularly in the RL1 sample (Figure 5.12A and B). In contrast, the
reads from the DNA ligation protocol are of better quality, with a median that remains
above Q30 well past the 150 or so nucleotides typically required for Decombinator
assignation (Figure 5.12C and D), with a V-J usage pattern far more in keeping both
with our own and others’ previous findings (c.f. Figures 5.8 and 5.2). We also note
that the percentage of reads filtered out from the Decombined subset (i.e. those that
contained ambiguous base-calls in their inter-tag region, or whose tags were too far
apart to encode a genuine receptor) has dropped relative to that seen in earlier runs,
again confirming a decline in the occurrence of errors.
5.2.4.3 Verdict
Initial trials with RNA and DNA ligation RACE approaches seemed to remedy the poor
clustering and low quality reads that characterised the poly-T libraries. Despite giving
slightly lower rates of TCR assignation by Decombinator than RNA ligation, DNA
ligation appears to offer better quality data, with a gene usage profile that better fits
those of previous methods and other laboratories’ published data19. Therefore the DNA
ligation RACE approach appeared to be the best candidate for further development.
19It should also be noted that concurrent with testing these ligation protocols, Illumina modified
both the sequencing kits and base-calling software to the effect that the technology copes better with
low-diversity libraries (434).
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Figure 5.12: Performance of the basic RNA and DNA ligation RACE protocols.
A and B: Proportional V-J gene usage in the TRA and TRB data for sample RL1, prepared
using the RNA ligation strategy. C and D: The whole read and inter-tag quality scores
for the α FASTQ files of sample DL2, prepared with the DNA ligation protocol. E and
F: Proportional V-J gene usage in the α and β data for DL2, produced by PlotDCR. The
RNA ligation strategy was performed by Prof. Chain, while the DNA ligation sequencing
was performed by Prof. Chain and Dr. Theres Oakes.
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5.2.5 Randomly-barcoded V amplification (BV)
5.2.5.1 Protocol
I next addressed the twin issues of sequence error and PCR duplication. No matter
how effective an amplification procedure, all raw sequencing data will retain some errors
(substitutions, insertions or deletions) that differ from the sequence of the original input
molecules. While the nature of Decombinator analysis partially mitigates some errors
(discussed later in Section 5.3), errors could still remain within the inter-tag region.
PCR duplicates are an even harder problem to address: the heavy sampling intrinsic to
deep-sequencing libraries followed by logarithmic amplification makes it very hard to
know whether and how the frequency of reads belonging to a given TCR measured after
sequencing reflect the true frequency of that TCR in the sample. Some groups have
addressed this issue by using algorithms which cluster TCR sequences simply based on
their similarity (76, 126). While this will reduce the number of artifactual TCRs, it
could also combine genuine TCRs that just happen to differ by a small amount, thus
removing actual diversity.
Beyond merely increasing diversity at the start of our reads, the introduction of
random nucleotides to our libraries afforded an opportunity to identify and remove
errors that accumulate during PCR and sequencing. The addition of random sequences
prior to amplification can effectively label each initial input molecule, provided there are
enough random sequences. After sequencing, these random sequences can be used as
molecular barcodes: differences between TCRs sharing a barcode represent accumulated
errors, while the number of different barcodes associated with a given TCR reflects the
actual number of different TCR cDNA molecules that had daughter amplicons detected
in the sequencing run. Such approaches have begun to be explored across fields that
utilise HTS technology (435, 436, 437). The first paper to use the current generation
of deep-sequencing platforms to sequence variable antigen receptor repertoires actually
made use of such a technique (438), but the practice has not been widely adopted in
subsequent protocols.
In order to test the feasibility of including such a technique in our protocols I again
reverted to a simpler amplification, selecting a restricted number of V genes from which
to prime, so that we could assess the results of ‘barcoding’ our libraries in a restricted
dataset (see Figure 5.13). I selected the two V regions targeted in our initial simple V
amplification protocol (TRAV8-4 and TRBV12-3), as well as TRAV21 and TRBV20-1,
the genes which appear to often be used most frequently in the repertoires yielded
from earlier experiments. Not only would this simplify the amplification procedure,
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Figure 5.13: Schematic of the barcoded V (BV) amplification protocol. A: As in
previous protocols, TCR RNA is reverse transcribed using oligonucleotides directed against
the 5’ of the α and β constant regions (blue arrow). Red circle represents mRNA 5’ cap.
B: Second strand synthesis is achieved using oligonucleotides complementary to one of four
specific V genes. Sequences 5’ to the V-primer sequence add a random hexamer (6N) and
an Illumina sequencing primer (SP2). C: A ‘third strand’ single round extension reaction
incorporates another random hexamer at the other end of the amplicons (as well as SP1, the
other sequencing primer, and an index for demultiplexing), completing the 12-mer barcoding
of TCR cDNA. D: A four-cycle PCR is used to add: another index (that which is sequenced in
the dedicated Illumina indexing read) and P7 at one end (i) and P5 at the other (ii). P5 and
P7 are the elements required for cluster generation, as they bind to the oligonucleotides that
coat the flow-cell, permitting bridge amplification. E: A final PCR directed against the P5
and P7 elements (for 22 cycles) amplifies full-length amplicons to sufficient concentrations for
sequencing. Amplicons are finally purified, quantified, sized and normalised before sequencing
on the MiSeq. Three sequencing reads are obtained per library: the first (R1) from SP1, the
second (I1) from the reverse complement of SP2 (producing the standard Illumina index
read) and finally from SP2 itself (R3). R1 contains the V(D)J information, and therefore is
Decombined. R2 contains information pertaining to the other end of the amplicons, which
includes 5’ UTR (untranslated region) information. The concatenated first six bases of R1
and R2 form the random dodecamer barcode which is used to error-correct the sequence. R1
and I1 both contain index sequences, which allow multiplexing of multiple samples per run.
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but would allow us deeper insights into the clonal hierarchy within a small number of
V families.
Briefly, following reverse transcription a second strand extension reaction was per-
formed, which selectively adds Illumina sequencing primer 2 (SP2) followed by a ran-
dom hexamer to the targeted V regions. After removing unbound primers, a novel
‘third strand’ reaction is performed, wherein a single cycle extension is performed us-
ing an oligonucleotide bearing Illumina sequencing primer 1 (SP1) followed by a random
hexamer and the J-region proximal constant region sequence, followed by removal of
unbound primers. In this manner each molecule of cDNA (bearing the correct V re-
gions) is labelled with a dodecamer of random nucleotides. There are approximately
16.7 million different combinations of random nucleotides in a 12-mer (46 × 46). There-
fore when analysing RNA from small populations of T-cells20 the probability of any two
TCRs being labelled with the same barcode should be very small. Following ‘barcoding’
a short PCR introduces the final required sequencing elements and amplifies.
5.2.5.2 Sequencing results
This protocol produced a large number of reads, with good quality scores and high
rates of Decombinator assignation (Table C.8); an average 61% of reads from each
FASTQ file contained a rearranged TCR. The quality remains high well into the read
(Figure 5.14A) and throughout the inter-tag region (Figure 5.14B). As with the original
simple V amplification experiment that we ran on the HiSeq (Figure 5.4), I specifically
observed the targeted V regions in the output data, albeit with trace amounts of other,
non-primed Vs (Figure 5.14C and D).
5.2.5.3 Verdict
Only a small number of V genes were amplified and analysed in this manner so as to
simplify the protocol, both to allow testing of the barcoding and gain a deeper insight
into clonal structure within specific V genes. By efficiency of Decombinator assigna-
tion alone, barcoded single V amplification – combined with PCR library preparation
and MiSeq sequencing – could be regarded as the most efficient protocol discussed yet,
producing a large number of good quality, identifiably TCR reads. The major improve-
ment however appears to be the error- and frequency-correction capabilities provided
by the unique incorporation of random barcodes, which is discussed below in Section
5.3.
20The few ml of blood from which RNA is extracted in these experiments likely contains fewer than
five million T-cells, and only a fraction of the total RNA is used for sequencing.
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Figure 5.14: Overview of barcoded simple V amplication protocol results. A and
B: Representative FastQC quality score barplots for whole and inter-tag sequence FASTQs
for a representative sample (HV4), sequenced on the Illumina MiSeq. C and D: V-J pro-
portional usage heatmaps for sample HV4. V genes targeted in the PCR were TRAV8-4,
TRAV21, TRBV12-3 and TRBV20-1. The effect of adding and ‘collapsing’ our sequences
based on these molecular barcodes is discussed later in Section 5.3.
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5.2.6 Barcoded Ligation RACE (BLR)
5.2.6.1 Protocol
The final step in producing a TCR sequencing pipeline that fulfilled the initial goals
was to add the error-correcting functionality of barcoding to the pan-TCR amplifying
DNA-ligation RACE protocol, combining the best aspects of the more successful of the
previous protocols tested.
This new barcoded-ligation RACE (BLR) strategy consists of reverse transcribing
mRNA, ligating on a barcoded-SP2 oligonucleotide, performing second and third strand
syntheses (adding SP1 and a second random hexamer) and then proceeding with the
second and final PCR steps as in the randomly-barcoded specific-V protocol. This
protocol is shown in detail in Figure 5.15.
5.2.6.2 Sequencing results
The BLR amplification procedure proved highly effective, producing a large number of
reads per sample, a large percentage of which contained TCRs (Table C.9). Further-
more, these reads are of very good quality, with a sequencing error predicated to occur
on average only once per 3000 base calls, within the inter-tag region.
The quality profiles for representative files again show high quality data for the
entirety of the portion of the reads that contain the V(D)J sequence (Figure 5.16A
and B). Plotting the VJ gene usage reveals polyclonal repertoire usage (Figure 5.16C
and D), comparable to that of samples produced by other laboratories (Figure 5.2).
Moreover, these libraries are uniquely barcoded, permitting further error-correction
and frequency estimation by ‘collapsing’ (see Section 5.3), which will further improve
upon the quality and accuracy of the data.
147
5.2 Sequencing development
+
SP1
SP2
Index
P5/P7
RNA
DNA
5' UTR
6N
V region
D region
J region
C region
A
B
C
D
E
i
ii
i
ii
R1
R2
I1
Figure 5.15: Schematic of the barcoded ligation RACE (BLR) protocol. A: As in
previous protocols, TCR RNA is reverse transcribed using oligonucleotides directed against
the 5’ of the α and β constant regions (blue arrow). B: RACE is achieved through ligation of
DNA adapter to the 3’ end of the cDNA; adapter consists of Illumina sequencing primer SP2
and a hexamer of random nucleotides (6N). C: Separate single round second (i) and third
strand (ii) reactions allow incorporation of another random hexamer at the other end of the
amplicons (as well as SP1, the other sequencing primer, and an index for demultiplexing),
completing the random 12-mer barcoding of TCR cDNA. D: A four-cycle PCR is used to add:
another index (that which is sequenced in the dedicated Illumina indexing read) and P7 at
one end (i) and P5 at the other (ii). E: A final PCR directed against the P5 and P7 elements
(for 23 cycles) amplifies full-length amplicons to sufficient concentrations for sequencing.
Amplicons are finally purified, quantified, sized and normalised before sequencing on the
MiSeq. Three sequencing reads are obtained per library: the first (R1) from SP1, the second
(I1) from the reverse complement of SP2 (producing the standard Illumina index read) and
finally from SP2 itself (R3). R1 contains the V(D)J information, and therefore is Decombined.
R2 contains information pertaining to the other end of the amplicons, which includes 5’ UTR
(untranslated region) information. The concatenated first six bases of R1 and R2 form the
random dodecamer barcode which is used to error-correct the sequence. R1 and I1 both
contain index sequences, which allow multiplexing of multiple samples per run. This is the
protocol used to amplify and sequence the majority of the samples processed in this thesis.
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Figure 5.16: Quality score boxplots and VJ gene usage heatmaps for a repre-
sentative whole blood healthy donor sample (HV07), produced using the BLR
strategy. A: Quality score distribution for the raw, complete FASTQ file. B: Quality score
distribution for the inter-tag region (i.e. from the start of the V tag to the end of the J tag).
C and D: VJ proportional frequencies for α and β chain rearrangements.
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5.2.6.2.1 Assess bias
While this protocol should be exempt from primer bias – as all rearrangements are
amplified using the same primers – it is possible that bias gets introduced during the
ligation step, perhaps dependent on terminal nucleotide or V gene identity. In order
to address whether this was the case I first compared V gene usage profiles between
three healthy donor repertoires produced using the BLR strategy and those of previous
publications (summarised earlier in Table C.1 and Figure 5.2). The proportional usage
of each TRBV gene was calculated for each repertoire sample, and these distributions
were compared against all other samples both within and between different protocols,
using the Jensen-Shannon measure of divergence (JSD, Figure 5.17A). Intra-protocol
comparisons (i.e. comparing the results of different samples produced with the same
method) produce low and consistent levels of divergence. Of the intra-protocol com-
parisons, the Warren and Bolotin samples are the most internally conserved (yellow
and black), the Wang samples are the most divergent (red), while the BLR samples are
intermediate (cyan). We would expect the BLR samples to be more divergent as each
sample came from a different donor, while all of the data from the previously published
papers represent repeats from the same bleed of one donor; the Wang data therefore
appears to be the most inconsistent with regards to V gene usage. These findings are
reflected in the inter-protocol comparisons: the Warren and Bolotin samples are the
least divergent from one another (gold), either of these compared against the BLR
data are slightly more divergent (green and navy), and then any comparison against
the Wang data is yet still more divergent (purple, orange and brown). Therefore we can
deduce that in terms of usage profiles of the different TRBV genes, my data appears
to be within the divergence range of existing published data sets.
In order to look specifically at whether the DNA ligation process engineered a
specific bias, I made use of the data produced from the second of the paired-end Illumina
reads21 (see Figure 5.15E). As the ligation oligonucleotide consists of the binding site
for the R2 sequencing primer (SP2) followed by six random nucleotides, the first six
bases of the actual reads will correspond to the ligation-introduced barcode, while the
seventh base onwards will represent the 5’ end of that TCR transcript. I measured the
proportions with which each base is used at each position across the start of R2 (Figure
5.17B). I observed a noted bias in the prevalence of different bases in the random
hexamer, particularly in the first and last positions (-6 and -1). There seems to be
very little usage of guanosine, which corresponds to cytosine being used infrequently
21The ‘R2’ (read 2) data.
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in the adapter molecules at these positions. Similarly there exist large preferences in
the bases at the start of the actual transcript read, particularly in the first position –
which contains a guanosine in over half of the reads – which normalises around position
seven or eight. By measuring the proportion with which different dinucleotide pairs
occurred across the ligation junction, I could assess which bases were actually being
ligated together. Comparing these pairings to dinucleotides at other sites either at the
start of the random hexamer or within the early transcript read revealed a markedly
different pattern of dinucleotide usage across the different positions, with a particular
preference at the junction site for dinucleotides ending with a G residue (Figure 5.17C).
This was likely explained by the exceeding abundance of Gs at the +1 position observed
in Figure 5.17B. To control for this, the frequency of dinucleotide pairs was normalised
by dividing by the frequencies of the individual bases at each position, giving a truer
representation of how likely a base is to pair with another. Figure 5.17D reveals that
at the start of the random barcode (-6 to -5), there is practically no preference in
base pairing, and thus the prominent inequality of bases at the -6 position observed in
Figure 5.17B is likely some artefact of the oligonucleotide generation. At the ligation
junction (-1 to +1) there is a slight loss of uniformity in the base pairing observed for
dinucleotides that begin with a guanosine, although as Gs make up less than 10% of
bases at the last position of the adapter this finding could reflect a sampling artefact.
The two positions from later in the read show a similar pattern of dinucleotide usage
Figure 5.17 (preceding page): Assessment of bias in the BLR protocol. A: Infer-
ence of potential bias by comparing differences in V gene usage distributions, as measured by
Jensen-Shannon Divergence (JSD). Samples used were three healthy volunteer (HV) samples
produced using the BLR protocol, as well as three samples each from three previously pub-
lished data sets (see Section C.1). All possible pairwise sample combinations were compared
and JSD calculated (with a greater JSD meaning a greater difference in V gene usage). Hor-
izontal lines indicate group means. B: Proportional usage of each nucleotide position in the
read 2 (R2) data (see Figure 5.15E), for those paired-reads that successfully assigned a TCR
in their R1 reads (for the same HV samples used in A). Note that the first six base-calls of
every read correspond to the random hexamer barcode sequence incorporated at that end of
the molecule (-6 to -1), which would then be followed by the 5’ UTR sequence of the TCR
(1+). C: Raw proportions of all the different possible dinucleotides, at the four sites under-
lined with black bars in B, corresponding to the start of the random hexamer (-6 to -5), the
interface between the ligation oligo and the cDNA molecule (-1 to +1) and two sites within
the 5’ of the transcript (4 to 5 and 10 to 11). D: Normalised proportions of the dinucleotide
proportions displayed in C, where the value of each dinucleotide is divided by the proportion
of each of the individual nucleotides at their respective positions (and divided again by 16,
the number of dinucleotide combinations, in order to provide an equivalent scale to C). All
error bars indicate standard deviation.
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to each other that is different from the other two positions, likely reflecting the innate
biases and motifs of the human transcriptome. For example we observe a very low
frequency of CG dinucleotides, which is a well-documented feature of animal genomes
due to the propensity of methylated thymines to deaminate to thymidine residues (439).
Therefore at the site of ligation we do not appear to detect a particular bias that should
preclude or influence our protocol from detecting any particular TCR transcript based
on its 5’ primary sequence.
5.2.6.3 Verdict
The barcoded ligation RACE strategy fulfils the required criteria: it produces high
quality data (in the expected ranges of the machine), from which one can obtain a
large number of polyclonal TCRs. Furthermore, as each cDNA molecule gets uniquely
labelled with random barcodes one is able to pass output Decombinator data through
an error-correction process, further improving the qualitative and quantitative aspects
of the repertoire data.
I have demonstrated that the ligation occurs without an obvious bias. The observed
imbalance in the non-templated nucleotides in the ligation adapter does not necessarily
reflect on the likelihood of bias in our system, as the production of ‘random’ sequences
in synthetic oligonucleotides is not truly random (440), a feature that is often observed
in transcriptome sequencing efforts that use random primers for reverse-transcription
(441). Similarly the differential base preferences we observe here at the start of TCR
transcripts, particularly in the first position – where there is an extreme preference for
guanosine – are not themselves indicative of bias. Despite a great deal of heterogeneity,
there are a number of biased motifs that appear in or around transcriptional start sites
(TSSs), which often result in an increase production of G residues in the first bases
transcribed (442, 443, 444). There is also an additional methodological explanation for
the pronounced G bias in the first base of our transcripts, as a result of using a Moloney
Murine Leukemia Virus (MMLV) derived reverse transcriptase (RT) enzyme. MMLV
derived RTs possess terminal deoxynucleotidyl transferase activity, which results in the
addition of several non-templated bases after reverse transcribing an mRNA; however
this activity has a strong bias for the inclusion of cytosine residues22 (401, 402). Even
in reaction conditions such as these which aren’t optimised for such extension there is
often a single or double C residue added (401). As the sequences measured in Figure
22Incidentally this enzyme activity provides the basis for template-switching amplification protocols
used in other TCR repertoire RACE studies, as a poly-G containing oligonucleotide can anneal to this
tail and prime the second strand reaction.
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5.17 are in the complementary strand with respect to the cDNA, any C residues that
the RT incorporates to the cDNA would contribute to the G bias we see in the +1 and
+2 positions. When I normalise for the frequency of each nucleotide either at the end
of the ligation adapter or the start of the transcript we observe that there is very little
bias in nucleotide pairing (and no pairing that does not occur at all). This is supported
by a report which detailed that T4 RNA ligase does not show preferential bias when
considering the primary structure of cDNA adapters 3’-ligated to RNA molecules (a
process which was significantly improved through the addition of random nucleotides
at the end of the adapter) (445). Therefore all and any TCR cDNA species could
theoretically be labelled without preference using this protocol.
Due to the success of this protocol, I applied it to the major sample sets of this thesis,
those investigating the global TCR repertoires of healthy individuals and HIV patients,
as described in Chapters 3 and 4. However, the protocol has subsequently been further
refined within the group. Improvements include combining certain steps to reduce the
number of bead purifications that are required, which should reduce the number of low-
frequency TCR cDNAs lost throughout the protocol. We are additionally exploring the
use of quantitative, real-time PCRs in the amplification protocol, to allow us to halt the
reaction after an optimal number of samples. In this way we can reduce the number
of cycles to the absolute minimum required to produce sufficient concentrations for
sequencing: the fewer cycles of PCR, the less chance there is for any errors to occur.
5.3 Bioinformatic development
“Screening peripheral blood T cells for the expression of up to 20 different
Vβ families ... will provide an extensive characterisation of TCR Vβ
expression. However, this analysis would also require large numbers of
cells ... and generate massive amounts of data, which could quickly make
the analysis impossible to perform.”
Jeff Faint et al
From ‘Quantitative flow cytometry for the analysis of T cell receptor Vβ chain expression’,
Journal of Immunological Methods, 1999 (56).
5.3.1 TCR repertoire analysis with Decombinator
At the outset of this project, there existed very few published descriptions of TCR
analyses, and even fewer publicly available programs. Where described, most method-
ologies primarily made use of pairwise alignment algorithms to detect the presence of
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particular V, J (and sometime D) regions, such as: DNAPlot (as used in IMGT/HIGHV-
QUEST) (446, 447), BLAT (198, 448), BLAST, (97, 449) and SWA (83, 271, 450).
Whilst effective, these methodologies suffer from a relative lack of speed when com-
pared to certain other techniques which might be applied, limiting the rate of analysis
of large data sets. To overcome this hurdle, then-PhD student Dr. Niclas Thomas in our
group developed a novel TCR analysis suite named Decombinator (111), which has
been used for all of the TCR rearrangement analyses in this thesis. This makes use of
an extremely efficient string matching algorithm described by Aho and Corasick (451),
which is widely used across both bioinformatics and numerous other computing-related
fields (452).
2
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A
A
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T
T
C
C
3
C GG
Keyword patterns = ( ATC [1], CAT [2], GCG [3], ACC [4])
String = GCATCG
Figure 5.18: Schematic detailing an Aho-Corasick string matching automaton.
The trie is generated prior to searching, based on the four keyword patterns (or tags) to
search for. The trie is then applied to the search string (or read). The traversal of the trie
is illustrated in red. Starting at the leftmost node (the root), the branch to navigate to is
decided based on matching the next character in the string. If the criteria to continue along
the branch is not met, the automaton instead navigates along the failure functions (leftwards
arrows), using the longest suffix so far (e.g. the GC on the keyword 3) to find the longest
prefix match (the C at the start of pattern 2). In this example, one pass of the search string
will yield matches for patterns 2 and 1, in that order.
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In our implementation, Decombinator uses the Aho-Corasick (AC) finite state
automaton to rapidly search a given sequencing read for the presence of one of a list
of ‘tag’ sequences, the presence of which should uniquely identify a particular V or
J gene. Finding both a V and J tag allows full description of a TCR rearrangment
using a five-part classifier consisting of: which V and J genes were used; how many
nucleotides were exonucleolytically removed from each of these genes, and what the
intervening ‘insert’ DNA sequence is (from the end of the V to the beginning of the J).
From these five characteristics the entire DNA sequence of the rearranged chain can be
recapitulated. Note that we do not explicitly assign a D region (for β or δ chains), as
these are short sequences that are often typically too deleted to unambiguously assign
(75); any remaining D region sequences will be contained within the insert sequence.
Compared to raw sequencing data, the classifiers produced by Decombinator are
easily stored, transferred and manipulated in downstream processes.
The speed of AC string matching lies in how it finds sequences: before traversing
a string, it uses the panel of keyword patterns (i.e. the V or J tags) to generate a
trie (Figure 5.18). When passing through the string to be searched (the sequencing
read) the finite state automaton navigates the tree node by node, depending on which
nucleotide is present at the next position. The AC algorithm simultaneously looks for
each subsequence in one pass of the read, and in the event of a mismatch uses the
longest suffix matched at any one time to skip to the longest possible prefix match
in another branch of the trie. These features combine to produce the incredible rate
of V/J gene assignment we see with Decombinator, orders of magnitude above that
seen using pairwise alignment (111). As a direct pattern-matching algorithm, an error
within the tag sequence itself would ordinarily preclude assignation. To overcome this
limitation, if complete V or J tags are not found, Decombinator splits each tag into
two half-tag sequences and searches for these. Successfully finding a half-tag is followed
by checking the neighbouring sequence where the rest of the full tag would ordinarily lie
against the relevant partner half-tag: if the comparison of these two sequences produces
a Hamming distance of one (i.e. a one nucleotide mismatch) the V or J can be assigned.
5.3.1.1 Generation of new Decombinator tag sequences
In the course of this project I made several contributions to Decombinator, including
the generation of human V and J α chain tag sequences. α tags were designed in a
similar method to that used by Dr. Thomas for generation of the β tags (and later
γ/δ tags): complete sequences for the prototypic allele of all functional TRAV and
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TRAJ genes were downloaded from IMGT/GENE-DB (19), and then potential 20-
mer windows located 20 nucleotides away from the recombining edge (to allow room
for deletion) were assessed for uniqueness. If potential tags for multiple genes were
identical, the tag window was shifted and uniqueness re-assessed. Developing tags
for the α chain is simpler than for β in some respects, as the V genes share less
identity, demonstrable as fewer TRAV genes fall into subgroups23: there are only seven
subgroups containing 20 members in the TRA locus compared to 16 subgroups totalling
60 members in TRB (19, 453). Therefore in the tag set originally published with
Decombinator, only two TRAV genes – TRAV8-2 and TRAV8-4 – are included under
one tag. I also produced tags for the three δ chain V genes that reportedly do not
recombine with α J genes, for reasons discussed in Section 3.1.2.
Tags were originally designed to cover only the prototypical alleles (i.e. the first
one discovered) for all TCRs with ‘functional’ gene status in IMGT, thereby ignoring
those that were not thought to contribute. However, when investigating sequences
that failed to be assigned by Decombinator, I observed that a proportion contained
rearranged TCRs that make use of these other genes (as described above in Section
3.1.2). I therefore designed a new set of tags that covered the prototypical alleles of
every α and β V or J gene for which IMGT has an entry, regardless of functionality. As
shown earlier in Figure 3.2, a number of these are indeed used in multiple donors, and
are thus worthy of inclusion for recombination level analyses at least. In the design of
these extra tags, I also strove to maintain at least a minimum distance of 20 nucleotides
between the start of the tag and the end of the gene (where possible) to minimise the
possibility of tags being altered during recombination. By being able to move further
into the V region (thanks to longer read lengths from the MiSeq) I was also able to
design tags with increased resolution between related genes, lowering the chance that
errors could result in misassignment. In order to check whether this new extended
tag set was still able to recognise the same original clones, I ran Decombinator on
sample healthy individuals and compared the frequency at which I found each gene.
As Figures 5.19A and B and C.4 show, the extended tags are typically able to find
either equivalent or greater numbers of sequences. There are some exceptions, such as
TRAV1-1, the loss of which was found to be due to intra-V gene splicing to a cryptic
acceptor site (see Section 3.3). Comparison of the frequency of individual clones in
each tag set is remarkably conserved (Figure 5.19C and D). The new tag set therefore
largely recapitulates the findings of the original tags, save with increased resolution in
23Subgroups are classified as families of germ-line genes which posses greater than 75% nucleotide
identity.
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a small number of genes while permitting detection of genes which may be involved
in recombinations, regardless of their official IMGT status or expression at the cell
surface.
5.3.1.2 Limitations of standard Decombinator analysis
As with any analysis tool, Decombinator suffers from a number of small limitations
which must be taken into consideration when reviewing data produced using it. The
foremost is one of accuracy. Whilst Dr. Thomas demonstrated a 98.8% accuracy rate
when using in silico sequences allowed a 0.1% error rate (111) – a value on the order of
that which we might expect in an Illumina run (361) – errors are not equally distributed
among reads (405). Therefore it is probable that certain reads accrue enough errors
in the tag regions so as to be assigned incorrect V or J genes. Alternatively erroneous
production of a tag sequence at an inappropriate location in the read might result
in a sequence that contains a genuine, error-free recombination elsewhere in the read
being overlooked. Moreover, an error in the insert sequence cannot be corrected by any
comparison to germline, as this region contains non-germline-encoded information. A
2013 publication by Bolotin et al showed that in their hands Decombinator produced
a number of erroneous additional CDR3 sequences upon translation, despite scoring
very accurately on V and J assignation, implying that errors within the insert sequence
are artificially inflating diversity with false sequences (454), although this analysis made
use of an early version that lacks more recently added error-filters.
Tag-based gene assignation results in specific limitations based on the design of the
tags. With the inclusion of the extended tag set described in this thesis, Decombinator
is now able to detect rearrangements using a larger panel of genes, regardless of func-
tionality. However many TCR genes have multiple known alleles. If single nucleotide
polymorphisms (SNPs) occur within tag regions certain alleles may be less likely to be
detected. Conversely, alleles might differ in their ability to recognise antigen (recorded
for at least one TRAV and one TRBV gene (455, 456)) but remain conserved in their tag
region, which might affect correct data interpretation. Tag placement presents another
problem: despite being typically at least 20 nucleotides away from the recombining
Figure 5.19 (preceding page): Comparison of original and extended
Decombinator tags. Plots of a representative healthy donor (HV09) showing the com-
parative performance of Decombinator in combination with the original and extended tag
sets. A and B: Frequency of Decombinator rearrangements using particular TRAV and
TRBV genes, when using either the original or new extended tag sets. C and D: Correlation
of recombination frequency for α and β chain rearrangements.
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edge of the germline gene, it is possible that a rearrangement could still have a greater
number of deletions and remain productive, yet be undetectable to Decombinator
currently. A related issue is that some V genes are simply too homologous in their 3’
sequence, and thus one is unable to assign tag regions that are able to distinguish them.
These problems are largely soluble through the production of different panels of tags.
For instance, if one wished to distinguish between different allelic forms of V and J genes,
tags could be generated for each allele. Similarly, recognition of hyper-deleted genes
could be achieved through selection of tags further away from the recombining edges.
Both of these approaches would however require longer reads of higher quality than
are routinely achievable. Other problems remain, such as how to deal with potential
sequence errors remaining in the insert sequences. I have addressed this in this work
through the unique labelling of transcript molecules, as described in Section 5.3.2.
5.3.2 ‘Collapsing’ TCRs: error-correction and improved frequency
estimation
TCR 1A
TCR 1B
TCR 1C
TCR 2D
TCR 3E
TCR 4G
TCR 1B TCR 3E
TCR 4G
TCR 1A
TCR 1C
TCR 2D
TCR 2D
TCR 3F
TCR 3E
TCR 4GTCR 3F
TCR 1A
TCR 1 ?A
TCR 2 ?D
TCR 1B
TCR 1C ?
TCR 2 ?D
TCR 4 ?G
TCR 4G ?
Errors in TCR sequence produce 'new' TCRs
→ use barcode sequences to group into molecules derived 
     from same cDNA, take biggest/best quality as actual
Errors in barcodes produce 'more' of that TCR
→ cluster similar barcode sequences, count clusters, get 
     better estimate of true cDNA frequency
TCR transcript pool After amplification & sequencing
4 different TCRs
TCR 1 > 3 > 2 & 4
7 transcripts total
9 different TCRs
Different clonal heirarchy
18 transcripts total
All mitigated by collapsing
Figure 5.20: Schematic detailing the need for error-correction. Following processing,
a labelled transcript pool (left) accrues PCR and sequencing errors (right), and differential
amplification or sampling may result in changes to the frequency hierarchy.
Both PCR and deep-sequencing (which invariably requires additional PCR steps)
produce sequence errors that may artificially inflate the diversity and disrupt the heirar-
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chy of a repertoire sample (Figure 5.20). As discussed in Sections 5.2.5 and 5.2.6 above,
the addition of random molecular barcodes to cDNA molecules prior to PCR ampli-
fication provides us the ability to mitigate for PCR and sequencing errors and dupli-
cations. In order to take advantage of this feature, I developed an alternative TCR
analysis pipeline. The first step involves concatenating the two random hexamer se-
quences from the start of both sequencing reads (see Figure 5.15E) to form the 12-mer
barcode. Next, a modified version of Decombinator analyses each read, outputting
the sequence and the quality information of this barcode as well as the inter-tag region,
in addition to the standard five fields. The product of this ‘verbose’ Decombinator
(vDCR) can then be fed into the final script in the pipeline that performs the error-
correction and frequency-estimation. ‘Collapsing’ in this context refers to the reduction
both in frequency and number of clones, by both mitigating PCR duplication and re-
moving clones produced by PCR or sequencing errors. This is achieved in two steps.
First, all assigned TCRs that share the same barcode are examined in turn; the most
frequent nucleotide sequence is presumed to be that which most likely represents the
genuine transcript. Any reads that share the same barcode sequence yet do not match
this prototypical sequence are thus likely to be errors and can be ignored. The second
step is to count the number of different barcodes that associate with a given rearrange-
ment – after performing some clustering to account for errors in the barcodes themselves
– thus providing a far more accurate estimation of the true frequency of that transcript
than the read count. A flowchart detailing these steps is shown in Appendix C, in
Figure C.3.
With the addition of the error-correction software – named CollapseTCR – the
entire bioinformatic pipeline as used in this thesis is summarised in Figure 5.21A.
Collapsing repertoire data leads to approximately twofold and fourfold reductions in
the the number of unique TCR sequences for the BLR and BV protocols respectively
due to removal of erroneous TCRs, and a 40-fold and 170-fold decrease in total number
of rearrangements, due to mitigated PCR duplication (Figure 5.21B). An example of
the effect this might have for a given rearrangement is illustrated in Figure 5.21C, where
I have shown all of the unique Decombinator assignations that were associated with
a particular random barcode sequence before collapsing. Due to the the large number
of possible barcodes (which is far in excess of the number of TCR cDNA molecules
we would expect in samples of this size) the expectation would be that all of these
classifiers therefore represent the PCR progeny of one original founder molecule. In
the pattern typically displayed in all samples, there is one rearrangement that is far
more frequent than all others, with a number of lower frequency but highly similar
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CCCTCCTACCTCCTTGTAGGAACTGGTGGGAACACGTTTTTCAGGTCCTCTGTGACCGT... 
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69x:  3,  33,  8,  7,  CCAGGCGGGGGGGGG
 2x:  3,  33,  8,  9,  CCAGGCGGGGGGGGGCA
 2x:  3,  33,  8,  7,  CCGGGCGGGGGGGGG
 2x:  3,  33,  8,  7,  CCAGGGGGGGGGGGGG
 1x:  4,  33,  9,  7,  TCCAGGGGGGGGGGGG
 1x:  3,  33,  9,  7,  GCCAGGGGGGGGGGGG
 1x:  3,  33,  9,  7,  CCCAGGCGGGGGGGGG
 1x:  3,  33,  8,  7,  CCAGGGGGGGGGGGG
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 1x:  3,  33,  8,  7,  CAAGGCGGGGGGGGG
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C
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rearrangements. In this particular example, there were 83 reads all associated with the
same barcode, which between them comprised 20 different inter-tag DNA sequences
producing 12 unique Decombinator classifiers. Therefore instead of the 12 different
clonotypes we would na¨ıvely interpret as having a cumulative frequency of 83, collapsing
allows us to disregard the sequences that have emerged through PCR amplification and
error, revealing the single, accurate TCR representation.
Plotting the relationship between raw and collapsed frequency – at least for those
genuine sequences that survive collapsing – reveals that the overall correlation is strong
(Figure 5.22). However, variance is much greater for lower frequency clones, so that
one is less able to reliably infer the collapsed frequency of a TCR if its raw frequency
is below a certain threshold. Depending on the sample, this threshold seems to lie
somewhere between 100 and 1000 copies, which likely reflects the various sampling pro-
cesses involved. The frequency collapsing data can also be expressed as a duplication
rate, calculated by dividing the raw observed frequency of a TCR chain by its eventual
error-corrected, collapsed frequency, telling us to what extent that sequence was mul-
tiplied. I observed a similar pattern of duplication rates across the different samples;
a representative example is shown in Figure 5.23A. Low frequency recombinations ex-
hibit a wide variance in duplication rates, as might be expected given the large spread
of low frequency clones illustrated in Figure 5.22. Moreover these low frequency data
fall into one of a number of gradients, which is determined by their collapsed frequency
(the denominator of the duplication rate). However, similar to previous findings, above
a certain size (an approximate raw frequency between 500 and 1000, or a collapsed
Figure 5.21 (preceding page): The global effect of collapsing TCR repertoires.
A: Schematic of the various steps of the full bioinformatic pipeline used in this thesis. i:
FASTQ data as produced by sequencing our amplified libraries on the Illumina MiSeq, which
contains both nucleotide sequence and base-call quality information. ii: TCRs are assigned
by vDCR, containing the typical Decombinator five-part classifier in addition to the se-
quence and quality information for both the inter-tag region as well as the barcode region (a
concatenation of the two random hexamer sequences that were uniquely incorporated prior
to amplification). iii: CollapseTCR uses barcode information to remove erroneous TCR
classifiers and produce a better estimate of true cDNA frequency in sample. iv: Collapsed
repertoires can then be translated and CDR3 regions extracted for further analysis, using the
CDR3ulator script. B: Overview effect of collapsing by showing the decrease in frequency of
unique and total TCRs detected from the raw, unprocessed samples of the healthy peripheral
blood controls from both the barcoded V (BV) and barcoded ligation race (BLR) protocols.
C: All of the Decombinator classifiers that were associated with a particular unique molec-
ular barcode (ACCGCCGGGGAC) in the α TCR vDCR output file for healthy peripheral blood
sample HV01v1.
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Figure 5.22: Correlation between raw and collapsed TCR frequencies. A and B:
α and β TCR samples produced using the BV protocol (sample HV5). C and D: α and
β samples produced using the BLR protocol (sample HV01v1). R2 values for all samples
in order: 0.96, 0.96, 0.92, 0.92 . P-values were all lower than 2.2e-16, the smallest value
calculable using the R statistical analysis software linear regression module.
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frequency above 15) duplication rates began to normalise. Therefore clones above a
certain size are amplified at a rate proportional to their prevalence (explaining the good
correlation of high frequency clones in Figure 5.22). I also observed that the different
barcoded protocols produce different duplication rates, with BV amplification showing
a fourfold median increase relative to BLR (Figure 5.23B). Close examination revealed
that the different V genes targeted in the BV protocol do not always display the same
average duplication rates, while the BLR protocol, which amplifies all rearrangements
using the same primers, does (Figure 5.23C and D). This difference is particularly ob-
vious when comparing the difference in TRAV and TRBV gene duplication rates in the
BV protocol (where α genes are duplicated approximately 17% more), but holds true
when comparing the two different specific β genes targeted (TRBV12-3 and TRBV20-1,
Figure 5.23D and Table C.10). Some of the increased variance in the BLR duplication
rates may be due to these data coming a greater number of batches than the BV data:
BLR results are the product of four preparation batches sequenced across five different
sequencing runs, while all BV data is the product of two experiments.
Figure 5.23 (preceding page): Use of unique molecular identifiers allows mea-
surement of duplication rates of different TCR rearrangements. Duplication rate
= raw rearrangement frequency / collapsed frequency. A: Representative plot illustrating
the typical distribution of duplication rates within a given TCR sample (sample HV04b, BV
protocol). Clonotypes are coloured by their collapsed frequency (red dotted line hightlights
broken x axis at 1000, which switches to a logged axis). Lower frequency clones display highly
variant duplication rates along paths determined by their actual collapsed frequency (as this
value is the denominator in the calculation of the rate), while larger clones (those with col-
lapsed frequencies greater than 15, or raw values greater than 1000, approximately) tend to
show approximately equivalent duplication rates. Grey horizontal bar indicates the mean
frequency of the rearrangements with collapsed frequencies greater than 15. B: Duplication
rates for all the healthy control barcoded sample rearrangements with collapsed frequencies
greater than 15 (apart from BV HV09, as this had a very small sample with a very ‘flat’
repertoire, with very little duplication observed). Median group values are shown as hori-
zontal lines (104.15 for BV, 24.0 for BLR). C: Example plot section showing the difference
in duplication rate between the two different V regions primed for in the BV β amplification
protocol. Analysis limited to those rearrangements that have a collapsed frequency greater
than 15 (shown with larger and darker plot points); TRBV12-3/4 duplication rate is signif-
icantly higher than that of TRBV20-1 (p-value = 0.002, unpaired one-sided Welch’s t-test).
D: Duplication rates of all rearrangements with collapsed frequencies greater than 15 for each
of the different V genes targeted in the BV protocol. Horizontal lines indicate group means.
166
5.3 Bioinformatic development
5.3.2.1 vDCR/Collapsing verdict
The pipeline described in this thesis employs a modified version of Decombinator to
detect and classify TCR rearrangements, followed by error- and frequency-correction
made possible by the introduction of random molecular barcodes to transcript sequences
prior to amplification. The modifications made to Decombinator itself largely fall
into two categories: those that increase the breadth and specificity of TCRs which it
can detect, through the design of new sets of V and J tag sequences, and those that
remove specific kinds of errors, through the addition of simple filters. The other major
change made was to make Decombinator output some additional fields, containing
sequence and quality information for the TCR and barcode sequences, which allows
us to collapse the data and obtain a more accurate representation of what the actual
repertoire in our sample was.
Collapsing is probably the single most important contribution to the robustness
of the protocol. In developing this methodology I have demonstrated that using raw
high-throughput TCR sequence data is flawed both qualitatively and quantitatively.
Over half of the unique TCRs measured are actually the product of sequencing or PCR
errors. Moreover the raw frequency of these TCRs only correlates well with the the
collapsed frequency above a given frequency: this stochasticity of low-frequency clono-
types (which make up the majority each sample) would correspond to an inability to
correctly assign the clonal hierarchy or perform any number of quantitative assessments
accurately. These lower frequency clones display a highly variable rate of duplication
throughout our pipeline, which is perhaps not well explained by the standard paradigm
of PCR amplification. It is perhaps possible that the random sampling that occurs
throughout the various purifications and dilutions throughout the protocol play a role,
and that larger clones simply rise above the noise.
I also observed that average duplication rates varied between the two protocols that
employ cDNA-barcoding. The BV protocol rearrangements unexpectedly displayed
larger average duplication rates than the BLR protocol, which seems counter-intuitive
given that the BLR protocol samples underwent one more PCR cycle in total than the
BV samples (27 rather than 26). A possible explanation is that the final duplication
rate is related to the amount of input nucleic acid: equivalent amounts were used in
both protocols, however BV specifically only targets a fraction of the overall repertoire,
and thus will produce a smaller amount of cDNA from a given blood RNA sample. It
is feasible that this lesser amount of input material has therefore more ‘room’ during
the PCR, and can attain higher duplication rates than protocols in which there might
be more competition in the reaction. Other members of the group have performed
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quantitative PCR of subseqeuent versions of the BLR protocol and demonstrated that
these reactions are highly efficient (in terms of the fold increase in number of molecules
per cycle, giving values close to the maximum of two, data not shown), which makes it
difficult to attribute the difference in duplication rates to differential amplification. In
addition to these differences between the protocols, I also observed a marked difference
in duplication rates between rearrangements making use of the different V genes tar-
geted in the BV compared to the BLR protocol. This is not unexpected: primer bias
– where amplicons using different primers are amplified to different extents – has been
reported to occur as a result of differences in both DNA binding energies (395, 396)
and certain DNA motifs being preferentially favoured for priming by different DNA
polymerases (457). This is indeed the reason why we strove to develop an unbiased
RACE based protocol. It is possible that with the addition of barcoding a large portion
of primer bias might be mitigated.
There are two recognised limitations to the collapsing methodology I have employed.
The first is that there will be a subset of erroneous reads remaining: those reads which
contained incorrect base-calls in both their (inter-tag) TCR and barcode sequences
will not be collapsed together, as currently it relies on a match of either one in order
to recognise that clonotypes are likely derived from the same original molecule. This
could be addressed in later versions of the software, however given the throughput
we typically work with in our samples the number of these sequences are probably
very low. The second limitation is that the clustering of barcode sequences (so as to
estimate the actual frequency of the rearrangement) allows for a relatively large number
of edits when considering the length of the string (all barcodes that are up to three
bases different from one another are considered to represent one sequence that has
accrued errors). It is for this reason that we only claim to be estimating, not exactly
measuring the true frequency of that cDNA. This could be addressed by including a
greater number of random bases in the barcode sequences and placing these barcodes in
sections of the read from which one obtains higher quality sequence data, which would
allow us to be more confident that we are both observing the barcode accurately and
not artificially shrinking a rearrangement’s frequency by clustering.
I have demonstrated that the current pipeline is able to accurately detect and
describe polyclonal TCR repertoires in a high-throughput manner, producing robust
quantitative and qualitative data, a feature that has largely been enabled through the
addition of random barcodes thus allowing us to collapse our data. Furthermore this
analysis has highlighted some of the flaws and biases that will presumably be present in
similar repertoire sequencing efforts that have not been comparably processed; therefore
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these findings should be of great interest to any group that seeks to accurately deep-
sequence receptors of the adaptive immune system.
5.4 Protocol development discussion
In the course of this thesis I have developed and refined a protocol that permits unbi-
ased amplification, effective high-throughput DNA sequencing and robust bioinformatic
analysis of TCR repertoires. In the course of developing this protocol I have gleaned
various findings that would aid others undergoing a similar process. In my data an un-
biased RACE approach, sequenced on the Illumina platform (and avoiding the addition
of homopolymers wherever possible) produced the most reliable, unbiased repertoires
with the highest sequencing quality. Furthermore I have shown that a large proportion
of errors unavoidably produced during the process of amplification and sequencing can
be mitigated through incorporation of random molecular barcodes, which allows one to
correct errors after sequencing. This pipeline therefore meets the major criteria that
an effective repertoire sequencing effort should.
One might argue that the principle of barcoding could be combined with a multiplex
repertoire PCR (such as I have shown using the BV protocol) and achieve comparable
results to an unbiased RACE, cancelling out the effect of primer bias. I contend that
this is not the case. Even if one uses barcodes to negate the effect of differential
amplification rates in a multiplex PCR (meaning that the data you end up with is
more accurate in terms of what TCRs are there in what frequencies), the very fact that
there has been an imbalance could mean that any disfavoured target molecules are
less likely to survive the various sampling events (e.g. carrying over from one PCR to
the next, or sampling to the correct concentration for the sequencing machine). Such
reads would therefore not be represented in the final data; collapsing can obviously only
work on TCRs for which sequences are observed. Multiplex PCRs for TCR repertoires
also require generation of panels of primers targeting different V (and potentially J)
genes; typically this involves selecting the functional gene sections from a repository
such as IMGT and selecting primer sites by some criteria. This could be expected to
fail to amplify some TCR rearrangements in two ways: allelic differences at primer
binding sites could result in failure to prime, which would cause an apparent reduction
or loss in gene use, and inappropriately curated or inaccurate references could result
in certain genes being omitted when they do in fact make up part of the repertoire
(as I have demonstrated is the case with various supposedly non-functional or not-
α-rearranging TRDV genes). This more philosophical failing of multiplex strategies
can be extended further: in priming for each V gene (typically as close to the V(D)J
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border as will still allow V gene identification) one loses a great deal of biological
information which might be useful in elucidating further TCR biology (such as the
investigation of alternative splicing I undertook in Section 3.3). It is for this reason
that I would especially recommend a RACE based approach when sequencing either
immunoglobulin genes (which due to somatic hypermutation might lose priming sites)
and variable antigen receptor repertoires from other species (whose germline loci are
likely to be less well annotated than say human or mouse).
We are not the first group to have made use of such a cDNA labelling approach.
The first group to deep-sequence adaptive immune repertoires – measuring the anti-
body repertoires of zebrafish – used such an approach (438), and it has been explored
for use in general RNA sequencing (435, 458). However for reasons unknown to this
researcher, the field at large has not adopted the practice, with one exception: the
Russian laboratory that produced the Bolotin et al data used for comparison through-
out this chapter has since developed and published new protocols that make use of a
comparable barcoded RACE technique (and similarly observe the associated improve-
ments following normalisation) (454, 459, 460). An interesting corollary of the impact
of collapsing TCR repertoire data is that existing repertoire data that does not make
use of such an approach could well be intrinsically flawed with respect to its error pro-
file and frequency distributions. Some groups reduce sequencing error with ‘nearest
neighbour’ or similar clustering algorithms (76, 126, 183). However this potentially
could mistakenly conflate genuine rearrangements that happen to be highly similar.
The barcoded ligation RACE strategy is still being further honed and developed
in the group, focusing particularly on how to drive down the PCR duplication rate.
Even though we can still account for said duplication by collapsing on barcodes, a
lower rate would effectively free up space on the sequencing flow-cell, allowing us to
theoretically sequence a greater proportion of low-frequency clones. It would also be
highly beneficial to reduce the number of PCR cycles each sample receives to the bare
minimum, not only to reduce duplication but the range of accumulative errors than can
occur (461, 462, 463). Reducing the cycle number could be achieved by performing the
final amplification in a real-time quantitative PCR in comparison to samples of known
concentration; this should allow users to halt the amplification reaction at the exact
cycle at which there is enough DNA to sequence. Other protocol alterations currently
being tested involve incorporation of longer random stretches, solely in the ligation
adapter, reducing the number of purifications required and increasing the resolution
between similar barcodes.
170
5.4 Protocol development discussion
In this study I have primarily made use of the Illumina MiSeq platform for sequenc-
ing our repertoires, as it produced a sufficient number of reads of lengths more than
suitable for our purposes, with quality score distributions that are consistently found to
best rival technologies. Moreover it does so with less cost than many alternatives and in
a time frame that is conducive to research, and potentially clinical applications as well.
These features make it the most suitable technology for most repertoire sequencing
applications, which is reflected in the fact that the major commercial entities offering
repertoire sequencing make use of it (464, 465). However, like all second-generation
DNA sequencing technologies (which are defined by amplifying clonal populations of
DNA fragments in a hugely parallel manner, followed by independent sequencing), DNA
amplification is required at one if not more stages (as most machines require relatively
high input DNA concentrations). This requirement can theoretically be dispensed with
when working with third-generation sequencing platforms as these technologies are
defined by being able to sequence single DNA molecules (372, 373, 375). Adoption
of such technology (such as the SMRT platform from Pacific Biosciences (382) or the
MinIon from Oxford Nanopore Technologies (388)) for sequencing un-amplified immune
repertoire libraries could provide the first truly unbiased repertoire data. Furthermore
these technologies are able to sequence both very long molecules (which would allow
sequencing of unrearranged and genomic TCR loci in one pass) and modified nucleic
acids (which might elucidate further sites of regulation of TCR expression).
In conclusion, the research that I have undertaken suggests that in order to obtain
the highest quality sequence data that contains the greatest amount of biological infor-
mation one should bear in mind three main points: an unbiased amplification procedure
(e.g. 5’ RACE) should be employed, to ensure coverage of all genuine rearrangements in
the sample; an appropriate sequencing technology must be used (which in the current
market will most likely involve an offering from Illumina), and final output data can
be significantly improved through the inclusion of random barcode sequences prior to
amplification. High-throughput DNA sequencing of variable antigen receptors repre-
sents a powerful tool in being able to dissect and understand how vertebrate immune
systems operate; it is imperative that our protocols for doing so are fit enough for the
task.
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The T-cell receptor repertoire is an incredibly complex and dynamic biological system,
and the ability to accurately measure and model it could greatly aid the understanding
of a diverse range of immune processes. However this very complexity makes repertoires
intrinsically difficult to measure. Technologies born out of the genomics revolution are
enabling greater interrogation of the clonal make up of TCR repertoires then ever
before.
In this thesis I demonstrate the development of a protocol that uses unbiased ampli-
fication, random molecular barcoding and error-correcting analysis software to sequence
the TCR repertoires of RNA samples. I have used this protocol both to characterise
elements of healthy donor repertoires and measure how some of these features are per-
turbed during HIV infection.
A number of themes emerge from the interpretation of this data and related pub-
lished findings. Perhaps the most significant is the degree of sharing of TCR sequences
and profiles between unrelated individuals, which might seem counter-intuitive for a
system that is generally regarded to exist as a means for producing receptor diversity.
Data such as these begin to redefine our conception of variable antigen receptor genera-
tion, in which the stochasticity produced by V(D)J recombination does indeed produce
a tremendously diverse repertoire, but within pre-determined bounds. This seems es-
pecially true of so-called ‘invariant’ TCR chains, which appear in multiple individuals
in phenotypically defined cell subsets. These bounds likely reflect a combination of
the constraints of the recombination machinery and selection processes (both thymic
and peripheral), although the contribution that each of these makes is still yet to be
dissected.
The other predominant theme of this work is that of unexpected complexity. As
our ability to measure TCR rearrangements increases, the limit of detection for rare
and aberrant events recedes. Furthermore using an unbiased amplification reaction
removes the confirmation bias associated with targeted multiplex primer approaches.
These effects have manifested several times in this thesis, such as in the detection of
high-frequency rearrangements using purportedly non-functional gene segments and
low-frequency alternative splicing events. While the biological significance of these
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phenomena remain to be established, these findings demonstrate the diverse potential
applications of the technology and inform the design of future experiments.
Application of TCR RepSeq to HIV patient blood samples demonstrates the utility
of the technology in understanding the pathogenesis of clinically relevant infections.
The data presented complements and elaborates on the established hypotheses, pro-
ducing a model in which the drastic loss of TCR diversity – as a result of both CD4+
T-cell depletion and considerable expansion of a subset of CD8+ T-cells – perturbs all
features of the repertoire. In this data I observed significant alterations in the frequen-
cies of CDR3s associated with antiviral responses identified in previous studies. These
observations were made despite this study only sequencing a small sample of blood at
relatively low depth; were we to sequence more blood or increase our read depth (and
harvest or otherwise obtain more pathogen-specific TCR sequences) I predict that such
analyses would prove even more fruitful.
I contend that I have demonstrated the power of deep-sequencing as a tool to in-
vestigate the repertoire, being able to both answer a variety of biological questions and
generate hypotheses for future studies. I anticipate that repertoire sequencing will be-
come an invaluable tool in a wide variety of immune studies, that will continue to grow
both more commonplace and more powerful as sequencing and related technologies
progress. Used in conjunction with other technologies (such as cell sorting or transcrip-
tomics) would permit gathering of linked rearrangement and phenotypic information,
increasing the dimensionality and potential information content of output data.
6.1 Future work
There remain a great number of experiments and improvements that could be made
both in this work and the field of TCR receptor repertoires more generally.
With respect to the data presented here, the majority of future experiments would
involve collection of both more sequences and more samples. Greater numbers of se-
quences per sample – by taking more blood, amplifying from more RNA or sequencing
more of our libraries – would allow greater detection of rare and potentially shared
sequences. Taking samples from more healthy donors and HIV patients would allow
us to greater characterise the differences in TCR features both within and between
groups, while taking more longitudinal samples from the same donors would provide
data on the dynamics and diversity of the peripheral pool. From a clinical perspective,
with enough patients and longer follow up this could be extended to measure whether
and which TCR properties might show prognostic value or aid in the stratification of
patients for treatment regimes. Cell sorting, particularly of CD4+/CD8+ populations
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in the context of HIV patients, would be expected to permit greater understanding of
the dynamics of the repertoire in these subsets. The major factor limiting these works
is simply one of cost; given sufficient funds all of these experiments are possible today.
On a practical level, there are a number of improvements which could be made to
increase the yield of information from the data produced by our (and similar) deep-
sequencing protocols. Primarily, barcoding of some sort should become far more preva-
lent than it already is, as it is the only solution that I am aware of that counters all
aspects of PCR- and sequencing-introduced errors. Modulation of primer concentra-
tions in multiplex PCRs may well be able to effectively counteract primer bias at the
gene level (399), but it is still unable to normalise read frequencies back to nucleotide
frequency, and nor can it correct nucleotide sequences save by clustering, which may
conflate genuinely different rearrangements that happen to have similar sequences. The
barcoding protocol detailed in this thesis could itself be improved through the addi-
tion of longer barcode sequences, in order to provide better resolution between barcode
sequences during the estimation of true rearrangement frequency. Improvement of
sequencing quality of both TCR and barcode sequences would greatly minimise the
chance of developing or retaining erroneous sequences. A related constraint is that of
read length. An ideal situation might involve reading the entire variable domain of all
TCR mRNA molecules in a sample (or even the whole message). This would remove
all requirements for sequence inference, allowing unequivocal interpretation as to the
nature and productivity of a given mRNA. This might produce enough sequence to
allow development of Decombinator tags that would be able to detect and distin-
guish all TCR V gene families and alleles, and would allow far greater investigation of
TCR splicing. These practical issues are largely limited by the nature of the sequencing
technology available to us: improvements in read length and quality would help address
these concerns.
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Postscript
In 1989 Charles Janeway wrote the seminal paper ‘Approaching the Asymptote? Evo-
lution and Revolution in Immunology’ (466). In addition to expounding a variety of
predictions and frameworks that bore fruit across the range of immunological fields, he
made the following statement:
“... I believe it is safe to state that our understanding of immunological
recognition is approaching some sort of asymptote, where future
experiments are obvious, technically difficult to perform, and aim to
achieve ever higher degrees of precision rather than revolutionary
changes in our understanding.”
This could arguably be applied to the practice of investigating immune repertoires,
where the majority of improvements in the last two decades largely correspond to tech-
nical advances permitting analyses with greater throughput and resolution. However, I
contest the notion that increasing precision and making changes in our understanding
cannot go hand in hand.
Immunology is in some respects still a comparatively young field, consisting of the
study of one of the most complex biological systems known (second perhaps only to
that of the nervous system). Tremendous advances have been made identifying the
physiological, cellular and molecular components of the immune system – only a tiny
portion of which have even been touched upon in this thesis – yet large gaps in our
understanding remain. Findings can be difficult to translate between models or from
basic to clinical research. and the effects of interventions remain hard to predict both
quantitatively and qualitatively.
However, higher-dimensional, higher-throughput technologies such as those described
in this thesis can help us move towards system level understandings. By gaining greater
ability to measure the constituents of the immune system, at all scales, we increase our
ability to model emergent properties. A Grand Unified Theory of Immunology is still a
long way off, but we can still move towards it, even if we are only increasing precision.
As Jacques Miller concluded in a review article recounting his incredible contributions
to the field (38):
“There is still a great future for immunology!”
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AAppendix A - exploring the TCR
repertoire of healthy individuals
>TRDV1-TRAJ44-TRAC
...CCATTTCAGCCTTACAGCTAGAAGATTCAGCAAAGTACTTTTGTGCT
CTTGGGGAACTGGCAGGCACTGCCAGTAAACTCACCTTTGGGACTGGAAC
AAGACTTCAGGTCACGCTCGATATCCAGAACCCTGACCCTGCCGTGT...
>TRDV2-TRAJ44-TRAC
...GAGAGAGATGAAGGGTCTTACTACTGTGCCTGTGACACTCTAGGATT
CCGACCTAAAATACCGGCACTGCCAGTAAACTCACCTTTGGGACTGGAAC
AAGACTTCAGGTCACGCTCGATATCCAGAACCCTGACCCTGCCGTGT...
>TRDV3-TRAJ43-TRAC
...CCCAGAAAGCCTTTCACTTGGTGATCTCTCCAGTAAGGACTGAAGAC
AGTGCCACTTACTACTGTGCCTCCAATGACATGCGCTTTGGAGCAGGGAC
CAGACTGACAGTAAAACCAAATATCCAGAACCCTGACCCTGCCGTGT...
A
B
C
TRDV gene TRAJ gene TRAC gene
Figure A.1: Detection of TRDV usage in α chain TCR data. Identification of α chain
rearrangements (i.e. containing TRAJ and TRAC) using the IMGT-defined δ chain specific
V genes TRDV1 (A), TRDV2 (B) and TRDV3 (B), in publicly available TCR sequence data
(from Wang et al (83), accession number SRA010149 ).
Gene * Allele Sequence
TRBD1*01 GGGACAGGGGGC
TRBD2*01 GGGACTAGCGGGGGGG
TRBD2*02 GGGACTAGCGGGAGGG
Table A.1: Germline sequences of the human TRBD genes. Obtained from IMGT
GENE-DB (19).
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Figure A.2: Purity of CD4 and CD8 sorted T-cells. A: Purity of CD4+ sorted cells
before lysis, having sorted first for lymphocytes based on FSC/SCC (not shown), then CD3+
(left) and CD4+CD8-(right). B: Purity of CD8+ sorted cells before lysis, having sorted first
for lymphocytes based on FSC/SCC (not shown), then CD3+ (left) and CD8+CD4- (right).
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Figure A.3: Alpha chain VJ pairing frequencies for HV01. VJ pairing frequencies
for HV01 VJ pairing for CD4 (A) and CD8 (B) sorted repertoires. 10,000 rearrangements
were sampled from whole files.
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Figure A.4: Alpha chain VJ pairing frequencies for HVD4. VJ pairing frequencies
for HVD4 VJ pairing for CD4 (A) and CD8 (B) sorted repertoires. 10,000 rearrangements
were sampled from whole files.
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Figure A.5: Beta chain VJ pairing frequencies for HV01. VJ pairing frequencies
for HV01 VJ pairing for CD4 (A) and CD8 (B) sorted repertoires. 20,000 rearrangements
were sampled from whole files.
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Figure A.6: Beta chain VJ pairing frequencies for HVD4. VJ pairing for CD4 (A)
and CD8 (B) sorted repertoires. 20,000 rearrangements were sampled from whole files.
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Figure A.7: Adult and cord blood β chain TCR length distributions. A: Box plot of
β chain rearrangement insert lengths. B: Box plot of β chain CDR3 lengths. Data produced
using the BV protocol, and therefore only targets rearrangements using TRAV8-2/TRAV8-4,
TRAV21, TRBV12-3 and TRBV20-1.
182
Invariant Population Reference α β
GEM Van Rhijn et al, 2013 (140) X X
MAIT Gold et al, 2010 (467) X
MAIT Greenaway et al, 2013 (282) X
MAIT Reantragoon et al, 2013 (281) X
MAIT Van Rhijn et al, 2013 (140) X X
MAIT Lepore et al, 2014 (138) X X
MAIT Van Schaik et al, 2014 (141) X
NKT Exley et al, 1997 (468) X
NKT Han et al, 1999 (469) X
NKT Demoulins et al, 2003 (153) X
NKT Sanderson et al, 2012 (470) X
NKT Greenaway et al, 2013 (282) X
NKT Van Rhijn et al, 2013 (140) X X
Putative Van Schaik et al, 2014 (141) X
Table A.2: Sources of the TCRs of T-cell subpopulations bearing invariant α
chain and semi-invariant β chain rearrangements.
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TRAV gene TRAJ gene CDR3 Number donors Found in CD4 Found in CD8
TRAV13-1 TRAJ6 CAASKGGSYIPTF 10 X
TRAV12-2 TRAJ15 CAVNNQAGTALIF 9 X X
TRAV13-1 TRAJ53 CAASSGGSNYKLTF 9 X X
TRAV14/DV4 TRAJ3 CAMREGGYSSASKIIF 9 X X
TRAV8-3 TRAJ6 CAVGAASGGSYIPTF 9 X X
TRAV12-1 TRAJ15 CVVNNQAGTALIF 8 X X
TRAV12-2 TRAJ5 CAVNNTGRRALTF 8 X X
TRAV12-3 TRAJ8 CAMMNTGFQKLVF 8 X X
TRAV13-2 TRAJ52 CAENNAGGTSYGKLTF 8 X X
TRAV16 TRAJ37 CALSGGSGNTGKLIF 8 X X
TRAV2 TRAJ5 CAVEEDTGRRALTF 8 X
TRAV21 TRAJ11 CAVMNSGYSTLTF 8 X X
TRAV21 TRAJ15 CAVPNQAGTALIF 8 X X
TRAV29/DV5 TRAJ52 CAASGAGGTSYGKLTF 8 X X
TRAV9-2 TRAJ13 CALMNSGGYQKVTF 8 X
TRAV12-1 TRAJ23 CVVNNQGGKLIF 7 X X
TRAV12-1 TRAJ20 CVVNNDYKLSF 7 X
TRAV12-1 TRAJ30 CVVNMNRDDKIIF 7 X X
TRAV12-2 TRAJ17 CAVMIKAAGNKLTF 7 X X
TRAV12-2 TRAJ8 CAVNMNTGFQKLVF 7 X X
TRAV12-2 TRAJ48 CAVNNFGNEKLTF 7 X X
TRAV12-3 TRAJ17 CAMMIKAAGNKLTF 7 X X
TRAV12-3 TRAJ23 CAMMIYNQGGKLIF 7 X X
TRAV13-2 TRAJ53 CAENKNSGGSNYKLTF 7 X X
TRAV17 TRAJ9 CATDGTGGFKTIF 7 X X
TRAV2 TRAJ26 CAVEEDNYGQNFVF 7 X X
TRAV21 TRAJ36 CAVKTGANNLFF 7 X X
TRAV21 TRAJ17 CAVMIKAAGNKLTF 7 X X
TRAV21 TRAJ8 CAVMNTGFQKLVF 7 X X
TRAV21 TRAJ58 CAVKETSGSRLTF 7 X
TRAV21 TRAJ42 CAVMNYGGSQGNLIF 7 X X
TRAV21 TRAJ50 CAVMKTSYDKVIF 7 X X
TRAV23/DV6 TRAJ12 CAASRMDSSYKLIF 7 X
TRAV29/DV5 TRAJ45 CAASEGGGADGLTF 7 X X
TRAV29/DV5 TRAJ53 CAASGSGGSNYKLTF 7 X
TRAV29/DV5 TRAJ43 CAASANNDMRF 7 X
TRAV3 TRAJ7 CAVRDDYGNNRLAF 7 X
TRAV3 TRAJ8 CAVRDNTGFQKLVF 7 X X
TRAV8-3 TRAJ52 CAVGAAGGTSYGKLTF 7 X
TRAV8-3 TRAJ10 CAVGFTGGGNKLTF 7 X
Table A.3: Table of putative invariant α chain TCRs from the BLR data. To
qualify, sequences had to be present in seven out of ten of our healthy donor samples and not
belong to any other pre-existing known or putative invariant TCR group. Presence of these
sequences in sorted CD4 and CD8 repertoires (see Section 3.2.1) is indicated.
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V J CDR3 CB Adult BV BLR Sum CD4 CD8
TRAV8-2 TRAJ42 CVVMNYGGSQGNLIF 5 4 9 6 15 X
TRAV8-2 TRAJ13 CVVMNSGGYQKVTF 5 4 9 6 15 X X
TRAV8-2 TRAJ36 CVVSDQTGANNLFF 6 3 9 2 11 X X
TRAV21 TRAJ13 CAVMNSGGYQKVTF 5 3 8 5 13 X X
TRAV8-2 TRAJ23 CVVMIYNQGGKLIF 6 2 8 5 13 X
TRAV21 TRAJ23 CAVMIYNQGGKLIF 4 4 8 4 12 X X
TRAV8-2 TRAJ32 CVVMNYGGATNKLIF 4 4 8 3 11
TRAV21 TRAJ20 CAVNDYKLSF 5 3 8 2 10 X
TRAV21 TRAJ11 CAVMNSGYSTLTF 5 2 7 8 15 X X
TRAV21 TRAJ42 CAVMNYGGSQGNLIF 6 1 7 7 14 X X
TRAV21 TRAJ36 CAVKTGANNLFF 4 3 7 7 14 X X
TRAV21 TRAJ39 CAVMNNNAGNMLTF 5 2 7 6 13 X X
TRAV8-2 TRAJ4 CVVSLSGGYNKLIF 4 3 7 6 13 X X
TRAV8-2 TRAJ7 CVVSDDYGNNRLAF 4 3 7 5 12 X X
TRAV8-2 TRAJ4 CVVSRSGGYNKLIF 4 3 7 5 12 X
TRAV8-2 TRAJ3 CVVSEGYSSASKIIF 4 3 7 4 11 X
TRAV8-2 TRAJ10 CVVSFTGGGNKLTF 4 3 7 3 10 X X
TRAV8-2 TRAJ13 CVVTLSGGYQKVTF 5 2 7 3 10 X
TRAV8-2 TRAJ5 CVVSGDTGRRALTF 2 5 7 3 10 X
TRAV8-2 TRAJ12 CVVSRMDSSYKLIF 3 4 7 3 10 X
TRAV8-2 TRAJ6 CVVSGSGGSYIPTF 3 4 7 3 10 X
TRAV8-2 TRAJ17 CVVMIKAAGNKLTF 6 1 7 3 10 X
TRAV21 TRAJ32 CAVMNYGGATNKLIF 4 3 7 2 9 X X
TRAV8-2 TRAJ3 CVVTGYSSASKIIF 4 3 7 2 9
TRAV8-2 TRAJ4 CVVSFSGGYNKLIF 4 3 7 2 9 X
TRAV8-2 TRAJ4 CVVTFSGGYNKLIF 5 2 7 2 9 X X
TRAV8-2 TRAJ11 CVVSVNSGYSTLTF 4 3 7 1 8 X
TRAV8-2 TRAJ15 CVVSEGQAGTALIF 4 3 7 1 8 X
TRAV8-2 TRAJ13 CVVSYSGGYQKVTF 5 2 7 0 7
TRAV21 TRAJ15 CAVPNQAGTALIF 3 3 6 8 14 X X
TRAV21 TRAJ17 CAVMIKAAGNKLTF 3 3 6 7 13 X X
TRAV21 TRAJ8 CAVMNTGFQKLVF 5 1 6 7 13 X X
TRAV21 TRAJ58 CAVKETSGSRLTF 2 2 4 7 11 X
TRAV21 TRAJ50 CAVMKTSYDKVIF 3 1 4 7 11 X X
Table A.4: Table of putative invariant α chain TCRs from the BV data. Upper
section: VJ-CDR3 sequences that were present in the results of seven or more donors’ data
produced using the barcoded and targeted V (BV) protocol (see Sections 3.2.2.2 and 5.2.5),
with the number of donors given. Lower section: Presence of sequences identified in Table
A.3, using the barcoded ligation RACE (BLR) strategy (see Sections 3.1.5 and 5.2.6) in the
BV data. Column headers: CB = number of cord blood samples containing the sequence;
Adult = peripheral blood healthy volunteer samples; BV = total number of samples amplified
using the barcoded V protocol with the sequence; BLR = total number of barcoded ligation
RACE samples with the sequence (in bold if seven or greater); Sum = total number of donors
across both protocols, and CD4 and CD8 ticks designate whether that sequence was detected
in the two sorted healthy donor repertoires (see Section 3.2.1).
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Gene Splice Sequence Number donors
TRAV1-1 D1A2 TGTTTCCATGAAGATGGGAG|GAGCTCCAGATGAAAGACTC 10
TRAV1-1 D2A2 AGCCATTGTCCAGATAAACT|GAGCTCCAGATGAAAGACTC 10
TRAV1-1 D3A2 GGGTTTTATGGGCTGTCCTG|GAGCTCCAGATGAAAGACTC 10
TRAV1-1 D4A2 CACATTTCTTTCTTACAATG|GAGCTCCAGATGAAAGACTC 8
TRAV8-1 D2A2 GGAACTGTTAATCTCTTCTG|GAAACCCTCTGTGCAGTGGA 1
TRAV8-3 D2A2 GCAACACCTTATCTCTTCTG|GAAACCCTCTGTGCATTGGA 1
TRAV13-2 D2A2 CAAGCAAGAATCTGGAAAAG|CTACTCAACCTGGAGACTCA 1
TRAV14/DV4 D2A2 CAAAGTTATGGTCTATTCTG|AAGGCAAGAAAATCCGCCAA 1
CCAAGTTATGGTCTATTCTG|AAGGCAAGAAAATCCGCCAA
TRAV22 D2A2 GTGAGTTGGGGCTGTCCAAG|GGACAAAACAGAATGGAAGA 1
TRAV41 D2A2 CAATCAACTGCAGTTACTCG|GAAAAGCACAGCTCCCTGCA 9
TRDV1 D2A2 GCAGTCACCCTGAACTGCCT|GGTTCTGATGAACAGAATGC 10
TRDV1 D2A3 GCAGTCACCCTGAACTGCCT|AATGCAAAAAGTGGTCGCTA 3
TRBV2 D2A2 TAATCACTTATACTTCTATT|GTTGAAAGGCCTGATGGATCA 10
TRBV7-2 D2A2 GGGAAAGGATGTAGAGCTCA|GGCAACAGTGCACCAGACAAA 9
TRBV7-2 D2A3 GGGAAAGGATGTAGAGCTCA|GTGCACCAGACAAATCAGGGC 9
TRBV7-2 D2A4 GGGAAAGGATGTAGAGCTCA|GAGAGGACTGGGGGATCCGTC 3
TRBV7-3 D2A2 GGGAAAATATGTAGAGCTCA|GGCACGGGTGCGGCAGATGAC 7
TRBV7-3 D2A3 GGGAAAATATGTAGAGCTCA|GTCAGGCCTGAGGGATCCGTC 9
TRBV7-6 D-1A2 GCTCACAGTGACACTGATCT|GAGAGGCCTGAGGGATCCATC 3
TRBV7-6 D1A2 TCCTGGGTTTCCTAGGGACA|GAGAGGCCTGAGGGATCCATC 4
TRBV7-6 D2A2 TGGAGTCTCCCAGTCTCCCA|GAGAGGCCTGAGGGATCCATC 10
TRBV7-6 D3A2 GGGACAGGATGTAGCTCTCA|GAGAGGCCTGAGGGATCCATC 10
TRBV7-8 D1A3 TCCTGGGTTTCCTAGGGACA|GAAAGGCCTGAGGGATCCGTC 8
TRBV7-8 D2A2 AGGACAGGATGTAGCTCTCA|GAATGAAGCTCAACTAGACAA 10
TRBV7-8 D2A3 AGGACAGGATGTAGCTCTCA|GAAAGGCCTGAGGGATCCGTC 9
TRBV7-9 D2A2 GGGACAGAATGTAACTTTCA|GAATGAAGCTCAACTAGAAAA 10
TRBV7-9 D2A3 GGGACAGAATGTAACTTTCA|GAGAGGCCTAAGGGATCTTTC 2
TRBV10-2 D2A2 CAAGATCACAGAGACAGGAA|GATAAAGGAGAAGTCCCCGAT 7
TRBV10-2 D3A3 GAGCCACAGCTATATGTTCT|GATCCAAGACAGAGAATTTCC 3
TRBV11-2 D1A2 CCCTCTGTCTCCTGGGAGCA|GAGAGGCTCAAAGGAGTAGAC 10
TRBV11-2 D2A3 TGGCCATGCTACCCTTTACT|GGCTCAAAGGAGTAGACTCCA 1
TRBV18 D2A2 ATCGGCAGCTCCCAGAGGAA|GAGGGCCCCAGCATCCTGAGG 10
Table A.5: List of intra-V gene splicing events. Paired-end reads for one donor were
overlapped and sequences that successfully merged – thus containing whole transcripts – and
contained valid rearrangements as determined by Decombinator were mapped against the
germline loci. Alternative splicing was determined by the presence of sequences mapping to
non-canonical TCR exon boundaries, i.e. anything that was not joining L-PART1 to L-PART2
to complete the leader sequence. Splice terminology: the splice donor and acceptor sites of the
leader exon were termed D1 and A1, then all novel sites were numbered relatively based on
their position. ‘|’ characters indicate splice junctions. Note that there are two TRAV14/DV4
- D2A2 entries, as this region happened to fall on a single nucleotide polymorphism.
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Figure B.1: Clinical score-diversity correaltions. A: The CD4 cell count does not
correlate with the Gini index of the untreated v1 bleed in HIV patients (R2 = -0.03317, p =
0.9458). B: P-values of the various possible explanatory v1 variables included in a multiple
regression, showing that CD8+ lymphocyte count explains the low diversity (by either Gini
index or Shannon entropy) better than other variables. Multiple regression analysis performed
by group colleague Katharine Best. See Figure 4.1.
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Reference Specificity
Pantaleo et al. 1994 (471) HIV
Wilson et al. 1998 (242) HIV
Kolowos et al. 1999 (472) HIV
Kou et al. 2000 (473) HIV
Bourcier et al. 2001 (156) HIV
Lee et al. 2002 (474) HIV
Dong et al. 2004 (248) HIV
Gillespie et al. 2006 (274) HIV
Lichterfeld et al. 2006 (475) HIV
Meyer-Olson et al. 2006 (476) HIV
Almeida et al. 2007 (249) HIV
Lichterfeld et al. 2007 (477) HIV
Yu et al. 2007 (478) HIV
Simons et al. 2008 (479) HIV
Berger et al. 2011 (276) HIV
Iglesias et al. 2011 (480) HIV
Chen et al. 2012 (481) HIV
Conrad et al. 2012b (482) HIV
Mendoza et al. 2012 (277) HIV
Stewart-Jones et al. 2012 (483) HIV
Motozono et al. 2014 (278) HIV
Sun et al. 2014 (166) HIV
List collated by Zvyagin et al. 2014 (484) EBV
List collated by Zvyagin et al. 2014 (484) CMV
Table B.1: Sources of published viral- or subset-specific CDR3s. Collated CDR3 amino
acid sequences are available for download (see Section 2.5) (485)
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Figure B.2: HIV infection is associated with a loss of publicness and translational
convergence in β chain CDR3s. A: β CDR3s are less public in HIV-infected than
healthy comparator donors, measured by counting in how many donors each group specific
(i.e. found in only HIV-infected or healthy donors) CDR3 appears. This applies for both
whole samples (solid lines) and a subsample of 5000 CDR3s (dotted lines). To account for
the greater number of HIV+ patients than healthy controls, for any given analysis ten HIV
samples were randomly selected from the total pool, and publicness measured: this was
repeated 100 times, shaded areas represent standard deviation. B: β CDR3s display a lower
mean translational convergence in HIV+ donors than healthy, i.e. were encoded by fewer
nucleotide sequences (and thus recombination events), as determined by counting unique
Decombinator identifiers that produce the same CDR3. Blue and red lines indicate the
mean translational convergence for each group (healthy/HIV respectively) for each CDR3
rank; green and purple lines show a sliding window averaging across 100 ranks. See Figure
4.3A and C.
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Figure B.3: Healthy donor and HIV-patient gene usage divergence. Barplots show-
ing the difference in TRAJ (A), TRBV (B) and TRBJ (C) usage, by Jensen-Shannon Diver-
gence (JSD). Donor-specific proportional gene usage matrices, before each pair of healthy or
HIV+ donors were compared. Only interquartile ranges and medians are shown. See Figure
4.3D.
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Figure B.4: Raw TCR proportional gene usage in healthy and HIV-infected
samples. Raw mean (solid lines) and standard deviations (shaded areas) for proportional
gene usage of TRAV (A), TRAJ (B), TRBV (C) and TRBJ (D) TCR genes. Asterisks
indicate significance comparing all healthy donor values to HIV-patient values for that gene
in an unpaired Wilcoxon rank sum test.
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Figure B.5: Clinical features of the HIV patient samples. A: Change in absolute
count of CD3+CD4+ lymphocytes, which significantly increased during this course of ART (p
= 0.0039). B: Change in absolute count of CD3+CD8+ lymphocytes; no significant change
observed (p = 0.17). C: Change in CD4:CD8 cell ratio; a significant increase was obvserved
(p = 0.0046). D: Significant decrease in viral load on therapy, as measured by qPCR (p =
1.526e-05). ND = not detectable, which corresponds to 50 copies or lower. All p-values in
this figure measured by paired, one-sided Wilcoxon signed rank tests.
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Figure B.6: Relationship between years before treatment and CD4:CD8 ratio.
An unexpected feature of our patient data is that there is a correlation between the amount
of time passed before starting antiretroviral treatment and the CD4:CD8 ratio at time of
start therapy (R2 = 0.1967, p = 0.04844).
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Figure B.7: Change in HIV patients’ gene usage divergence in the first three
months of ART. Log2 fold change in median TRAJ (A), TRBV (B) and TRBJ (C)
Jensen-Shannon Divergence (JSD) from v1 to v2 (red). Blue bars indicate the log2 change in
median JSD that would be required for that patient to reach the mean value of the median
JSDs for the ten healthy controls, i.e. return them to the average level of divergence healthy
controls display in Figure B.3. See Figure 4.4B.
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Figure B.8: HIV patients’ change in diversity indexes on ART. A and B: Log2
fold-change in whole CDR3 repertoire Gini indexes and Shannon entropies from v1 to v2.
Horizontal lines indicate group (healthy/HIV) medians. HIV+ patients show a significantly
lower median fold change in Gini index compared to healthy controls (p = 0.005427, unpaired
one-sided Wilcoxon test). See Figure 4.4C and D.
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Figure B.9: HIV-associated CDR3s decrease in frequency on ART, while CMV-
and EBV-associated CDR3s increase. A: Log2 fold-change in frequency of HIV- and
CMV-associated CDR3s detected in all of the HIV-infected donors. Most HIV-related CDR3s
decreased proportionally (9/13, left), while the majority of CMV-related CDR3s increased
(13/17, right). CDR3s were only included in this analysis if they occurred at least twice in
both v1 and v2 bleeds of a donor. B: Left: proportional frequencies of the published, EBV-
specific CDR3s that were also found in our whole CDR3 repertoires pre- and post-treatment.
Right: Log2 fold-change in frequency of EBV-implicated CDR3s. EBV-associated responses
were found in five HIV+ and two uninfected donors. See Figure 4.5.
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CAppendix C - developing a TCR
sequencing pipeline
C.1 Previously published datasets
The earliest of the three publicly available data sets used in this thesis was produced
by Wang et al (83). This paper sequenced the repertoires of various T-cell subsets,
but I have here only analysed their ‘pan T-cell’ group in which CD3+ peripheral
blood mononuclear cells (PBMCs) were obtained using magnetic assorted cell sorting
(MACS). As with all of the papers with available datasets, RNA was chosen as the in-
put nucleic acid, and so cells were lysed, RNA extracted and mRNA reverse transcribed
into cDNA. TCR rearrangements were then amplified with a so-called amplicon rescued
multiplex (ARM)-PCR, which is a modified version of the Templex PCR (TEM-PCR)
system developed by the same group (486). In these protocols, there is first a multiplex
PCR using primers directed against the constant region (of the alpha and beta con-
stant regions in this case) and against the different V genes. In this first PCR, there
are actually two nested sets of primers for each target (V and C regions), with the inner
set at a higher concentration: the lower-concentration out primers purportedly enrich
the target molecules for the inner primers in the early cycles of the reaction (487). The
inner primers contain one of a pair of ‘universal’ priming sites 5’ of the V or C specific
sections. Amplicons are then ‘rescued’ (an ambiguous term which presumably reflects
a sampling, purification or dilution event) and amplified with primers directed against
the universal sites, allowing amplification of all TCR rearrangements (that have been
labelled with these universal sites in the previous PCR) using the same primers. The
authors claim that this produces semi-quantitative results, as all rearrangements have
been amplified using the same primers for the exponential phase of the PCR, however
as the patent describing their technique reports that 10 to 15 cycles are used in the
first PCR this statement is open to debate (488). Libraries produced by ARM-PCR
were then sequenced on the Roche 454 platform.
The second dataset came from Warren et al (77). These authors reverse transcribe
lysed PBMC RNA using TRBC specific primers, and perform a template switch reac-
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tion. Next they amplified from their TRBC primer to their TS primer in a first round
of PCR, and purified rearranged beta chain transcripts by purifying excised bands from
agarose gel electrophoresis. A second round of PCR was performed using nested TS and
TRBC primers, the latter of which contained 5’ biotin moieties. The products of this
PCR were then purified and randomly sheared by sonication, before using streptavidin
beads to purify sequences that contain the biotinylated TRBC sequence; after another
gel excision to size-select the authors have thus obtained shorter fragments (125-175bp)
that contain just the TRBC proximal sequence, which contains the V(D)J information.
These amplicons then underwent standard adapter-ligation library preparation (illus-
trated in Figure 5.3), and were sequenced on the Illumina GAIIx platform. Note that
the sonication step was required to bring the amplicon lengths within the parameter
range that could be sequenced on this platform at this time.
The final paper that has uploaded appropriate was from Bolotin et al (126). This
paper actually tried several different combinations of protocols, however I have only
used the data from one of these in my comparisons. In this technique PBMC RNA was
reverse-transcribed and amplified using a template-switch approach as was performed
by Warren et al. A nested PCR was then performed on the products of this PCR, in
which 5’ overhanging sequences added adapter regions for 454 sequencing.
There were two additional data sets that were available during the time frame in
which we were developing and testing our own protocols, however these were not suit-
able for comparison with my data. Freeman et al (75) produced very short read data,
which would need to be assembled into longer contigs in order for to Decombinator
to process it, while Mamedov et al (97) sequenced blood from a patient with ankylos-
ing spondylitis before and after stem cell therapy, and thus would likely not produce
repertoires consistent with those of typical, healthy individuals.
C.2 Protocol development supplementary figures
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>D7β2
GTCATAGCTGTTTCCTGTGTGATTTTTTTTTTTTTTTTTTTTTTTTGATGCTCACAGAGGGCCTGGTCTAGA
ATATTCCACATCTGCTCTCACTCTGCCATGGACTCCTGGACCTTCTGCTGTGTGTCCCTTTGCATCCTGGTA
GCGAAGCATACAGATGCTGGAGTTATCCAGTCACCCCGCCATGAGGTGACAGAGATGGGACAAGAAGTGACT
CTGAGATGTAAACCAATTTCAGGCCACAACTCCCTTTTCTGGTACAGACAGACCATGATGCGGGGACTGGAG
TTGCTCATTTACTTTAACAACAACGTTCCGATAGATGATTCAGGGATGCCCGAGGATCGATTCTCAGCTAAG
ATGCCTAATGCATCATTCTCCACTCTGAAGATCCAGCCCTCAGAACCCAGGGACTCAGCTGTGTACTTCTGT
GCCAGCAGTTTAGGGGACGCCAAGGAAAAACTGTTTTTTGGCAGTGGAACCCAGCTCTCTGTCTTGGAGGAC
>D7α
TCACACAGGAAACAGCTATGACTTTTTTTTTTTTTTTTTTTTTTTGAGACGGAGTCTCACTTTGTCGCCCAG
GCTGGAGTGCAGTGGCGCGATCTCTGCTCACTGCAAACTCCGCCTCCCGGGTTCCCGCCATTCTCCTGCCTC
AGCCTCTCGAGTAGCTGGGACTACAGGCGCCCGCCACAGCGCCCAGCTAATTTTTTTGTATTTTTTGGTAGA
GACGGGGTTTCACCGTGTTAGCCAGGATGGTCTCGATCTCCTGACCTCGTGATCCGCCCACCTCGGCCTCCC
AAAGCGCTGGGATTAAAGGCGTGAGCCACCGCGCCCGGCCTACTTTGTCTTATGTTATTCCCATTTGCCGTC
TCTGTTCCTTATACATTATGCTTTTTCAACTTTACCAGAATCACTTGGATTAAAACCCGTGGATTTCTCAGT
AGGAAATGTTCATGTGAAGACACTTCTGTAGTAACAGAACCTACAGCTGCTCCTGTAGAAGGAAGTTGAAAG
TCATCCCTTCAAGAAAGGGGCTCCTCCCCTTGTAATTCTACTGGGTTTTGCATCCAGACTGAGTTTCCTTCC
CTCACCCACATGAAGTGTCTACCTTCTGCAGACTCCAATGGCTCAGGAACTGGGAATGCAGTGCCAGGCTCG
TGGTATCCTGCAGCAGATGTGGGGAGTTTTCCTTCTTTATGTTTCCATGAAGATGGGAGGCACTACAGGACA
AAACATTGACCAGCCCACTGAGATGACAGCTACGGAAGGTGCCATTGTCCAGATCAACTGCACGTACCAGAC
ATCTGGGTTCAACGGGCTGTTCTGGTACCAGCAACATGCTGGCGAAGCACCTACATTTCTGTCTTACAATGT
TCTGGATGGTTTGGAGGAGAAAGGTCGTTTTTCTTCATTCCTTAGTCGGTCTAAAGGGTACAGTTACCTCCT
TTTGAAGGAGCTCCAGATGAAAGACTCTGCCTCTTACCTCTGTGCTGCCGTGGATAGCAACTATCAGTTAAT
CTGGGGCGCTGGGACCAAGCTAATTATAAAGCCAGATATCCAGAA
>D8α
ACGGCAGGGTCAGGGTTCTGCTGAGGTGCAACTATTCATCGTCTGTTCCACCATATCTCTTCTGGTATGTGC
AATACCCCAACCAAGGACTCCAGCTTCTCCTGAAGTACACATCAGCGGCCACCCTGGTTAAAGGCATCAACG
GTTTTGAGGCTGAATTTAAGAAGAGTGAAACCTCCTTCCACCTGACGAAACCCTCAGCCCATATGAGCGACG
CGGCTGAGTACTTCTGTGCTGTGAGTGATCTCGAACCGAACAGCAGTGCTTCCAAGATAATCTTTGGATCAG
GGACCAGACTCAGCATCCGGCCAAATATCCAGAACCCTGATCCTGCCCT
aRC1                    ACGGCAGGGTCAGGGTTCTGGATAT
D8α                     ACGGCAGGGTCAGGGTTCTGCTGAGGTGCAACTATTCAT...
GermlineTRAV8-4      ...CTGAAGGAGCCCTGGTTCTGCTGAGGTGCAACTACTCAT...
A
B
C
D
E
>D7β1
TCACACAGGAAACAGCTATGACTTTTTTTTTTTTTTTTTTTTTTTGCATGCTCACAGAGGGCCTGGTCTAGA
ATATTCCACATCTGCTCTCACTCTGCCATGGACTCCTGGACCTTCTGCTGTGTGTCCCTTTGCATCCTGGTA
GCGAAGCATACAGATGCTGGAGTTATCCAGTCACCCCGCCATGAGGTGACAGAGATGGGACAAGAAGTGACT
CTGAGATGTAAACCAATTTCAGGCCACAACTCCCTTTTCTGGTACAGACAGACCATGATGCGGGGACTGGAG
TTGCTCATTTACTTTAACAACAACGTTCCGATAGATGATTCAGGGATGCCCGAGGATCGATTCTCAGCTAAG
ATGCCTAATGCATCATTCTCCACTCTGAAGATCCAGCCCTCAGAACCCAGGGACTCAGCTGTGTACTTCTGT
GCCAGCAGTGACGATTCTAGTCTTCGGCCCCAGCATTTTGGTGATGGGACTCGACTCTCCATCCTAGAGGAC
V region D region C regionJ regionL region Poly-T primer
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Figure C.1 (preceding page): Example amplicons cloned from the DNA ampli-
fied from two healthy donors’ PBMC using our poly-T RACE PCR. Bands both
expected and unexpected sizes were selected. TCR genes used in these rearrangements are
A (D7β1): TRBV12-3 – TRBD2 – TRBJ1-5; B (D7β2): TRBV12-3 – TRBD1 – TRBJ1-4;
C (D7α): TRAV1-2 – TRAJ33; D (D8α): TRAV8-4 – TRAJ33. Bold residues indicate mis-
matches relative to expected sequences. A and C contain the expected number of thymidines
in their RACE homopolymer (23). B contains 24, while a clone relating to a non-productive
rearrangement (not shown) was found to contain 25. E shows the overlap between the 5’ end
of the D8α clone, αRC1 primer and germline TRAV8-4 sequences, revealing the presumed
exonucleation of the primer and subsequent mis-priming. Note that C is a MAIT-cell TCR
sequence (see Section 3.1.5).
Sample Reads % % Mean Mean Predicted
Decombined Filtered Quality P Error Accuracy
Wang1α 37,097 63.63% 0.26% 36.2 1.77× 10−4 99.98%
Wang1β 37,097 30.92% 1.28% 36.0 2.63× 10−4 99.97%
Wang2α 15,614 62.86% 0.32% 36.5 1.52× 10−4 99.98%
Wang2β 15,614 32.22% 0.75% 36.3 2.42× 10−4 99.98%
Wang3α 143,944 55.59% 0.88% 36.7 1.40× 10−4 99.99%
Wang3β 143,944 37.11% 4.06% 36.6 1.97× 10−4 99.98%
Warren1β 1,893,628 80.15% 1.61% 36.8 3.92× 10−4 99.96%
Warren2β 1,625,571 79.71% 0.11% 36.7 3.36× 10−4 99.97%
Warren3β 1,794,595 80.33% 0.02% 36.8 3.04× 10−4 99.97%
Bolotin1β 12,300 59.46% 1.10% 26.1 2.44× 10−3 99.76%
Bolotin2β 10,990 56.93% 0.78% 25.7 2.55× 10−3 99.74%
Bolotin3β 8,347 44.79% 1.71% 24.1 3.22× 10−3 99.68%
Table C.1: Overview read statistics for three sets of publicly available healthy
human datasets that were available from papers published prior to completion of
our own protocols. FASTQ files were downloaded from the Sequence Read Archive (SRA),
with accession numbers in the displayed order: SRR030416, SRR030417 and SRR030709
(83); SRR060699, SRR060700 and SRR060701 (77); SRR494403, SRR494404 and SRR494405
(126). For each paper, the three files represent separate amplifications from different aliquots
of either blood or RNA, from the same bleed of one donor. Both Wang et al and Bolotin
et al FASTQ files were produced using 454 technology, while the Warren et al paper used
the Illumina Genome Analyser (GA) IIx, the precursor machine to the HiSeq. Note that the
Bolotin et al paper also published sequences from comparable libraries sequenced on both
the GAIIx and Ion Torrent platforms, but were not included in this analysis; the reads from
their GAIIx run were too short (72bp) for reliable TCR assignation by Decombinator, and
the V gene distributions of their Ion Torrent data were inconsistent with the other platforms,
suggesting a possible bias.
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>Pa1
CAAGCAGAAGACGGCATACGAGATGGCTACGTGACTGGAGTTCAGACGTGTGCTCTTCCAATCTTTTTTTTTTTTTTTTTTTTTTGTTCT
GCAGCTGCAATGGGTGAGCAGCAAACAGGAGGTGACGCAGATTCCTGCAGCTCTGAGTGTCCCAGAAGGAGAAAACTTGGTTCTCAACTG
CAGTTTCACTGATAGCGCTATTTACAACCTCCAGTGGTTTAGGCAGGACCCTGGGAAAGGTCTCACATCTCTGTTGCTTATTCAGTCAAG
TCAGAGAGAGCAAACAAGTGGAAGACTTAATGCCTCGCTGGATAAATCATCAGGACGTAGTACTTTATACATTGCAGCTTCTCAGCCTGG
TGACTCAGCCACCTACCTCTGTGCTGTAGACGACTACAAGCTCAGCTTTGGAGCCGGAACCACAGTAACTGTAAGAGCAAATATCCAGAA
CCCTGACCCTGCCGTAGTGTAGATCTCGGTGGTCGCCGTATCATT
>Pa2
CAAGCAGAAGACGGCATACGAGATGGCTACGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTTTTTTTTTTTTTTTTTGCAGCTCAG
ACACAGCGAAAGAGCCTAGAACCTGGGTCCTAGTTTGCACCTAGAATATGAGGTACTTTGAGCCTTGCTAAGACCACCCAGCCCATCTCC
ATGGACTCATATGAAGGACAAGAAGTGAACATAACCTGTAGCCACAACAACATTGCTACAAATGATTATATCACGTGGTACCAACAGTTT
CCCAGCCAAGGACCACGATTTATTATTCAAGGATACAAGACAAAAGTTACAAACGAAGTGGCCTCCCTGTTTATCCCTGCCGACAGAAAG
TCCAGCACTCTGAGCCTGCCCCGGGTTTCCCTGAGCGACACTGCTGTGTACTACTGCCTCGTGGGTGACTGGGATAACTATGGTCAGAAT
TTTGTCTTTGGTCCCGGAACCAGATTGTCCGTGCTGCCCTATATCCAGAACCCTGACCCTGCCGTAGTGTAGATCTCGATGGTCGCCGTA
TCATT
>Pa3
CAAGCAGAAGACGGCATACGAGATGGCTACGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTTTTTTTTTTTTTTTTTTTTTTGGCC
ATGGCTTTGCAGAGCACTCTGGGGGCGGTGTGGCTAGGGCTTCTCCTCAACTCTCTCTGGAAGGTTGCAGAAAGCAAGGACCAAGTGTTT
CAGCCTTCCACAGTGGCATCTTCAGAGGGAGCTGTGGTGGAAATCTTCTGTAATCACTCTGTGTCCAATGCTTACAACTTCTTCTGGTAC
CTTCACTTCCCGGGATGTGCACCAAGACTCCTTGTTAAAGGCTCAAAGCCTTCTCAGCAGGGACGATACAACATGACCTATGAACGGTTC
TCTTCATCGCTGCTCATCCTCCAGGTGCGGGAGGCAGATGCTGCTGTTTACTACTGTGCTGTGGTAGGAGGAAGCTACATACCTACATTT
GGAAGAGGAACCAGCCTTATTGTTCATCCGTATATCCAGAACCCTGACCCTGCCGTAGTGTAGATCTCGGTGGTCGCCGTATCATT
>Pa7
CAAGCAGAAGACGGCATACGAGATGGCTACGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTTTTTTTTTTTTTTTTTTTTTTGGCA
TTTTGGCCATGGCTTTGCAGAGCACTCTGGGGGCGGTGTGGCTAGGGCTTCTCCTCAACTCTCTCTGGAAGGTTGCAGAAAGCAAGGACC
AAGTGTTTCAGCCTTCCACAGTGGCATCTTCAGAGGGAGCTGTGGTGGAAATCTTCTGTAATCACTCTGTGTCCAATGCTTACAACTTCT
TCTGGTACCTTCACTTCCCGGGATGTGCACCAAGACTCCTTGTTAAAGGCTCAAAGCCTTCTCAGCAGGGACGATACAACATGACCTATG
AACGGTTCTCTTCATCGCTGCTCATCCTCCAGGTGCGGGAGGCAGATGCTGCTGTTTACTACTGTGCTGTGGCCTCTTCTTCTGGTTCTG
CAAGGCAACTGACCTTTGGATCTGGGACACAATTGACTGTTTTACCTGATATCCAGAACCCTGACCCTGCCGTAGTGTAGATCTCGGTGG
TCGCCGTATCATT
>Pb1
CAAGCAGAAGACGGCATACGAGATACTTGAGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTTTTTTTTTTTTTTTTTTTTTTGGGT
GTGAGGCCATCACGGAAGATGCTGCTGCTTCTGCTGCTTCTGGGGCCAGGCTCCGGGCTTGGTGCTGTCGTCTCTCAACATCCGAGCTGG
GTTATCTGTAAGAGTGGAACCTCTGTGAAGATCGAGTGCCGTTCCCTGGACTTTCAGGCCACAACTATGTTTTGGTATCGTCAGTTCCCG
AAACAGAGTCTCATGCTGATGGCAACTTCCAATGAGGGCTCCAAGGCCACATACGAGCAAGGCGTCGAGAAGGACAAGTTTCTCATCAAC
CATGCAAGCCTGACCTTGTCCACTCTGACAGTGACCAGTGCCCATCCTGAAGACAGCAGCTTCTACATCTGCAGTGCCATTCCGGGACTA
GCGGGAAGGGGCGAGCAGTACTTCGGGCCGGGCACCAGGCTCACGGTCACAGAGGACCTGAACAAGGTGTTCCCACCAGTGTAGATCTCG
GTGGTCGCCGTATCATT
>Pb3
CAAGCAGAAGACGGCATACGAGATACTTGAGTGACTGGAGTTCGGACGTGTGCTCTTCCGATCTTTTTTTTTTTTTTTTTTTTTTTGCTG
AGCACAGACACAGTGCTGCCTGCCCCTTTGTGCCATGGGCTCCAGGCTGCTCTGTTGGGTGCTGCTTTGTCTCCTGGGAGCAGGCCCAGT
AAAGGCTGGAGTCACTCAAACTCCAAGATATCTGATCAAAACGAGAGGACAGCAAGTGACACTGAGCTGCTCCCCTATCTCTGGGCATAG
GAGTGTATCCTGGTACCAACAGACCCCAGGACAGGGCCTTCAGTTCCTCTTTGAATACTTCAGTGAGACACAGAGAAACAAAGGAAACTT
CCCTGGTCGATTCTCAGGGCGCCAGTTCTCTAACTCTCGCTCTGAGATGAATGTGAGCACCTTGGAGCTGGGGGACTCGGCCCTTTATCT
TTGCGCCAGCACAAGGACAGCCGGGCAATCTGGCTACACCTTCGGTTCGGGGACCAGGTTAACCGTTGTAGAGGACCTGAACAAGGTGTT
CCCACCAGTGTAGATCTCGGTGGTCGCCGTATCATT
>Pb6
CAAGCAGAAGACGGCATACGAGATACTTGAGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTTTTTTTTTTTTTTTTTTTTTTTTTGC
CCATCCTGCCCTGACCCTGCCATGGGCACCAGCCTCCTCTGCTGGATGGCCCTGTGTCTCCTGGGGGCAGATCACGCAGATACTGGAGTC
TCCCAGGACCCCAGACACAAGATCGCTAAGAGGGGACAGAATGTAACTTTCAGGTGTGATCCAATTTCTGAACACAACCGCCTTTATTGG
TACCGACAGACCCTGGGGCAGGGCCCAGAGTTTCTGACTTACTTCCAGAATGAAGCTCAACTAGAAAAATCAAGGCTGCTCAGTGATCGG
TTCTCTGCAGAGAGGCCTAAGGGATCTTTCTCCACCTTGGAGATCCAGCGCACAGAGCAGGGGGACTCGGCCATGTATCTCTGTGCCAGC
AGCTTAGTAAGCGGGAAAGGGTTCGAGCAGTACTTCGGGCCGGGCACCAGGCTCACGGTCACAGAGGACCTGAACAAGGTGTTCCCACCA
GTGTAGATCTCGGTGGTCGCCGTATCATT
>DD21
CAAGCAGAAGACGGCATACGAGATACATCGGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTACTTCCCGATGAAGGTATTGTGGAAG
AAACTACACTATCGGCATTACGCGTGGCCAATGAGGTCAATGAGCTACGCATTGAATACGAATCCGCTATAAAATCCGGGTTTTCTGCCT
TTTCCACCTTTGTTAGGCATCGCCACGCCGAATGGGAGATCGGAAGAGCGTCGTGTAGGGAAAGAGTGTAGATCTCGGTGGTCGCCGTAT
CATT
V region J region SP1/SP2 P5/P7IndexC regionL region
A
B
C
D
E
F
G
H
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Figure C.2 (preceding page): Sanger sequenced clones produced using the step-
wise PCR protocol. Presence and orientation of sequences indicates that the stepwise
PCR protocol is adding the required elements in the correct positions, and thus theoretically
libraries should be able to be sequenced. TCR genes used in each rearrangement are A:
TRAV21 – TRAJ20; B: TRAV4 – TRAJ26; C: TRAV2 – TRAJ6; D: TRAV2 – TRAJ22;
E: TRBV20-1 – TRBJ2-7; F: TRBV5-1 – TRBJ1-2; G: TRBV7-9 – TRBJ2-7. H shows
an example sequence cloned from a non-TCR library (genomic varicella-zoster virus) that
sequenced with expected run output, to demonstrate matching adapter sequences. Note that
SP1 sequences are absent in A-G as these clones were produced with the initial protocol,
in which custom sequencing oligonucleotides were targeted against the end of the constant
regions (underlined). Sequencing of clones from later libraries showed that the SP1 element
was similarly correctly incorporated (analysis performed by other laboratory members, data
not shown). Poly-T homopolymer lengths for clones A to H (not counting the thymidine that
makes up the ultimate base of the SP2 sequence) are: 21; 17; 22; 22; 22; 22 and 24 (compared
to the 23 T residues found in the primer). Base-calls that differ to reference sequences are in
bold. VZV library kindly donated by Dr. Daniel Depledge.
Sample Reads Extended %
D2 10,875,543 1,943,685 17.87%
D3 na¨ıve 17,493,702 2,207,696 12.62%
D3 memory 16,410,241 1,786,562 10.89%
D4 na¨ıve 13,068,337 1,988,492 15.22%
D5 memory 10,553,778 1,702,220 16.13%
Table C.2: Merging HiSeq reads. Number and percentages of HiSeq FASTQ reads that
were successfully merged using FLASH, which uses overlapping portions of paired-end data
to recapitulate entire target amplicons contained within the sequencing primers.
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Figure C.3 (preceding page): Flowchart overview of how the error- and
frequency-correcting code of CollapseTCR works. A: Files decombined with vDCR
are read into memory; all rearrangements whose barcode is of sufficiently high FASTQ quality
is stored in the Clone dictionary. B: The script loops through all the entries in the Clone
dictionary, which looks within each barcode sequence to establish what the ‘prototypical’
rearrangement is, i.e. the most frequent, which is assumed to represent the true receptor
chain. Also performs several other checks and assesses whether there are any instances of
‘barcode clash’, i.e. TCR chains that are not related detected in conjunction with the same
barcode. This section is responsible for collapsing the actual Decombinator identifiers
down, i.e. reducing the number of unique TCRs by merit of erroneous sequences being re-
moved. C: Having removed erroneous sequences, the script then loops through all of the
barcodes that were associated with a given rearrangement. In order to account for errors in
the barcode itself, barcodes that are highly similar to one another (in this instance having an
edit distance of three or less) are clustered together; the number of unique clusters are then
taken as the truer estimated frequency of that TCR. Finally results are output as collapsed
Decombinator files. Flowchart produced using yEd (yWorks).
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A
B
Figure C.4: TRAJ and TRBJ usage difference between original and extended
Decombinator tag sets. Plots of a representative healthy donor (HV09) showing the
comparative performance of Decombinator in combination with the original and extended
tag sets. A and B: Frequency of Decombinator rearrangements using particular TRAJ
and TRBJ genes, when using either the original or new extended tag sets.
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% % Mean Mean Predicted
Sample Reads Decombined Filtered Quality P Error Accuracy
D2 extα 1,943,685 9.93% 0.16% 33.5 2.01× 10−3 99.80%
D2 extβ 1,943,685 21.91% 0.22% 35.3 1.41× 10−3 99.86%
D2 R1α 8,931,858 0.05% 0.23% 34.6 2.25× 10−3 99.78%
D2 R1β 8,931,858 0.14% 0.29% 34.7 1.87× 10−3 99.81%
D2 R2α 8,931,858 0.04% 0.89% 34.9 2.68× 10−3 99.73%
D2 R2β 8,931,858 0.07% 0.24% 34.8 2.55× 10−3 99.75%
D3 na¨ıve extα 2,207,696 7.70% 0.16% 33.5 2.06× 10−3 99.79%
D3 na¨ıve extβ 2,207,696 26.98% 0.21% 35.3 1.42× 10−3 99.86%
D3 na¨ıve R1α 15,286,006 0.15% 0.24% 35.0 1.84× 10−3 99.82%
D3 na¨ıve R1β 15,286,006 0.29% 0.26% 34.8 1.79× 10−3 99.82%
D3 na¨ıve R2α 15,286,006 0.10% 0.97% 35.2 2.35× 10−3 99.77%
D3 na¨ıve R2β 15,286,006 0.17% 0.17% 34.8 2.56× 10−3 99.74%
D3 memory extα 1,786,562 7.73% 0.25% 33.2 2.29× 10−3 99.77%
D3 memory extβ 1,786,562 24.83% 0.33% 35.1 1.53× 10−3 99.85%
D3 memory R1α 14,623,679 0.04% 0.42% 34.9 1.96× 10−3 99.80%
D3 memory R1β 14,623,679 0.06% 0.45% 34.7 1.88× 10−3 99.81%
D3 memory R2α 14,623,679 0.03% 1.11% 35.0 2.49× 10−3 99.75%
D3 memory R2β 14,623,679 0.04% 0.35% 34.8 2.55× 10−3 99.74%
D4 na¨ıve extα 1,988,492 14.89% 0.20% 33.6 1.96× 10−3 99.80%
D4 na¨ıve extβ 1,988,492 20.93% 0.26% 35.2 1.45× 10−3 99.85%
D4 na¨ıve R1α 11,079,845 0.07% 0.33% 34.4 2.33× 10−3 99.77%
D4 na¨ıve R1β 11,079,845 0.10% 0.24% 34.3 2.19× 10−3 99.78%
D4 na¨ıve R2α 11,079,845 0.06% 1.03% 34.7 2.87× 10−3 99.71%
D4 na¨ıve R2β 11,079,845 0.08% 0.25% 34.5 2.70× 10−3 99.73%
D4 memory extα 1,702,220 17.44% 0.15% 33.7 1.92× 10−3 99.81%
D4 memory extβ 1,702,220 20.47% 0.19% 35.2 1.42× 10−3 99.86%
D4 memory R1α 8,851,558 0.11% 0.10% 34.7 2.02× 10−3 99.80%
D4 memory R1β 8,851,558 0.09% 0.14% 34.8 1.86× 10−3 99.81%
D4 memory R2α 8,851,558 0.09% 0.95% 35.1 2.43× 10−3 99.76%
D4 memory R2β 8,851,558 0.07% 0.20% 34.9 2.50× 10−3 99.75%
Table C.3: Read and Decombinator output data for the Simple V amplification
protocol, as sequenced on the Illumina HiSeq. Reads that were extended (overlapped)
by FLASH are highlighted in grey. Records: number of FASTQ reads; number of those reads
successfully assigned by Decombinator; how many assignations survived the N/length filter;
percentage of total reads that were assigned TCRs; percentage of assigned TCRs removed
by N/length filter; average quality score of inter-tag region (i.e. fastq record from the start
of Decombinator-assigned V tag to the end of the J tag); average per base probability of
an error having occurred in that inter-tag FASTQ file, and the related predicated accuracy
of that sequence data.
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% % Mean Mean Predicted
Sample Reads Decombined Filtered Quality P Error Accuracy
D2α 10,875,543 1.85% 0.18% 33.6 2.03× 10−3 99.80%
D2β 10,875,543 4.09% 0.23% 35.3 1.44× 10−3 99.86%
D3 na¨ıveα 17,493,702 1.19% 0.23% 33.8 2.06× 10−3 99.79%
D3 na¨ıveβ 17,493,702 3.81% 0.21% 35.2 1.49× 10−3 99.85%
D3 memoryα 16,410,241 0.90% 0.28% 33.3 2.28× 10−3 99.77%
D3 memoryβ 16,410,241 2.80% 0.33% 35.0 1.55× 10−3 99.84%
D4 na¨ıveα 13,068,337 2.37% 0.22% 33.6 1.99× 10−3 99.80%
D4 na¨ıveβ 13,068,337 3.33% 0.25% 35.1 1.49× 10−3 99.85%
D4 memoryα 10,553,778 2.98% 0.17% 33.7 1.94× 10−3 99.81%
D4 memoryβ 10,553,778 3.44% 0.19% 35.2 1.45× 10−3 99.86%
Table C.4: Overall read statistics for the Simple V amplification protocol Se-
quenced on the Illumina HiSeq. Fields are as in Table C.3.
% % Mean Mean Predicted Mean
Sample Reads Decombined Filtered Quality P Error Accuracy Length
D2 α 13,330 42.52% 0.12% 37.7 4.05× 10−4 99.96% 421.9
D2 β 9,714 48.45% 0.53% 36.4 6.64× 10−4 99.93% 480.4
D3 α 23,456 61.22% 0.33% 38.0 3.60× 10−4 99.96% 413.3
D3 β 25,686 28.83% 0.16% 37.2 5.88× 10−4 99.94% 282.5
D9 α 12,587 33.32% 0.00% 37.4 4.73× 10−4 99.95% 375.7
D9 β 12,432 46.45% 0.36% 35.4 8.63× 10−4 99.91% 507.3
D10 α 12,587 33.32% 0.00% 37.4 4.73× 10−4 99.95% 375.7
D10 β 38,044 33.89% 0.45% 37.0 6.19× 10−4 99.94% 331.6
Table C.5: Overall read statistics for the poly-T RACE protocol, sequenced on
the Roche 454 GS FLX. Fields are as in Table C.3, with an additional column reporting
the average read length of the original FASTQ files. Note that D9 and D10 report identical
results for alpha chain files; on closer inspection, the FASTQ files were identical. One file
must have been accidentally overwritten somewhere between sequencing and final processing.
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% % Mean Mean Predicted
Sample Reads Decombined Filtered Quality P Error Accuracy
D3α 113,002 35.27% 0.00% 24.9 2.04× 10−2 97.96%
D3β 452,284 25.27% 0.02% 31.4 6.38× 10−3 99.36%
D10α 16,014 36.51% 0.03% 25.8 1.75× 10−2 98.25%
D10β 28,326 26.74% 0.03% 32.6 4.72× 10−3 99.53%
Table C.6: Overall read statistics for the poly-T RACE protocol, with NEBNext
adapter-ligation library preparation. Sequenced on the Illumina MiSeq (2 x 150bp
paired end (PE), version 1 chemistry kits). Fields are as in Table C.3.
% % Mean Mean Predicted
Sample Reads Decombined Filtered Quality P Error Accuracy
RL1α 611,664 76.88% 0.00% 37.4 4.47× 10−4 99.96%
RL1β 491,388 61.11% 0.01% 37.4 3.90× 10−4 99.96%
RL2α 827,843 62.13% 0.01% 38.1 2.47× 10−4 99.98%
RL3β 1,079,562 68.47% 0.00% 37.5 3.84× 10−4 99.96%
DL1α 3,437,933 51.84% 0.02% 37.8 3.48× 10−4 99.97%
DL1β 3,237,576 54.13% 0.01% 37.6 3.67× 10−4 99.96%
DL2α 2,477,170 31.14% 0.00% 37.9 3.15× 10−4 99.97%
DL2β 2,116,423 64.44% 0.00% 37.6 3.48× 10−4 99.97%
Table C.7: Summary statistics for the ligation RACE protocols, sequenced on
the Illumina MiSeq. RL = RNA ligation, DL = DNA ligation, numbers indicate test run
number per protocol. RNA and DNA ligation protocols were performed by Prof. Chain and
Dr Oakes, and are included in this thesis to explain the downstream protocol choices.
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% Total % Mean Mean Predicted
Sample Reads Decombined % Filtered Quality P Error Accuracy
HV4α 2,844,497 42.56% 66.78% 0.00% 37.6 3.80× 10−4 99.96%
HV4β 2,844,497 24.22% 0.00% 37.8 3.29× 10−4 99.97%
HV5α 2,465,640 39.65% 65.50% 0.01% 37.6 3.98× 10−4 99.96%
HV5β 2,465,640 25.85% 0.00% 37.7 3.37× 10−4 99.97%
HV7α 1,610,847 27.26% 44.92% 0.00% 33.5 1.78× 10−3 99.82%
HV7β 1,610,847 17.66% 0.00% 34.6 1.36× 10−3 99.86%
HV9α 1,533,948 22.58% 35.79% 0.00% 33.5 1.78× 10−3 99.82%
HV9β 1,533,948 13.21% 0.00% 34.6 1.33× 10−3 99.87%
HV10α 1,199,385 28.18% 47.59% 0.00% 33.4 1.80× 10−3 99.82%
HV10β 1,199,385 19.42% 0.00% 34.6 1.37× 10−3 99.86%
Table C.8: Summary statistics for the randomly barcoded simple V amplification
protocol, sequenced on the Illumina MiSeq. Fields are as in Table C.3, with an
additional total percentage Decombined column, as both alpha and beta reads for the same
donors were sequenced under the same index, and thus were demultiplexed together into one
output FASTQ file. Files were sequenced in two batches along with other samples, with ten
samples multiplexed per run. Thanks go to James Opzoomer, an intern in the laboratory who
performed the initial processing on the blood samples once the protocol had been sufficiently
refined.
% % Mean Mean Predicted
Sample Reads Decombined Filtered Quality P Error Accuracy
HV07α 1,530,742 77.23% 0.01% 37.5 4.18× 10−4 99.96%
HV07β 1,692,780 68.36% 0.00% 37.7 3.24× 10−4 99.97%
HV08α 1,674,080 85.50% 0.01% 37.5 4.20× 10−4 99.96%
HV08β 1,431,872 73.98% 0.00% 37.8 3.18× 10−4 99.97%
HV09α 1,549,771 82.02% 0.01% 37.7 3.68× 10−4 99.96%
HV09β 1,296,475 76.72% 0.00% 37.7 3.27× 10−4 99.97%
HV10α 1,482,059 82.15% 0.00% 37.8 3.54× 10−4 99.96%
HV10β 1,006,028 79.66% 0.00% 37.8 3.03× 10−4 99.97%
HV11α 1,377,301 85.72% 0.01% 38.0 2.90× 10−4 99.97%
HV11β 1,283,645 82.40% 0.00% 37.7 3.29× 10−4 99.97%
HV13α 1,136,590 85.15% 0.00% 38.0 2.84× 10−4 99.97%
HV13β 1,521,705 75.66% 0.00% 37.7 3.23× 10−4 99.97%
Table C.9: Summary statistics for the randomly barcoded ligation RACE (BLR)
amplification protocol, sequenced on the Illumina MiSeq. Fields are as in Table C.3.
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TRAV8-24 TRAV21 TRBV12-34 TRBV20-1
BV BLR BV BLR BV BLR BV BLR
TRAV8-24 BV
BLR ***
TRAV21 BV ns *
BLR *** ns *
TRBV12-34 BV *** *** ns ***
BLR *** ns * ns ***
TRBV20-1 BV *** *** * *** ** ***
BLR *** ns * ns *** ns ***
Table C.10: Differential amplification observed between V genes during multiplex
PCR. Levels of significance observed when comparing all of the different groups shown in
Figure 5.23 with one another. All comparisons were made using Welch’s t-test (unpaired
Student’s t-test without assumption of equal variance). P-values ¡ 0.001 = ***, ¡ 0.01 = **,
¡ 0.05 = *, ¿= 0.05 = not significant (ns). BV = barcoded V protocol, BLR = barcoded
ligation RACE protocol. Purple cells indicate BV-BV comparisons, blue are BLR-BLR, while
yellow indicates inter-protocol comparisons. Grey cells represent redundant combinations.
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